0001628280-17-008259.txt : 20170808 0001628280-17-008259.hdr.sgml : 20170808 20170808080424 ACCESSION NUMBER: 0001628280-17-008259 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 62 CONFORMED PERIOD OF REPORT: 20170630 FILED AS OF DATE: 20170808 DATE AS OF CHANGE: 20170808 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioScrip, Inc. CENTRAL INDEX KEY: 0001014739 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOME HEALTH CARE SERVICES [8082] IRS NUMBER: 050489664 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-11993 FILM NUMBER: 171013291 BUSINESS ADDRESS: STREET 1: 1600 BROADWAY STREET 2: SUITE 950 CITY: DENVER STATE: CO ZIP: 80202 BUSINESS PHONE: 720 697 5200 MAIL ADDRESS: STREET 1: 1600 BROADWAY STREET 2: SUITE 950 CITY: DENVER STATE: CO ZIP: 80202 FORMER COMPANY: FORMER CONFORMED NAME: MIM CORP DATE OF NAME CHANGE: 19960516 10-Q 1 bios-20170630x10q.htm 10-Q Document



 
 
 
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 10-Q

(Mark One)
 
þ
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the quarterly period ended June 30, 2017
 
OR
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from     to             

Commission file number: 001-11993

logowithregisteredtm06.jpg
BioScrip, Inc.
(Exact name of registrant as specified in its charter)
Delaware
05-0489664
(State of incorporation)
(I.R.S. Employer Identification No.)
1600 Broadway, Suite 700, Denver, Colorado
80202
(Address of principal executive offices)
(Zip Code)

Registrant’s telephone number, including area code:
720-697-5200

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes þ     No o

Indicate by check mark whether the registrant has submitted electronically and posted to its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes þ No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer o     Accelerated filer þ     Non-accelerated filer o      Smaller reporting company o Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes o     No þ

On August 7, 2017, there were 127,475,226 shares of the registrant’s Common Stock outstanding.



TABLE OF CONTENTS


2

PART I
FINANCIAL INFORMATION
Item 1.
Financial Statements
BIOSCRIP, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(in thousands, except share amounts)
 
June 30,
2017
 
December 31,
2016
 
(unaudited)
 
 
ASSETS
 
 
 
Current assets
 
 
 
Cash and cash equivalents
$
40,533

 
$
9,569

Restricted cash
5,055


—

Receivables, less allowance for doubtful accounts of $45,651 and $44,730 as of June 30, 2017 and December 31, 2016, respectively
103,089

 
111,811

Inventory
28,822

 
36,165

Prepaid expenses and other current assets
12,998

 
18,507

Total current assets
190,497

 
176,052

Property and equipment, net
30,063

 
32,535

Goodwill
365,947

 
365,947

Intangible assets, net
24,672

 
31,043

Other non-current assets
2,204

 
2,163

Total assets
$
613,383

 
$
607,740

LIABILITIES AND STOCKHOLDERS’ DEFICIT
 

 
 

Current liabilities
 

 
 

Current portion of long-term debt
$
1,731

 
$
18,521

Accounts payable
46,381

 
59,134

Amounts due to plan sponsors
4,825

 
3,799

Accrued interest
6,736

 
6,705

Accrued expenses and other current liabilities
43,209

 
42,191

Total current liabilities
102,882

 
130,350

Long-term debt, net of current portion
475,674

 
433,413

Deferred taxes
3,504

 
2,281

Other non-current liabilities
17,942

 
1,257

Total liabilities
600,002

 
567,301

Series A convertible preferred stock, $.0001 par value; 825,000 shares authorized; 21,645 shares issued and outstanding as of June 30, 2017 and December 31, 2016; and $2,754 and $2,603 liquidation preference as of June 30, 2017 and December 31, 2016, respectively
2,639

 
2,462

Series C convertible preferred stock, $.0001 par value; 625,000 shares authorized; 614,177 shares issued and outstanding as of June 30, 2017 and December 31, 2016; and $79,858 and $75,491 liquidation preference as of June 30, 2017 and December 31, 2016, respectively
74,229

 
69,540

Stockholders’ deficit
 

 
 

Preferred stock, $.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of June 30, 2017 and December 31, 2016, respectively
—

 
—

Common stock, $.0001 par value; 250,000,000 shares authorized; 127,441,893 and 117,682,543 shares issued and outstanding as of June 30, 2017 and December 31, 2016, respectively
13

 
12

Additional paid-in capital
628,545

 
611,844

Accumulated deficit
(692,045
)
 
(643,419
)
Total stockholders’ deficit
(63,487
)
 
(31,563
)
Total liabilities and stockholders’ deficit
$
613,383

 
$
607,740


See accompanying Notes to Unaudited Consolidated Financial Statements.

3

BIOSCRIP, INC. AND SUBSIDIARIES
UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)

 
Three Months Ended 
 June 30,
 
Six Months Ended 
 June 30,
 
2017
 
2016
 
2017
 
2016
Net revenue
$
218,106

 
$
232,462

 
$
435,916

 
$
470,924

Cost of revenue (excluding depreciation expense)
149,796

 
168,298

 
302,022

 
342,528

Gross profit
68,310

 
64,164

 
133,894

 
128,396

 
 
 
 
 
 
 
 
Other operating expenses
42,486

 
40,619

 
86,844

 
80,277

Bad debt expense
6,223

 
4,279

 
13,387

 
11,871

General and administrative expenses
10,025

 
9,414

 
19,504

 
20,465

Restructuring, acquisition, integration, and other expenses, net
3,911

 
4,291

 
7,134

 
6,958

Depreciation and amortization expense
6,789

 
4,252

 
13,777

 
8,790

Interest expense
12,715

 
9,469

 
25,459

 
18,881

Loss on extinguishment of debt
13,453

 
—

 
13,453

 
—

Loss (gain) on dispositions
685

 
—

 
685

 
(939
)
Loss from continuing operations, before income taxes
(27,977
)
 
(8,160
)
 
(46,349
)
 
(17,907
)
Income tax expense
718

 
149

 
1,337

 
172

Loss from continuing operations, net of income taxes
(28,695
)
 
(8,309
)
 
(47,686
)
 
(18,079
)
(Loss) income from discontinued operations, net of income taxes
(503
)
 
75

 
(940
)
 
308

Net loss
$
(29,198
)
 
$
(8,234
)
 
$
(48,626
)
 
$
(17,771
)
Accrued dividends on preferred stock
(2,303
)
 
(2,056
)
 
(4,517
)
 
(4,054
)
Deemed dividends on preferred stock
(175
)
 
(173
)
 
(349
)
 
(345
)
Loss attributable to common stockholders
$
(31,676
)
 
$
(10,463
)
 
$
(53,492
)
 
$
(22,170
)
 
 
 
 
 
 
 
 
Loss per common share:
 
 
 
 
 
 
 
Loss from continuing operations, basic and diluted
$
(0.26
)
 
$
(0.14
)
 
$
(0.44
)
 
$
(0.32
)
Loss from discontinued operations, basic and diluted
—

 
—

 
(0.01
)
 
—

Loss per common share, basic and diluted
$
(0.26
)
 
$
(0.14
)
 
$
(0.45
)
 
$
(0.32
)
 
 
 
 
 
 
 
 
Weighted average common shares outstanding, basic and diluted
121,189

 
73,186

 
119,993

 
70,978


See accompanying Notes to Unaudited Consolidated Financial Statements.

4

BIOSCRIP, INC. AND SUBSIDIARIES
UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
 
Six Months Ended 
 June 30,
 
2017
 
2016
Cash flows from operating activities:
 
 
 
Net loss
$
(48,626
)
 
$
(17,771
)
Less: (Loss) income from discontinued operations, net of income taxes
(940
)
 
308

Loss from continuing operations, net of income taxes
(47,686
)
 
(18,079
)
Adjustments to reconcile net loss from continuing operations, net of income taxes to net cash used in operating activities:
 
 
 
Depreciation and amortization
13,777

 
8,790

Amortization of deferred financing costs and debt discount
2,875

 
1,987

Change in fair value of contingent consideration
—

 
102

Change in deferred income tax
1,223

 
352

Compensation under stock-based compensation plans
1,027

 
1,993

Loss (gain) on dispositions
685

 
(939
)
Loss on extinguishment of debt
13,453

 
—

Changes in assets and liabilities:
 
 
 
Receivables, net of bad debt expense
8,721

 
(1,281
)
Inventory
7,343

 
10,537

Prepaid expenses and other assets
5,469

 
322

Accounts payable
(12,753
)
 
(16,190
)
Amounts due to plan sponsors
1,027

 
62

Accrued interest
31

 
(192
)
Accrued expenses and other liabilities
714

 
(3,140
)
Net cash used in operating activities from continuing operations
(4,094
)
 
(15,676
)
Net cash used in operating activities from discontinued operations
(940
)
 
(5,913
)
Net cash used in operating activities
(5,034
)
 
(21,589
)
Cash flows from investing activities:
 
 
 
Purchases of property and equipment
(4,292
)
 
(5,466
)
Proceeds from dispositions
—

 
1,132

Investment in restricted cash
(5,055
)
 
—

Net cash used in investing activities
(9,347
)
 
(4,334
)
Cash flows from financing activities:
 
 
 
Proceeds from priming credit agreement, net of expenses
23,060

 
—

Fees attributable to extinguishment of debt
(311
)
 
—

Net proceeds from issuance of equity, net of issuance costs
20,776

 
83,267

Borrowings on long-term debt, net of expenses
294,446

 
—

Borrowings on revolving credit facility
563

 
45,000

Repayments on revolving credit facility
(55,863
)
 
(60,000
)
Principal payments of long-term debt
(236,770
)
 
(6,274
)
Repayments of capital leases
(401
)
 
(129
)
Other
(155
)
 
(93
)
Net cash provided by financing activities
45,345

 
61,771

Net change in cash and cash equivalents
30,964

 
35,848

Cash and cash equivalents - beginning of period
9,569

 
15,577

Cash and cash equivalents - end of period
$
40,533

 
$
51,425

DISCLOSURE OF CASH FLOW INFORMATION:
 
 
 
Cash paid during the period for interest
$
22,613

 
$
17,325

Cash paid during the period for income taxes
$
249

 
$
229

DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
 
 
 
Entry into capital lease
$
1,327

 
$
—


See accompanying Notes to Unaudited Consolidated Financial Statements.

5

BIOSCRIP, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1 — BASIS OF PRESENTATION
These Unaudited Consolidated Financial Statements should be read in conjunction with the Audited Consolidated Financial Statements, including the notes thereto, and other information included in the Annual Report on Form 10-K of BioScrip, Inc. and its wholly-owned subsidiaries (the “Company”) for the year ended December 31, 2016 (the “Annual Report”) filed with the U.S. Securities and Exchange Commission (“SEC”). These Unaudited Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information, and the instructions to Form 10-Q and Article 10 of Regulation S-X promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.
The information furnished in these Unaudited Consolidated Financial Statements reflects all adjustments, including normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the results for the interim periods presented. Operating results for the three months and six months ended June 30, 2017 require management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes and are not necessarily indicative of the results that may be expected for the full year ending December 31, 2017.
The Unaudited Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Business Combinations
Business combinations are accounted for using the acquisition method as of the acquisition date, the date on which control is transferred to the Company. Goodwill is measured at the acquisition date as the fair value of the consideration transferred, plus the fair value of the identifiable assets acquired and liabilities assumed. Transaction costs are expensed as incurred. Contingent consideration payable is measured at fair value at the acquisition date. Contingent consideration classified as equity is not re-measured and settlement is accounted for within equity.
Reclassifications
Prior period financial statement amounts have been reclassified to conform to current period presentation.
Cash and Cash Equivalents and Restricted Cash

Highly liquid investments with a maturity of three months or less when purchased are classified as cash equivalents. Restricted cash consists of cash balances held by financial institutions as collateral for letters of credit. These balances are reclassified to cash and cash equivalents when the underlying obligation is satisfied, or in accordance with the governing agreement. Restricted cash balances expected to become unrestricted during the next twelve months are recorded as current assets. As of June 30, 2017, the Company had a restricted cash balance, in a money market account, of $5.1 million to cash collateralize outstanding letters of credit.

Collectability of Accounts Receivable

The following table sets forth the aging of our net accounts receivable (net of allowance for contractual adjustments, and prior to allowance for doubtful accounts), aged based on date of service and categorized based on the three primary overall types of accounts receivable characteristics (in thousands):
 
 
June 30, 2017
 
December 31, 2016
 
 
0 - 180 days
 
Over 180 days
 
Total
 
0 - 180 days
 
Over 180 days
 
Total
Government
 
$
18,714

 
$
7,512

 
$
26,226

 
$
19,891

 
$
8,278

 
$
28,169

Commercial
 
84,190

 
23,589

 
107,779

 
97,744

 
19,848

 
117,592

Patient
 
5,195

 
9,540

 
14,735

 
3,955

 
6,825

 
10,780

Gross accounts receivable
 
$
108,099

 
$
40,641

 
148,740

 
$
121,590

 
$
34,951

 
156,541

Allowance for doubtful accounts
 
 
 
 
 
(45,651
)
 
 
 
 
 
(44,730
)
Net accounts receivable
 
 
 
 
 
$
103,089

 
 
 
 
 
$
111,811


6

Recent Accounting Pronouncements
In July 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-11—Earnings Per Share (Topic 260), Distinguishing Liabilities From Equity (Topic 480), and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features and II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. ASU 2017-11 eliminates the requirement that a down round feature precludes equity classification when assessing whether an instrument is indexed to an entity’s own stock. A freestanding equity-linked financial instrument no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. The effective date for ASU 2017-11 is for annual or any interim periods beginning after December 15, 2018. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements.
In May 2017, the FASB issued ASU 2017-09—Compensation–Stock Compensation (Topic 718): Scope of Modification Accounting. ASU 2017-09 modifies when a change to the terms or conditions of a share-based payment award must be accounted for as a modification. The new guidance requires modification accounting if the fair value, vesting condition or the classification of the award is not the same immediately before and after a change to the terms and conditions of the award. The effective date for ASU 2017-09 is for annual or any interim periods beginning after December 15, 2017. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements.
In January 2017, the FASB issued ASU 2017-04—Intangibles–Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. ASU 2017-04 modifies the accounting for goodwill impairment. The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The effective date for ASU 2017-04 is for annual or any interim periods beginning after December 15, 2019. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements.
In November 2016, the FASB issued ASU 2016-18—Statement of Cash Flows (Topic 230): Restricted Cash. ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The effective date for ASU 2016-18 is for annual or any interim periods beginning after December 15, 2017. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements.
In August 2016, the FASB issued ASU 2016-15—Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 provides guidance for eight specific cash flow issues with respect to how cash receipts and cash payments are classified in the statements of cash flows, with the objective of reducing diversity in practice. The effective date for ASU 2016-15 is for annual periods beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements.
In February 2016, the FASB issued ASU 2016-02—Leases (Topic 842), requiring lessees to recognize a right-of-use asset and a lease liability on the balance sheet for all leases with the exception of short-term leases. For lessees, leases will continue to be classified as either operating or finance leases in the income statement. The effective date of the new standard for public companies is for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition and requires application of the new guidance at the beginning of the earliest comparative period presented. The Company is evaluating the effect that the updated standard will have on its consolidated financial statements.
In May 2014, the FASB issued ASU 2014-09—Revenue from Contracts with Customers (Topic 606). The guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The FASB delayed the effective date to annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. In addition, in March and April 2016, the FASB issued new guidance intended to improve the operability and understandability of the implementation guidance on principal versus agent considerations. Both amendments permit the use of either a retrospective or cumulative effect transition method and are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017, with early application permitted. The Company has not elected early adoption and will apply the modified retrospective approach upon adoption. The Company continues to evaluate the impact of the adoption of the new revenue standard on its consolidated financial statements.

7

NOTE 2 — LOSS PER SHARE
The Company presents basic and diluted loss per share for its common stock, par value $0.0001 per share (“Common Stock”). Basic loss per share is calculated by dividing the net loss attributable to common stockholders of the Company by the weighted average number of shares of Common Stock outstanding during the period. Diluted loss per share is determined by adjusting the profit or loss attributable to stockholders and the weighted average number of shares of Common Stock outstanding adjusted for the effects of all dilutive potential common shares comprised of options granted, unvested restricted stocks, stock appreciation rights, warrants and Series A and Series C Preferred Stock (as defined below). Potential Common Stock equivalents that have been issued by the Company related to outstanding stock options, unvested restricted stock and warrants are determined using the treasury stock method, while potential common shares related to Series A and Series C Preferred Stock are determined using the “if converted” method.
The Company's Series A Convertible Preferred Stock, par value $0.0001 per share (the “Series A Preferred Stock”), and Series C Convertible Preferred Stock, par value $0.0001 per share (the “Series C Preferred Stock” and, together with the Series A Preferred Stock, the “Preferred Stock”), is considered a participating security, which means the security may participate in undistributed earnings with Common Stock. The holders of the Preferred Stock would be entitled to share in dividends, on an as-converted basis, if the holders of Common Stock were to receive dividends. The Company is required to use the two-class method when computing loss per share when it has a security that qualifies as a participating security. The two-class method is an earnings allocation formula that determines loss per share for each class of common stock and participating security according to dividends declared (or accumulated) and participation rights in undistributed earnings. In determining the amount of net earnings to allocate to common stockholders, earnings are allocated to both common and participating securities based on their respective weighted-average shares outstanding during the period. Diluted loss per share for the Company’s Common Stock is computed using the more dilutive of the two-class method or the if-converted method.
The following table sets forth the computation of basic and diluted loss per common share (in thousands, except for per share amounts):
 
Three Months Ended 
 June 30,
 
Six Months Ended 
 June 30,
 
2017
 
2016
 
2017
 
2016
Numerator:
 
 
 
 
 
 
 
Loss from continuing operations, net of income taxes
$
(28,695
)
 
$
(8,309
)
 
$
(47,686
)
 
$
(18,079
)
Income (loss) from discontinued operations, net of income taxes
(503
)
 
75

 
(940
)
 
308

Net loss
$
(29,198
)
 
$
(8,234
)
 
$
(48,626
)
 
$
(17,771
)
Accrued dividends on preferred stock
(2,303
)
 
(2,056
)
 
(4,517
)
 
(4,054
)
Deemed dividend on preferred stock
(175
)
 
(173
)
 
(349
)
 
(345
)
Loss attributable to common stockholders
$
(31,676
)
 
$
(10,463
)
 
$
(53,492
)
 
$
(22,170
)
 
 
 
 
 
 
 
 
Denominator - Basic and Diluted:
 

 
 

 
 

 
 

Weighted average common shares outstanding
121,189

 
73,186

 
119,993

 
70,978

 
 
 
 
 
 
 
 
Loss per Common Share:
 
 
 
 
 
 
 
Loss from continuing operations, basic and diluted
$
(0.26
)
 
$
(0.14
)
 
$
(0.44
)
 
$
(0.32
)
Loss from discontinued operations, basic and diluted
—

 
—

 
(0.01
)
 
—

Loss per common share, basic and diluted
$
(0.26
)
 
$
(0.14
)
 
$
(0.45
)
 
$
(0.32
)
The loss attributable to common stockholders is used as the basis of determining whether the inclusion of common stock equivalents would be anti-dilutive. Accordingly, the computation of diluted shares for the three months ended June 30, 2017 and 2016 excludes the effect of 18.3 million and 14.0 million shares, respectively, and the computation of the diluted shares for the six months ended June 30, 2017 and 2016 excludes the effect of 18.4 million and 15.5 million shares, respectively, issued in connection with the PIPE Transaction and the Rights Offering, as well as the 2017 Warrants (see Note 3 - Stockholders’ Deficit), stock options and restricted stock awards, as their inclusion would be anti-dilutive to loss attributable to common stockholders.

8

NOTE 3 — STOCKHOLDERS’ DEFICIT
Securities Purchase Agreement
On March 9, 2015, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with Coliseum Capital Partners L.P., a Delaware limited partnership, Coliseum Capital Partners II, L.P., a Delaware limited partnership, and Blackwell Partners, LLC, Series A, a Georgia limited liability company (collectively, the “PIPE Investors”). Pursuant to the terms of the Purchase Agreement, the Company issued and sold to the PIPE Investors in a private placement (the “PIPE Transaction”) an aggregate of (a) 625,000 shares of Series A Preferred Stock at a purchase price per share of $100.00, (b) 1,800,000 Class A warrants (the “Class A Warrants”), and (c) 1,800,000 Class B warrants (the “Class B Warrants” and, together with Class A Warrants, the “PIPE Warrants”), for gross proceeds of $62.5 million. The initial conversion price for the Series A Preferred Stock is $5.17. The PIPE Warrants may be exercised to acquire shares of Common Stock. Pursuant to an addendum (the “Warrant Addendum”), dated as of March 23, 2015, to the Warrant Agreement, dated as of March 9, 2015, with the PIPE Investors, the PIPE Investors paid the Company $0.5 million in the aggregate, and the per share exercise price of the Class A Warrants and Class B Warrants was set at $5.17 and $6.45, respectively, reduced from $5.295 to $5.17 and from $6.595 to $6.45, respectively.
Series A, Series B, and Series C Convertible Preferred Stock
In connection with the PIPE Transaction, the Company authorized 825,000 shares and issued 625,000 shares of Series A Preferred Stock at $100.00 per share. In connection with the Rights Offering (as defined below), the Company issued an additional 10,822 shares of Series A Preferred Stock at $100.00 per share. The Series A Preferred Stock may, at the option of the holder, be converted into Common Stock and receive a Liquidation Preference upon voluntary or involuntary liquidation, dissolution, or winding up of the Company as described in the Annual Report. The Company may pay a noncumulative cash dividend on each share of the Series A Preferred Stock as previously disclosed in the Annual Report. In the event the Company does not declare and pay a cash dividend, the Liquidation Preference of the Series A Preferred Stock will be increased to an amount equal to the Liquidation Preference in effect at the start of the applicable quarterly dividend period, plus an amount equal to such then applicable Liquidation Preference multiplied by 11.5% per annum.
On June 10, 2016, in order to allow the shares of Common Stock reserved for issuance for the conversion of the Series A Preferred Stock and exercise of the PIPE Warrants to be released from reservation and sold pursuant to the 2016 Equity Offering (see below), we entered into an Exchange Agreement with the PIPE Investors (the “Series B Exchange Agreement”) pursuant to which the PIPE Investors agreed:
i)
to exchange 614,177 shares of the existing Series A Preferred Stock for an identical number of shares of Series B Convertible Preferred Stock (the “Series B Preferred Stock”), which have the same terms as the Series A Preferred Stock previously described in the Company’s prior public filings, except that the terms of the Series B Preferred Stock include the authority of the holders of the Series B Preferred Stock to waive the requirement that the Company reserve a sufficient number of shares of Common Stock reserved at all times to allow for the conversion of the Series B Preferred Stock; and
ii)
to waive the requirement under the Warrant Agreement governing the PIPE Warrants to reserve 3,600,000 shares of our Common Stock for the exercise of the PIPE Warrants.
On June 14, 2016, the Company entered into another Exchange Agreement (the “Series C Exchange Agreement”) with the PIPE Investors, pursuant to which the PIPE Investors agreed to exchange their shares of Series B Preferred Stock issued pursuant to the Series B Exchange Agreement on a one for one basis for shares of Series C Preferred Stock.
Under the terms of the Series C Exchange Agreement, the PIPE Investors agreed to exchange 614,177 shares of the Series B Preferred Stock for an identical number of shares of Series C Preferred Stock, which have the same terms as the Series B Preferred Stock, except that the terms of the Series C Preferred Stock provide that the 11.5% per annum rate of non-cash dividends payable on the shares of the Series C Preferred Stock will be reduced based on the achievement by the Company of specified “Consolidated EBITDA” as defined in the Senior Credit Facilities. In addition, pursuant to the Series C Exchange Agreement, the PIPE Investors agreed to waive the requirement under the Warrant Agreement governing the PIPE Warrants held by the PIPE Investors to reserve 3,600,000 shares of Common Stock for the exercise of the PIPE Warrants.
As a result of the exchanges discussed above, there are, as of June 30, 2017, (a) 21,645 shares of Series A Preferred Stock outstanding, of which 10,823 shares are owned by the PIPE Investors, (b) no shares of Series B Preferred Stock outstanding, and (c) 614,177 shares of Series C Preferred Stock outstanding, all of which are owned by the PIPE Investors.
As of June 30, 2017, the Liquidation Preference of the Series A Preferred Stock and Series C Preferred Stock was $2.8 million and $79.9 million, respectively.

9

PIPE Warrants
In connection with the PIPE Transaction, the Company issued 1,800,000 Class A Warrants and 1,800,000 Class B Warrants which may be exercised to acquire shares of Common Stock. The rights and terms of the Class A Warrants and the Class B Warrants are identical except for the exercise price. Pursuant to the Warrant Addendum with the PIPE Investors, the PIPE Investors paid the Company $0.5 million in the aggregate, and the per share exercise price of the Class A Warrants and Class B Warrants was set at $5.17 and $6.45, respectively, reduced from $5.295 to $5.17 and from $6.595 to $6.45, respectively.
The Company entered into a registration rights agreement, as amended (the “Registration Rights Agreement”), with the PIPE Investors that, among other things and subject to certain exceptions, requires the Company, upon the request of the PIPE Investors, to register the Common Stock of the Company issuable upon conversion of the PIPE Investors’ Series A Preferred Shares, the Series C Preferred Shares, or exercise of the PIPE Warrants. Pursuant to the terms of the Registration Rights Agreement, the costs incurred in connection with such registrations will be borne by the Company. As provided under the Registration Rights Agreement, the Company on April 1, 2016 filed a shelf registration statement on Form S-3 under the Securities Act of 1933, as amended (the “Securities Act”), to register, among other things, the Common Stock of the Company issuable upon conversion of the PIPE Investors’ Series A and Series C Preferred Shares.
Rights Offering
On June 30, 2015, the Company commenced a rights offering (the “Rights Offering”) pursuant to which the Company distributed subscription rights to purchase units consisting of (1) Series A Preferred Stock, each share convertible into shares of Common Stock at a conversion price of $5.17 per share, (2) Class A warrants to purchase one share of Common Stock at a price of $5.17 per share (the “Public Class A Warrants”), and (3) Class B warrants to purchase one share of Common Stock at a price of $6.45 per share (the “Public Class B Warrants” and, together with the Public Class A Warrants, the “Public Warrants”). The Rights Offering expired on July 27, 2015 and was completed on July 31, 2015. Stockholders of the Company exercised subscription rights to purchase 10,822 units, consisting of an aggregate of 10,822 shares of the Series A Preferred Stock, 31,025 Public Class A Warrants, and 31,025 Public Class B Warrants, at a subscription price of $100.00 per unit. Pursuant to the Rights Offering, the Company raised gross proceeds of approximately $1.1 million.
With the exception of the expiration date, the Class A Warrants issued pursuant to the PIPE Transaction, as amended by the Warrant Addendum, have the same terms as the Public Class A Warrants issued pursuant to the Rights Offering. Similarly, with the exception of the expiration date, the Class B Warrants issued pursuant to the PIPE Transaction, as amended by the Warrant Addendum, have the same terms as the Public Class B Warrants issued pursuant to the Rights Offering.
Carrying Value of Series A Preferred Stock
As of June 30, 2017, the following values were accreted pursuant to the terms of the Exchange Agreement, dated as of June 10, 2016, among the Company and the signatories thereto and recorded as a reduction of additional paid in capital in Stockholders’ Deficit and a deemed dividend on the Unaudited Consolidated Statements of Operations. In addition, dividends were accrued at 11.5% from the date of issuance to June 30, 2017. The following table sets forth the activity recorded during the six months ended June 30, 2017 related to the Series A Preferred Stock (in thousands):
Series A Preferred Stock carrying value at December 31, 2016
$
2,462

Accretion of discount related to issuance costs
26

Dividends recorded through June 30, 2017 1
151

Series A Preferred Stock carrying value June 30, 2017
$
2,639

1 Dividends recorded reflect the increase in the Liquidation Preference associated with unpaid dividends.

10

Carrying Value of Series C Preferred Stock
As of June 30, 2017, the following values were accreted pursuant to the terms of the Exchange Agreement, dated as of June 16, 2016, among the Company and the signatories thereto and recorded as a reduction of additional paid in capital in Stockholders’ Deficit and a deemed dividend on the Unaudited Consolidated Statements of Operations. In addition, dividends were accrued at 11.5% from the date of issuance to June 30, 2017. The following table sets forth the activity recorded during the six months ended June 30, 2017 related to the Series C Preferred Stock (in thousands):
Series C Preferred Stock carrying value at December 31, 2016
$
69,540

Accretion of discount related to issuance costs
323

Dividends recorded through June 30, 2017 1
4,366

Series C Preferred Stock carrying value June 30, 2017
$
74,229


1 Dividends recorded reflect the increase in the Liquidation Preference associated with unpaid dividends.
Shelf Registration Statement
The Company filed a shelf registration statement on Form S-3 under the Securities Act on April 1, 2016, which was declared effective May 2, 2016 (the “2016 Shelf”). Under the 2016 Shelf at the time of effectiveness, the Company had the ability to raise up to $200.0 million, in one or more transactions, by selling Common Stock, preferred stock, debt securities, warrants, units and rights.
2016 Equity Offering
On June 22, 2016 the Company completed an underwritten public offering of 45,200,000 shares of Common Stock, including 5,200,000 shares of Common Stock issued upon the underwriters’ full exercise of the over-allotment option, at a public offering price of $2.00 per share, less underwriting discounts and commissions and offering expenses payable by us (the “2016 Equity Offering”). The Company received net proceeds of approximately $83.3 million from the 2016 Equity Offering, after deducting underwriting discounts and commissions and offering costs.
A portion of the net proceeds from the 2016 Equity Offering was used to fund the Cash Consideration (as defined below) and pay fees and expenses in connection with the closing of the Home Solutions Transaction (see below).
Home Solutions Transaction
On September 9, 2016, the Company acquired substantially all of the assets and assumed certain liabilities of HS Infusion Holdings, Inc. (“Home Solutions”) and its subsidiaries (the “Home Solutions Transaction”) pursuant to an Asset Purchase Agreement dated June 11, 2016 (as amended, the “Home Solutions Agreement”), by and among Home Solutions, a Delaware corporation, certain subsidiaries of Home Solutions, the Company and HomeChoice Partners, Inc., a Delaware corporation. Home Solutions, a privately held company, provides home infusion and home nursing products and services to patients suffering from chronic and acute medical conditions. On June 16, 2016, the Company, HomeChoice Partners, Inc. and Home Solutions entered into an amendment to the Home Solutions Agreement (the “First Amendment”), which modified the terms of the consideration payable by the Company to Home Solutions thereunder. On September 2, 2016, the same parties entered into a second amendment to the Home Solutions Agreement (the “Second Amendment”), which amended the Home Solutions Agreement to eliminate the condition to closing that the Company receive stockholder approval to increase its authorized share capital (the “Charter Amendment”) and facilitated the timely consummation of the Home Solutions Transaction. The Second Amendment instead provided that the Company will hold a stockholder meeting after the closing of the Home Solutions Transaction to seek stockholder approval of the Charter Amendment, and if the approval is not obtained at the first special meeting, the Company will submit the proposal on a twice per year basis beginning in 2017, at either the annual meeting or a special meeting of stockholders. The Charter Amendment was approved at a special meeting of stockholders held on November 30, 2016.
The aggregate consideration paid by the Company in the Home Solutions Transaction was equal to (i) $67.5 million in cash (the “Cash Consideration”); plus (ii) (a) 3,750,000 shares of Company common stock (the “Transaction Closing Equity Consideration”) and (b) the right to receive contingent equity securities of the Company, in the form of restricted shares of Company common stock (the “RSUs”), issuable in two tranches, Tranche A and Tranche B, with different vesting conditions (collectively, the “Contingent Shares”). The number of shares of Company common stock in Tranche A is 3.1 million and the number of shares of Company common stock in Tranche B is 4.0 million, each subject to certain vesting conditions. Upon close of the Home Solutions Transaction the RSUs had no intrinsic value, but are reported in our consolidated financial statements at their estimated fair value at the date of issuance. The Home Solutions Agreement provides Home Solutions with certain customary registration

11

rights that required us, within 30 days following the closing of the Home Solutions Transaction, to file a registration statement for the selling stockholder’s resale of the Transaction Closing Equity Consideration and the Contingent Shares pursuant to the Securities Act. The Company filed the registration statement on October 7, 2016 and it was declared effective on October 27, 2016.
The Company will issue the shares of our Common Stock issuable to Home Solutions pursuant to the RSUs in Tranche A promptly, and in any event within five business days, following the earlier of (a) the closing price of our Common Stock, as reported by NASDAQ, averaging $4.00 per share or above over 20 consecutive trading days during the period beginning on September 9, 2016 and ending December 31, 2019, or (b) a change of control that occurs on or prior to December 31, 2017 or a change of control thereafter but on or prior to December 31, 2019, pursuant to which the consideration payable per share equals or exceeds $4.00 per share. The Company will issue the shares of our Common Stock issuable to Home Solutions pursuant to the RSUs in Tranche B promptly, and in any event within five business days, following the earlier of (a) the closing price of our Common Stock, as reported by NASDAQ, averaging $5.00 per share or above over 20 consecutive trading days during the period beginning on September 9, 2016 and ending December 31, 2019, or (b) a change of control that occurs on or prior to December 31, 2017, or a change of control thereafter but on or prior to December 31, 2019, pursuant to which the consideration payable per share equals or exceeds $5.00 per share. The Home Solutions Agreement provides for a cash settlement option related to the RSUs, effective June 15, 2021, if, and only if, authorized shares are unavailable when the vesting conditions of Tranche A and Tranche B are met. At the date of acquisition, the Company did not have sufficient authorized shares available to satisfy the issuance of Tranche A and Tranche B RSUs and, accordingly, recognized a liability for the fair value of the contingent consideration. As of November 30, 2016, upon approval of the Charter Amendment, the Company had sufficient authorized shares available should the vesting conditions be met and the RSUs become issuable. The liability was reclassified to equity and a gain on the change in the fair value of the RSUs was recognized as of November 30, 2016. On March 13, 2017, the Company filed with the SEC a Registration Statement on Form S-3 to register the Contingent Shares and it was declared effective on April 18, 2017.
The Cash Consideration and the Transaction Closing Equity Consideration were paid at closing and were funded by cash on-hand and borrowings from our Revolving Credit Facility.
First Quarter 2017 Private Placement
On March 1, 2017, the Company entered into a Stock Purchase Agreement (the “First Quarter Stock Purchase Agreement”) with Venor Capital Master Fund Ltd., Map 139 Segregated Portfolio of LMA SPC, Venor Special Situations Fund II LP and Trevithick LP (the “First Quarter Stockholders”). Pursuant to the First Quarter Stock Purchase Agreement, the Company sold an aggregate of 3.3 million shares of its common stock (the “First Quarter Shares”) for aggregate gross proceeds of approximately $5.1 million in a private placement transaction (the “First Quarter 2017 Private Placement”). The purchase price for each Share was $1.5366, which was negotiated between the Company and the First Quarter Stockholders based on the volume-weighted average price of the Company's common stock on the NASDAQ Global Market on March 1, 2017.
In connection with the First Quarter 2017 Private Placement, the Company entered into a Registration Rights Agreement (the “First Quarter 2017 Registration Rights Agreement”) with the First Quarter Stockholders. Pursuant to the First Quarter 2017 Registration Rights Agreement, the Company agreed to prepare and file a registration statement with the SEC within ten days of the date it files its annual report on Form 10-K for the fiscal year ended December 31, 2016, for purposes of registering the resale of the First Quarter Shares and any shares of common stock issued as a dividend or other distribution with respect to the First Quarter Shares.
As provided under the First Quarter 2017 Registration Rights Agreement, the Company, on March 13, 2017, filed a shelf registration statement on Form S-3 under the Securities Act to register the First Quarter Shares and it was declared effective April 18, 2017.
Proceeds from the First Quarter 2017 Private Placement were used for working capital and general corporate purposes.
2017 Warrants
In connection with the Second Lien Note Facility (as defined below), the Company also issued warrants (the “2017 Warrants”) to the purchasers of the Second Lien Notes (as defined below) pursuant to a Warrant Purchase Agreement dated as of June 29, 2017 (the “Warrant Purchase Agreement”). The 2017 Warrants entitle the purchasers of the Warrants to purchase shares of Common Stock, representing at the time of any exercise of the 2017 Warrants an equivalent number of shares equal to 4.99% of the Common Stock of the Company on a fully diluted basis, subject to the terms of the Warrant Agreement governing the Warrants, dated as of June 29, 2017 (the “Warrant Agreement”); provided, however, the Warrants may not be converted to the extent that, after giving effect to such conversion, the holders of the 2017 Warrants would beneficially own, in the aggregate, in excess of (i) 19.99% of the shares of Common Stock outstanding as of June 29, 2017 (the “Closing Date”) minus (ii) the shares of Common Stock that

12

were sold pursuant to the Second Quarter 2017 Private Placement (as defined below) (the “Conversion Cap”). The Conversion Cap will not apply to the 2017 Warrants if the Company obtains the approval of its stockholders for the removal of the Conversion Cap, which the Company is required to take certain steps to attempt to obtain, subject to the terms of the Warrant Agreement.
The 2017 Warrants have a 10-year term and an initial exercise price of $2.00 per share, and may be exercised by payment of the exercise price in cash or surrender of shares of Common Stock into which the Warrants are being converted in an aggregate amount sufficient to pay the exercise price.  The exercise price and the number of shares that may be acquired upon exercise of the 2017 Warrants is subject to adjustment in certain situations, including price based anti-dilution protection whereby, subject to certain exceptions, if the Company later issues Common Stock or certain Common Stock Equivalents (as defined in the Warrant Agreement) at a price less than either the then-current market price per share or exercise price of the 2017 Warrants, then the exercise price will be decreased and the percentage of shares of Common Stock issuable upon exercise of the Warrants will remain the same, giving effect to such issuance. Additionally, the 2017 Warrants have standard anti-dilution protections if the Company effects a stock split, subdivision, reclassification or combination of its Common Stock or fixes a record date for the making of a dividend or distribution to stockholders of cash or certain assets. Upon the occurrence of certain business combinations the 2017 Warrants will be converted into the right to acquire shares of stock or other securities or property (including cash) of the successor entity.
Second Quarter 2017 Private Placement
On June 29, 2017, the Company entered into a Stock Purchase Agreement (the “Second Quarter Stock Purchase Agreement”) with a fund managed by Ares Management L.P. (“Ares” or the “Second Quarter Stock Purchaser”). Pursuant to the terms of the Second Quarter Stock Purchase Agreement, the Company issued and sold to the Second Quarter Stock Purchaser in a private placement (the “Second Quarter 2017 Private Placement”) 6,359,350 shares of Common Stock (the “Second Quarter Shares”) at a price of $2.50 per share, for proceeds of approximately $15.9 million, net of $0.2 million in associated costs.
Second Quarter Registration Rights Agreement
In connection with the 2017 Warrants and the Second Quarter 2017 Private Placement, the Company entered into a Registration Rights Agreement (the “Second Quarter 2017 Registration Rights Agreement”) with the holders of the 2017 Warrants and the Second Quarter Stock Purchaser. Pursuant to the Second Quarter 2017 Registration Rights Agreement, subject to certain exceptions, the Company is required, upon the request of the Second Quarter Stock Purchaser and holders of the 2017 Warrants, to register the resale of the Second Quarter Shares and the shares of Common Stock issuable upon exercise of the 2017 Warrants. Pursuant to the terms of the Second Quarter 2017 Registration Rights Agreement, these registration rights will not become effective until twelve months after the Closing Date, and the costs incurred in connection with such registrations will be borne by the Company.
NOTE 4 — ACQUISITIONS
On September 9, 2016, the Company completed the Home Solutions Transaction pursuant to the Home Solutions Agreement. The aggregate consideration paid by the Company in the Home Solutions Transaction was equal to (i) the Cash Consideration; plus (ii)(a) the Transaction Closing Equity Consideration and (b) the RSUs, issuable in two tranches, Tranche A and Tranche B, with different vesting conditions. The number of shares of Company common stock in Tranche A is 3.1 million and the number of shares of Company common stock in Tranche B is 4.0 million, each subject to vesting conditions (see Note 3 - Stockholders’ Deficit). Upon close of the Home Solutions Transaction the RSUs had no intrinsic value, but are reported in our consolidated financial statements at their estimated fair value at the date of issuance. Upon approval of the Charter Amendment on November 30, 2016, the date at which sufficient shares were available should the RSUs vest and become issuable, the liability was remeasured to its then-current fair value and reclassified to equity.
The following table sets forth the consideration transferred in connection with the acquisition of Home Solutions as of September 9, 2016 (in thousands):
Cash
$
67,516

Equity issued at closing
9,938

Capital lease obligation assumed
301

Fair value of contingent consideration
15,400

Total consideration
$
93,155


13

The following table sets forth the preliminary estimate of fair value of the assets acquired and liabilities assumed upon acquisition of Home Solutions (in thousands):
Accounts receivable
$
11,956

Inventories
3,199

Prepaids and other assets
852

Total current assets
$
16,007

Property and equipment
4,651

Goodwill
57,218

Managed care contracts
24,700

Licenses
5,400

Trade name
1,800

Non-compete agreements
200

Other non-current assets
891

Total assets
$
110,867

Accounts payable
14,576

Accrued liabilities
3,136

Current liabilities
$
17,712

Total fair value of cash and contingent consideration
$
93,155

The excess of the purchase price over the fair value of the tangible and identifiable intangible assets acquired and liabilities assumed in the acquisition was allocated to goodwill. The value of the goodwill represents the value the Company expects to be created by combining the operations of the companies, including the ability to cross-sell its services on a national basis with an expanded footprint in home infusion and the opportunity to focus on higher margin therapies.
In accordance with ASC Topic 805 Business Combinations (“ASC 805”), the allocation of the purchase price is subject to adjustment during the measurement period after the closing date (September 9, 2016) when additional information on assets and liability valuations becomes available. The Company has not finalized its valuation of certain assets and liabilities recorded pursuant to the acquisition including intangible assets and contingent consideration. Thus, the provisional measurements recorded are subject to change. Any changes will be recorded as adjustments to the fair value of the assets and liabilities with residual amounts allocated to goodwill.
Under the Home Solutions Agreement, the Company did not purchase, among other things, any accounts receivable associated with governmental payors. However, the Home Solutions Agreement stipulates that collections of government receivables, as of the first anniversary of the closing date, in an amount less than the amount estimated as government receivables in the Closing Certificate, must be paid to the seller. The Company continues to evaluate the collectability of the government receivables and will record a liability in the event collections fall short of the guarantee.
NOTE 5 — RESTRUCTURING, ACQUISITION, INTEGRATION, AND OTHER EXPENSES, NET
Restructuring, acquisition, integration and other expenses include non-operating costs associated with restructuring, acquisition, and integration initiatives such as employee severance costs, certain legal and professional fees, training costs, redundant wage costs, impacts recorded from the change in contingent consideration obligations, and other costs related to contract terminations and closed branches/offices.

14

Restructuring, acquisition, integration, and other expenses, net in the Unaudited Consolidated Statements of Operations for the three months and six months ended June 30, 2017 and 2016 consisted of the following (in thousands):
 
Three Months Ended 
 June 30,
 
Six Months Ended 
 June 30,
 
2017
 
2016
 
2017
 
2016
Restructuring expense
$
3,648

 
$
1,316

 
$
6,854

 
$
3,932

Acquisition and integration expense
263

 
2,924

 
280

 
2,924

Change in fair value of contingent consideration
—

 
51

 
—

 
102

Total restructuring, acquisition, integration, and other expense, net
$
3,911

 
$
4,291

 
$
7,134

 
$
6,958

NOTE 6 — DEBT
As of June 30, 2017 and December 31, 2016, the Company’s debt consisted of the following (in thousands):
 
June 30,
2017
 
December 31,
2016
Senior Credit Facilities
$
—

 
$
265,507

First Lien Note Facility, net of unamortized discount
198,000

 
—

Second Lien Note Facility, net of unamortized discount
82,931

 
—

2021 Notes, net of unamortized discount
197,008

 
196,670

Capital leases
3,134

 
2,209

Less: Deferred financing costs
(3,668
)
 
(12,452
)
Total Debt
477,405

 
451,934

Less: Current portion
(1,731
)
 
(18,521
)
Long-term debt, net of current portion
$
475,674

 
$
433,413

Debt Facilities
The Company was previously obligated under (i) a senior secured first-lien revolving credit facility in an aggregate principal amount of $75.0 million (the “Revolving Credit Facility”), (ii) a senior secured first-lien term loan B in an aggregate principal amount of $250.0 million (the “Term Loan B Facility”) and (iii) a senior secured first-lien delayed draw term loan B in an aggregate principal amount of $150.0 million (the “Delayed Draw Term Loan Facility” and, together with the Revolving Credit Facility and the Term Loan B Facility, the “Senior Credit Facilities”) with SunTrust Bank (“SunTrust”), Jefferies Finance LLC and Morgan Stanley Senior Funding, Inc., originally entered on July 31, 2013 and amended from time to time.
On January 6, 2017, the Company entered into a credit agreement (the “Priming Credit Agreement” and, together with the Senior Credit Facilities, the “Prior Credit Agreements”) with certain existing lenders under the Senior Credit Facilities and SunTrust, as administrative agent for itself and the lenders. The Priming Credit Agreement provided an aggregate borrowing commitment of $25.0 million, which was fully drawn at closing.
On June 29, 2017 (the “Closing Date”), the Company entered into (i) a first lien note purchase agreement (the “First Lien Note Facility”), among the Company, which is the issuer under the agreement, the financial institutions and note purchasers from time to time party to the agreement (the “First Lien Note Purchasers”), and Wells Fargo Bank, National Association, in its capacity as collateral agent for itself and the First Lien Note Purchasers (the “First Lien Collateral Agent”), pursuant to which the Company issued first lien senior secured notes in an aggregate principal amount of $200.0 million (the “First Lien Notes”); and (ii) a second lien note purchase agreement (the “Second Lien Note Facility” and, together with the First Lien Note Facility, the “Notes Facilities”) among the Company, which is the issuer under the agreement, the financial institutions and note purchasers from time to time party to the agreement (the “Second Lien Note Purchasers”), and Wells Fargo Bank, National Association, in its capacity as collateral agent for itself and the Second Lien Note Purchasers (the “Second Lien Collateral Agent” and, together with the First Lien Collateral Agent, the “Collateral Agent”), pursuant to which the Company (a) issued second lien senior secured notes in an aggregate initial principal amount of $100.0 million (the “Initial Second Lien Notes”) and (b) has the ability to draw upon the Second Lien Note Facility and issue second lien delayed draw senior secured notes in an aggregate initial principal amount of $10.0 million for a period of 18 months after the Closing Date, subject to certain terms and conditions (the “Second Lien Delayed Draw Notes” and, together with the Initial Second Lien Notes, the “Second Lien Notes”; the Second Lien Notes, together with the First Lien Notes, the “Notes”). Funds managed by Ares are acting as lead purchasers for the Notes Facilities.

15

The Company used the proceeds of the sale of the First Lien Notes and the Initial Second Lien Notes to repay in full all amounts outstanding under the Prior Credit Agreements and extinguished the liability. Each of the Prior Credit Agreements was terminated following such repayment. The Company used the remaining proceeds of $15.9 million, net of $0.2 million in issuance costs, from the Notes Facilities and the Second Quarter 2017 Private Placement for working capital and general corporate purposes.
The First Lien Notes accrue interest, payable monthly in arrears, at a floating rate or rates equal to, at the option of the Company, (i) the base rate (defined as the highest of the Federal Funds Rate plus 0.5% per annum, the Prime Rate as published by The Wall Street Journal and the one-month London Interbank Offered Rate (“LIBOR”) (subject to a 1.0% floor) plus 1.0%), or (ii) the one-month LIBOR rate (subject to a 1.0% floor), plus a margin of 6.0% if the base rate is selected or 7.0% if the LIBOR Option is selected. The First Lien Notes mature on August 15, 2020, provided that if the Company’s existing 8.875% Senior Notes due 2021 (the “2021 Notes”) are refinanced prior to August 15, 2020, then the scheduled maturity date of the First Lien Notes shall be June 30, 2022.
The First Lien Notes will amortize in equal quarterly installments equal to 0.625% of the aggregate principal amount of the First Lien Note Facility, commencing on September 30, 2019, and on the last day of each third month thereafter, with the balance payable at maturity. The First Lien Notes are pre-payable at the Company’s option at specified premiums to the principal amount that will decline over the term of the First Lien Note Facility. If the First Lien Notes are prepaid prior to the second anniversary of the Closing Date, the Company will be required to pay a make-whole premium based on the present value (using a discount rate based on the specified treasury rate plus 50 basis points) of all remaining interest payments on the First Lien Notes being prepaid prior to the second anniversary of the Closing Date, plus 4.0% of the principal amount of First Lien Notes being prepaid. On or after the second anniversary of the Closing Date, the prepayment premium is 4.0%, which declines to 2.0% on or after the third anniversary of the Closing Date, and declines to 0.0% on or after the fourth anniversary of the Closing Date. At any time, the Company may pre-pay up to $50.0 million in aggregate principal amount of the First Lien Notes from internally generated cash without incurring any make-whole or prepayment premium. The occurrence of certain events of default may increase the applicable rate of interest by 2.0% and could result in the acceleration of the Company’s obligations under the First Lien Note Facility prior to stated maturity and an obligation of the Company to pay the full amount of its obligations under the First Lien Note Facility.
The First Lien Note Facility contains customary events of default that include, among others, non-payment of principal, interest or fees, violation of covenants, inaccuracy of representations and warranties, bankruptcy and insolvency events, material judgments, cross-defaults to material indebtedness and events constituting a change of control. In addition, the obligations under the First Lien Note Facility will be guaranteed by joint and several guarantees from the Company’s subsidiaries.
In connection with the First Lien Note Facility, the Company, its subsidiaries and the First Lien Collateral Agent entered into a First Lien Guaranty and Security Agreement, dated as of June 29, 2017 (the “First Lien Guaranty and Security Agreement”). Pursuant to the First Lien Guaranty and Security Agreement, the obligations under the First Lien Notes will be secured by first priority liens on, and security interests in, substantially all of the assets of the Company and its subsidiaries.
The Second Lien Notes accrue interest, payable monthly in arrears, at a floating rate or rates equal to, at the option of the Company, (i) one-month LIBOR (subject to a 1.25% floor) plus 9.25% per annum in cash, (ii) one-month LIBOR (subject to a 1.25% floor) plus 11.25% per annum, which amount will be capitalized on each interest payment date, or (iii) one-month LIBOR (subject to a 1.25% floor) plus 10.25% per annum, of which one-half LIBOR plus 4.625% per annum will be payable in cash and one-half LIBOR plus 5.625% per annum will be capitalized on each interest payment date, provided that, in each case, if any permitted refinancing indebtedness with which the 2021 Notes are refinanced requires or permits the payment of cash interest, all of the interest on the Second Lien Notes shall be paid in cash. The Second Lien Notes mature on August 15, 2020, provided that if the 2021 Notes are refinanced prior to August 15, 2020, then the scheduled maturity date of the Second Lien Notes shall be June 30, 2022.
In connection with the Second Lien Note Facility, the Company also issued warrants (the “2017 Warrants”) to the purchasers of the Second Lien Notes pursuant to a Warrant Purchase Agreement dated as of June 29, 2017 (the “Warrant Purchase Agreement”). The 2017 Warrants entitle the purchasers of the Warrants to purchase shares of Common Stock, representing at the time of any exercise of the 2017 Warrants an equivalent number of shares equal to 4.99% of the Common Stock of the Company on a fully diluted basis, subject to the terms of the Warrant Agreement governing the Warrants, dated as of June 29, 2017 (the “Warrant Agreement”). The 2017 Warrants, considered a derivative and subject to remeasurement at each reporting period, are reflected in other non-current liabilities at a fair value of $16.9 million.
The Second Lien Notes are not subject to scheduled amortization installments. The Second Lien Notes are pre-payable at the Company’s option at specified premiums to the principal amount that will decline over the term of the Second Lien Note Facility. If the Second Lien Notes are prepaid prior to the third anniversary of the Closing Date, the Company will need to pay a make-whole premium based on the present value (using a discount rate based on the specified treasury rate plus 50 basis points) of all

16

remaining interest payments on the Second Lien Notes being prepaid prior to the third anniversary of the Closing Date, plus 4.0% of the principal amount of Second Lien Notes being prepaid. On or after the third anniversary of the Closing Date, the prepayment premium is 4.0%, which declines to 2.0% on or after the fourth anniversary of the Closing Date, and declines to 0.0% on or after the fifth anniversary of the Closing Date. The occurrence of certain events of default may increase the applicable rate of interest by 2.0% and could result in the acceleration of the Company’s obligations under the Second Lien Note Facility prior to stated maturity and an obligation of the Company to pay the full amount of its obligations under the Second Lien Note Facility.
The Second Lien Note Facility contains customary events of default that include, among others, non-payment of principal, interest or fees, violation of covenants, inaccuracy of representations and warranties, bankruptcy and insolvency events, material judgments, cross-defaults to material indebtedness and events constituting a change of control. In addition, the obligations under the Second Lien Note Facility will be guaranteed by joint and several guarantees from the Company’s subsidiaries.
In connection with the Second Lien Note Facility, the Company, its subsidiaries and the Second Lien Collateral Agent entered into a Second Lien Guaranty and Security Agreement, dated as of June 29, 2017 (the “Second Lien Guaranty and Security Agreement”). Pursuant to the Second Lien Guaranty and Security Agreement, the obligations under the Second Lien Notes will be secured by second priority liens on, and security interests in, substantially all of the assets of the Company and its subsidies.
In connection with the First Lien Note Facility and the Second Lien Note Facility, the Company, the First Lien Collateral Agent and the Second Lien Collateral Agent, entered into an intercreditor agreement containing customary provisions to, among other things, subordinate the lien priority of the liens granted under the Second Lien Note Facility to the liens granted under the First Lien Note Facility.
2021 Notes
On February 11, 2014, the Company issued $200.0 million aggregate principal amount of the 2021 Notes. The 2021 Notes are senior unsecured obligations of the Company and are fully and unconditionally guaranteed by all existing and future subsidiaries of the Company.
Interest on the 2021 Notes accrues at a fixed rate of 8.875% per annum and is payable in cash semi-annually on February 15 and August 15 of each year. The debt discount of $5.0 million at issuance is being amortized as interest expense through maturity which will result in the accretion over time of the outstanding debt balance to the principal amount. The 2021 Notes are the Company’s senior unsecured obligations and rank equally in right of payment with all of its other existing and future senior unsecured indebtedness and senior in right of payment to all of its existing and future subordinated indebtedness.
The 2021 Notes are guaranteed on a full, joint and several basis by each of the Company’s existing and future domestic restricted subsidiaries that is a borrower under any of the Company’s credit facilities or that guarantees any of the Company’s debt or that of any of its restricted subsidiaries, in each case incurred under the Company’s credit facilities. As of June 30, 2017, the Company does not have any independent assets or operations, and as a result, its direct and indirect subsidiaries (other than minor subsidiaries), each being 100% owned by the Company, are fully and unconditionally, jointly and severally, providing guarantees on a senior unsecured basis to the 2021 Notes.
Fair Value of Financial Instruments
The following details our financial instruments where the carrying value and the fair value differ (in thousands):
Financial Instrument
 
Carrying Value as of June 30, 2017
 
Markets for Identical Item (Level 1)
 
Significant Other Observable Inputs (Level 2)
 
Significant Unobservable Inputs (Level 3)
First Lien Note Facility
 
$
198,000

 
$
—

 
$
198,000

 
$
—

Second Lien Note Facility
 
82,931

 
—

 
82,931

 
—

2017 Warrants
 
16,908

 
—

 
16,908

 
—

2021 Notes
 
197,008

 
—

 
178,109

 
—

Total
 
$
494,847

 
$
—

 
$
475,948

 
$
—


17

The fair value hierarchy for disclosure of fair value measurements is as follows:
Level 1:  Quoted prices (unadjusted) in active markets for identical assets or liabilities.
Level 2:  Quoted prices, other than quoted prices included in Level 1, which are observable for the assets or liabilities, either directly or indirectly.
Level 3:  Inputs that are unobservable for the assets or liabilities. Financial assets with carrying values approximating fair value include cash and cash equivalents and accounts receivable. Financial liabilities with carrying values approximating fair value include accounts payable and capital leases. The carrying value of these financial assets and liabilities approximates fair value due to their short maturities.
NOTE 7 — COMMITMENTS AND CONTINGENCIES
Legal Proceedings
Breach of Contract Litigation in the Delaware Court of Chancery
On November 3, 2015, Walgreen Co. and various affiliates (“Walgreens”) filed a lawsuit in the Delaware Court of Chancery against the Company and certain of its subsidiaries (collectively, the “Defendants”). The complaint alleges that the Company breached certain non-compete provisions contained in the Community Pharmacy and Mail Business Purchase Agreement dated as of February 1, 2012, by and among Walgreens and certain subsidiaries and the Company and certain subsidiaries. The complaint seeks both money damages and injunctive relief. On December 7, 2015, the Defendants filed a motion to dismiss the case. Walgreens filed an answering brief on January 11, 2016 and the Defendants filed a reply on January 25, 2016. On March 11, 2016, the Court held oral argument on the Company’s motion to dismiss and granted the motion, holding that Walgreens’ breach of contract claims for money damages must be resolved in accordance with the 2012 Purchase Agreement’s alternative dispute resolution procedure. On March 15, 2016, Walgreens informed the Court that it would not be pursuing any claims for injunctive relief in the Court at that time, but instead would engage in the required alternative dispute resolution procedure. Walgreens requested that the Court keep the case open pending the results of that process. On March 16, 2016, the Court stayed the lawsuit and removed the trial from its calendar, but did not grant Walgreens any other relief or enjoin the Company from taking any action. On December 8, 2016, the parties submitted the dispute to an arbitrator. On December 28, 2016, the arbitrator rendered its decision, finding that the Company had not violated the non-compete, except for certain limited sales of oral oncology, HIV and transplant pharmaceuticals, constituting approximately 3 percent of the total sales that Walgreens claimed were made in violation of the agreement. The arbitrator also concluded that Walgreens was not entitled to recover its lost profits or lost revenues as a result of any such sales. Despite that ruling, the arbitrator awarded Walgreens $5.8 million in damages, or approximately 20 percent of the total amount requested. Such amount is included as a component of Accrued expenses and other current liabilities within the Consolidated Balance Sheets as of June 30, 2017 (unaudited) and December 31, 2016. The Company believes that arbitrator’s damages award ignored applicable law, contradicted the arbitrator’s liability findings and exceeded the scope of the arbitrator’s authority in light of both parties’ arbitration submissions. Accordingly, on January 13, 2017, the Company filed a motion to vacate the arbitration award. On February 10, 2017, Walgreens opposed the Company’s motion and filed a motion to confirm the arbitration award and for other relief. On July 19, 2017, the Court confirmed the arbitration award and denied Walgreens’ request for injunctive relief. The Company intends to continue to vigorously defend itself, but the Company can provide no assurance that any continued challenge to the award will be successful.
Derivative Lawsuit in the Delaware Court of Chancery
On May 7, 2015, a derivative complaint was filed in the Delaware Court of Chancery (the “Derivative Complaint”) by the Park Employees’ & Retirement Board Employees’ Annuity & Benefit Fund of Chicago (the “Derivative Plaintiff”). The Derivative Complaint names as defendants certain current and former directors of the Company, consisting of Richard M. Smith, Myron Holubiak, Charlotte Collins, Samuel Frieder, David Hubers, Richard Robbins, Stuart Samuels and Gordon Woodward (collectively, the “Director Defendants”), certain current and former officers of the Company, consisting of Kimberlee Seah, Hai Tran and Patricia Bogusz (collectively the “Officer Defendants”), Kohlberg & Co., L.L.C., Kohlberg Management V, L.L.C., Kohlberg Investors V, L.P., Kohlberg Partners V, L.P., Kohlberg TE Investors V, L.P., KOCO Investors V, L.P., and Jefferies LLC. The Company is also named as a nominal defendant in the Derivative Complaint. The Derivative Complaint was filed in the Delaware Court of Chancery as Park Employees and Retirement Board Employees’ Annuity and Benefit Fund of Chicago v. Richard M. Smith, Myron Z. Holubiak, Charlotte W. Collins, Samuel P. Frieder, David R. Huber, Richard L. Robbins, Stuart A. Samuels, Gordon H. Woodward, Kimberlee C. Seah, Hai V.Tran, Patricia Bogusz, Kohlberg & Co., L.L.C., Kohlberg Management V, L.L.C., Kohlberg Investors V, L.P., Kohlberg Partners V, L.P., Kohlberg TE Investors V, L.P., KOCO Investors V, L.P., Jefferies LLC and BioScrip, Inc., C.A. No. 11000-VCG (Del. Ch. Ct., May 7, 2015).
The Derivative Complaint alleges generally that certain defendants breached their fiduciary duties with respect to the Company’s public disclosures, oversight of Company operations, secondary stock offerings and stock sales. The Derivative

18

Complaint also contends that certain defendants aided and abetted those alleged breaches. The damages sought are not quantified but include, among other things, claims for money damages, restitution, disgorgement, equitable relief, reasonable attorneys’ fees, costs and expenses, and interest. The Derivative Complaint incorporates the same factual allegations from In re BioScrip, Inc., Securities Litigation (described below). On June 16, 2015, all defendants moved to dismiss the case. Briefing for the motion to dismiss was completed on November 30, 2015, and the court heard oral argument on the motion to dismiss on January 12, 2016. During the hearing, the court requested additional briefing, which was completed on February 12, 2016. On May 31, 2016, the court determined that the Derivative Plaintiff’s claims could not proceed as pled but granted the Derivative Plaintiff thirty days in which to make a motion to amend the Derivative Complaint. The court reserved decision on the motion to dismiss and on June 29, 2016, the Derivative Plaintiff filed a motion for leave to file an amended complaint. On October 10, 2016, all defendants moved to dismiss the amended complaint and the Court heard oral argument on January 19, 2017. On April 18, 2017, the Court granted the defendants’ motion to dismiss. Plaintiffs filed a notice of appeal on May 12, 2017.
The Company, Director Defendants and the Officer Defendants deny any allegations of wrongdoing in this lawsuit. The Company and those persons believe all of the claims in this lawsuit are without merit and intend to vigorously defend against these claims. However, there is no assurance that the defense will be successful or that insurance will be available or adequate to fund any settlement, judgment or litigation costs associated with this action. Certain of the defendants have sought indemnification from the Company pursuant to certain indemnification agreements, for which there may be no insurance coverage. Additional similar lawsuits may be filed. The Company is unable to predict the outcome or reasonably estimate a range of possible loss at this time. While no assurance can be given as to the ultimate outcome of this matter, the Company believes that the final resolution of this action is not likely to have a material adverse effect on results of operations, financial position, liquidity or capital resources.
Government Regulation
Various federal and state laws and regulations affecting the healthcare industry do or may impact the Company’s current and planned operations, including, without limitation, federal and state laws prohibiting kickbacks in government health programs, federal and state antitrust and drug distribution laws, and a wide variety of consumer protection, insurance and other state laws and regulations. While management believes the Company is in substantial compliance with all existing laws and regulations material to the operation of its business, such laws and regulations are often uncertain in their application to our business practices as they evolve and are subject to rapid change. As controversies continue to arise in the healthcare industry, federal and state regulation and enforcement priorities in this area can be expected to increase, the impact of which cannot be predicted.
From time to time, the Company responds to investigatory subpoenas and requests for information from governmental agencies and private parties. The Company cannot predict with certainty what the outcome of any of the foregoing might be. While the Company believes it is in substantial compliance with all laws, rules and regulations that affects its business and operations, there can be no assurance that the Company will not be subject to scrutiny or challenge under one or more existing laws or that any such challenge would not be successful. Any such challenge, whether or not successful, could have a material effect upon the Company’s Consolidated Financial Statements. A violation of the Federal anti-kickback statute, for example, may result in substantial criminal penalties, as well as suspension or exclusion from the Medicare and Medicaid programs. Moreover, the costs and expenses associated with defending these actions, even where successful, can be significant. Further, there can be no assurance the Company will be able to obtain or maintain any of the regulatory approvals that may be required to operate its business, and the failure to do so could have a material effect on the Company’s Consolidated Financial Statements.
NOTE 8 — CONCENTRATION OF RISK
Customer and Credit Concentration Risk
The Company provides trade credit to its customers in the normal course of business. One commercial payor, United Healthcare, accounted for approximately 21.9% and 24.4% of revenue during the three months ended June 30, 2017 and 2016, respectively, and approximately 22.4% and 25.2% of revenue during the six months ended June 30, 2017 and 2016, respectively. This contract, exclusive of certain provisions, will terminate effective September 30, 2017. In addition, Medicare accounted for approximately 7.1% and 8.3% of revenue during the three months ended June 30, 2017 and 2016, respectively, and 7.0% and 7.8% of revenue during the six months ended June 30, 2017 and 2016.
Therapy Revenue Concentration Risk
The Company sells products related to the Immune Globulin therapy, which represented 21.1% and 17.2% of revenue for the three months ended June 30, 2017 and 2016, respectively, and 21.6% and 17.2% of revenue for the six months ended June 30, 2017 and 2016.

19

NOTE 9 — INCOME TAXES
The Company’s federal and state income tax provision from continuing operations for the three months and six months ended June 30, 2017 and 2016 is summarized in the following table (in thousands):
 
Three Months Ended 
 June 30,
 
Six Months Ended 
 June 30,
 
2017
 
2016
 
2017
 
2016
Current
 
 
 
 
 
 
 
Federal
$
—

 
$
—

 
$
—

 
$
—

State
190

 
25

 
226

 
25

Total current
190

 
25

 
226

 
25

Deferred
 

 
 

 
 

 
 

Federal
437

 
108

 
932

 
125

State
91

 
16

 
179

 
22

Total deferred
528

 
124

 
1,111

 
147

Total income tax expense
$
718

 
$
149

 
$
1,337

 
$
172

The income tax expense recognized for the three months and six months ended June 30, 2017 is a result of an increase in the deferred tax liability.
The Company’s reconciliation of the statutory rate from continuing operations to the effective income tax rate for the three months and six months ended June 30, 2017 and 2016 is summarized as follows (in thousands):
 
Three Months Ended 
 June 30,
 
Six Months Ended 
 June 30,
 
2017
 
2016
 
2017
 
2016
Tax benefit at statutory rate
$
(9,790
)
 
$
(2,844
)
 
$
(16,236
)
 
$
(6,271
)
State tax expense, net of federal taxes
190

 
3

 
226

 
3

Valuation allowance changes affecting income tax provision
10,266

 
1,926

 
17,242

 
5,314

Non-deductible transaction costs and other
52

 
1,064

 
105

 
1,126

Income tax expense
$
718

 
$
149

 
$
1,337

 
$
172

At June 30, 2017, the Company had Federal net operating loss (“NOL”) carry forwards of approximately $373.8 million, of which $14.3 million is subject to an annual limitation, which will begin expiring in 2026 and later. The Company has post-apportioned state NOL carry forwards of approximately $414.4 million, the majority of which will begin expiring in 2017 and later.
NOTE 10 — STOCK-BASED COMPENSATION
BioScrip Equity Incentive Plans
Under the Company’s Amended and Restated 2008 Equity Incentive Plan (the “2008 Plan”), the Company may issue, among other things, incentive stock options, non-qualified stock options, stock appreciation rights (“SARs”), restricted stock grants, restricted stock units, performance shares and performance units to key employees and directors. While SARs are authorized under the 2008 Plan, they may also be issued outside of the plan. The 2008 Plan is administered by the Company’s Management Development and Compensation Committee (the “Compensation Committee”), a standing committee of the Board of Directors.

20

On November 30, 2016, at a special meeting, the stockholders approved (i) an amendment to the Company’s Second Amended and Restated Certificate of Incorporation to increase the number of shares of Common Stock that the Company is authorized to issue from 125 million shares to 250 million shares (the “Charter Amendment”); (ii) an amendment to the 2008 Plan to (a) increase the number of shares of Common Stock in the aggregate that may be subject to awards by 5,250,000 shares, from 9,355,000 to 14,605,000 shares and (b) increase the annual grant caps under the Company’s 2008 Plan from 500,000 Options, 500,000 Stock Appreciation Rights and 350,000 Stock Grants and Restricted Stock Units that are intended to comply with the requirements of Section 162(m) of the Code to a cap of no more than a total of 3,000,000 Options, Stock Appreciation Rights, Stock Grants and Restricted Stock Units that are intended to comply with the requirements of Section 162(m) of the Code combined; and (iii) if necessary, an adjournment of the Stockholders’ Meeting if there were insufficient votes in favor of the Charter Amendment.
As of June 30, 2017, 4,360,887 shares remain available for grant under the 2008 Plan.
Stock Options
The Company recognized compensation expense related to stock options of $0.3 million and $0.7 million during the three months ended June 30, 2017 and 2016, respectively, and $0.6 million and $1.7 million during the six months ended June 30, 2017 and 2016, respectively.
Restricted Stock
The Company recognized $0.1 million and a nominal amount of compensation expense related to restricted stock awards during the three months ended June 30, 2017 and 2016, respectively, and $0.3 million and a nominal amount of compensation expense during the six months ended June 30, 2017 and 2016, respectively.
Stock Appreciation Rights and Market Based Cash Awards
The Company recognized nominal amounts of compensation expense related to stock appreciation rights awards during the three months ended June 30, 2017 and 2016, and nominal and $0.1 million of compensation expense during the six months ended June 30, 2017 and 2016, respectively.
The Company recognized nominal compensation expense and $0.2 million compensation benefit related to market based cash awards during the three months ended June 30, 2017 and 2016, respectively, and nominal and $0.1 million compensation expense during six months ended June 30, 2017 and 2016, respectively.
Employee Stock Purchase Plan
On May 7, 2013, the Company’s stockholders approved the BioScrip, Inc. Employee Stock Purchase Plan (the “ESPP”). The ESPP is administered by the Compensation Committee. The ESPP provides all eligible employees, as defined under the ESPP, the opportunity to purchase up to a maximum number of shares of Common Stock of the Company as determined by the Compensation Committee. Participants in the ESPP may acquire the Common Stock at a cost of 85% of the lower of the fair market value on the first or last day of the quarterly offering period. The Company filed a Registration Statement on Form S-8 to register 750,000 shares of Common Stock, par value $0.0001 per share, for issuance under the ESPP.
As of June 30, 2017, 136,713 shares remained available for grant under the ESPP. Since inception, the ESPP’s third-party service provider has purchased 613,287 shares on the open market and delivered these shares to the Company’s employees pursuant to the ESPP. During the three months ended June 30, 2017 and 2016, and the six months ended June 30, 2017 and 2016, the Company incurred less than $0.1 million of expense related to the ESPP.

21

Item 2.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion should be read in conjunction with the Audited Consolidated Financial Statements, including the notes thereto, and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2016 (the “Annual Report”) filed with the U.S. Securities and Exchange Commission (“SEC”), as well as our Unaudited Consolidated Financial Statements and the related notes thereto included elsewhere in this report.
This Quarterly Report on Form 10-Q (this “Quarterly Report”) contains statements not purely historical and which may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including statements regarding our expectations, beliefs, future plans and strategies, anticipated events or trends concerning matters that are not historical facts or that necessarily depend upon future events. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “predict,” “potential,” and similar expressions. Specifically, this Quarterly Report contains, among others, forward-looking statements about:
•
our ability to successfully integrate the HS Infusion Holdings, Inc. (“Home Solutions”) business into our existing businesses;
•
our ability to make principal and interest payments on our debt and satisfy the other covenants contained in our debt agreements;
•
our high level of indebtedness;
•
our expectations regarding financial condition or results of operations in future periods;
•
our future sources of, and needs for, liquidity and capital resources;
•
our expectations regarding economic and business conditions;
•
our expectations regarding potential legislative and regulatory changes impacting the level of reimbursement received from the Medicare and state Medicaid programs;
•
periodic reviews and billing audits from governmental and private payors;
•
our expectations regarding the size and growth of the market for our products and services;
•
our business strategies and our ability to grow our business;
•
the implementation or interpretation of current or future regulations and legislation, particularly governmental oversight of our business;
•
our expectations regarding the outcome of litigation;
•
our ability to maintain contracts and relationships with our customers;
•
our ability to avoid delays in payment from our customers;
•
sales and marketing efforts;
•
status of material contractual arrangements, including the negotiation or re-negotiation of such arrangements;
•
future capital expenditures;
•
our ability to hire and retain key employees;
•
our ability to execute our acquisition and growth strategy; and
•
our ability to successfully integrate other businesses we may acquire.
Investors are cautioned that any such forward-looking statements are not guarantees of future performance, involve risks and uncertainties and that actual results may differ materially from those possible results discussed in the forward-looking statements as a result of various factors. Important factors that could cause such differences include, among other things:
•
risks associated with increased government regulation related to the health care and insurance industries in general, and more specifically, home infusion providers;
•
our ability to comply with debt covenants in our Notes Facility (as defined below) and unsecured notes indenture;
•
risks associated with our issuance of Preferred Stock and PIPE Warrants to the PIPE Investors (each as defined below);
•
risks associated with the exchanges of our Preferred Stock;
•
risks associated with our issuance of 2017 Warrants (as defined below);
•
risks associated with the First Quarter 2017 Private Placement and the Second Quarter 2017 Private Placement (each as defined below);
•
risks associated with the Notes Facilities (as defined below);
•
risks associated with our issuance of common stock in the 2016 Equity Offering, as defined below;
•
risks associated with the retention or transition of executive officers and key employees
•
our expectation regarding the interim and ultimate outcome of commercial disputes, including litigation;
•
unfavorable economic and market conditions;

22

•
disruptions in supplies and services resulting from force majeure events such as war, strike, riot, crime, or “acts of God” such as hurricanes, flooding, blizzards or earthquakes;
•
reductions in federal and state reimbursement for our products and services;
•
delays or suspensions of Federal and state payments for services provided;
•
efforts to reduce healthcare costs and alter health care financing;
•
effects of the 21st Century Cures Act (the “Cures Act”), the Patient Protection and Affordable Care Act (“PPACA”), any repeal or amendment thereof, and the Health Care and Education Reconciliation Act of 2010, which amended PPACA, and the related accountable care organizations;
•
existence of complex laws and regulations relating to our business;
•
availability of financing sources;
•
declines and other changes in revenue due to the expiration of short-term contracts;
•
network lockouts and decisions to in-source by health insurers including lockouts with respect to acquired entities;
•
unforeseen contract terminations;
•
difficulties in the implementation and ongoing evolution of our operating systems;
•
difficulties with the implementation of our growth strategy and integrating businesses we have acquired or will acquire;
•
increases or other changes in our acquisition cost for our products;
•
increased competition from competitors having greater financial, technical, reimbursement, marketing and other resources could have the effect of reducing prices and margins;
•
disruptions in our relationship with our primary supplier of prescription products;
•
the level of our indebtedness and its effect on our ability to execute our business strategy and increased risk of default under our debt obligations;
•
the UnitedHealthcare contract termination, including potential accounting charges and impacts on other contract provisions and their associated revenue;
•
introduction of new drugs, which can cause prescribers to adopt therapies for existing patients that are less profitable to us;
•
changes in industry pricing benchmarks, which could have the effect of reducing prices and margins; and
•
other risks and uncertainties described from time to time in our filings with the SEC.
You should not place undue reliance on such forward-looking statements as they speak only as of the date they are made. Except as required by law, we assume no obligation to publicly update or revise any forward-looking statement even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized.
Business Overview
We are a national provider of infusion solutions. We partner with physicians, hospital systems, skilled nursing facilities, and healthcare payors to provide patients access to post-acute care services. We operate with a commitment to bring customer-focused healthcare infusion therapy services into the home or alternate site setting. By collaborating with the full spectrum of healthcare professionals and the patient, we aim to provide cost-effective care that is driven by clinical excellence, customer service and values that promote positive outcomes and an enhanced quality of life for those whom we serve. As of the filing of this Quarterly Report, we have a total of 67 service locations in 27 states.
Our platform provides nationwide service capabilities and the ability to deliver clinical management services that offer patients a high-touch, community-based and home-based care environment. Our core services are provided in coordination with, and under the direction of, the patient’s physician. Our multidisciplinary team of clinicians, including pharmacists, nurses, dietitians and respiratory therapists, work with the physician to develop a plan of care suited to our patient’s specific needs. Whether in the home, physician office, ambulatory infusion center, skilled nursing facility or other alternate sites of care, we provide products, services and condition-specific clinical management programs tailored to improve the care of individuals with complex health conditions such as gastrointestinal abnormalities, infectious diseases, cancer, multiple sclerosis, organ and blood cell transplants, bleeding disorders, immune deficiencies and heart failure.
We operate in one segment, Infusion Services, and accordingly, we do not present disaggregated segment information.
Strategic Assessment and Transactions
We regularly examine our business operations, assess our market strengths, and compare our position to that of our competitors. As a result, we have focused our growth on investments in the Infusion Services business, which remains the primary driver of our growth strategy. Transactions executed to further strengthen our position in the Infusion Services business include:
•
On March 31, 2014, we completed the sale of substantially all of our Home Health Services segment (the “Home Health Business”) to LHC Group, Inc.

23

•
On August 27, 2015, we completed the sale of substantially all of our pharmacy benefit management services segment (the “PBM Business”) pursuant to an Asset Purchase Agreement dated as of August 9, 2015 (the “PBM Asset Purchase Agreement”), by and among the Company, BioScrip PBM Services, LLC and ProCare Pharmacy Benefit Manager Inc. (the “PBM Buyer”). Under the PBM Asset Purchase Agreement, the PBM Buyer agreed to acquire substantially all of the assets used solely in connection with the PBM Business and to assume certain PBM Business liabilities (the “PBM Sale”). On the closing date, pursuant to the terms of the PBM Asset Purchase Agreement, we received total cash consideration of approximately $24.6 million, including an adjustment for estimated closing date net working capital. On October 20, 2015, we finalized working capital adjustment negotiations in relation to the PBM Sale whereby we agreed to repay approximately $1.0 million to the PBM Buyer. We used the net proceeds from the PBM Sale to pay down a portion of our outstanding debt.
•
On September 9, 2016, we acquired substantially all of the assets and assumed certain liabilities of Home Solutions and its subsidiaries (the “Home Solutions Transaction”) pursuant to an Asset Purchase Agreement dated June 11, 2016 (as amended, the “Home Solutions Agreement”), by and among Home Solutions, a Delaware corporation, certain subsidiaries of Home Solutions, the Company and HomeChoice Partners, Inc., a Delaware corporation. Home Solutions, a privately held company, provides home infusion and home nursing products and services to patients suffering from chronic and acute medical conditions.
Regulatory Matters Update
Approximately 15.7% and 18.8% of revenue for the three months ended June 30, 2017 and 2016, respectively, and approximately 16.0% and 18.5% of revenue for the six months ended June 30, 2017 and 2016 was derived directly from Medicare, state Medicaid programs and other government payors. We also provide services to beneficiaries of Medicare, Medicaid and other government-sponsored healthcare programs indirectly through managed care entities. Medicare Part D, for example, is administered through managed care entities. In the normal course of business, we and our customers are subject to legislative and regulatory changes impacting the level of reimbursement received from the Medicare and state Medicaid programs.
State Medicaid Programs
Over the last several years, increased Medicaid spending, combined with slow state revenue growth, led many states to institute measures aimed at controlling spending growth. Spending cuts have taken many forms including reducing eligibility and benefits, eliminating certain types of services, and provider reimbursement reductions. In addition, some states have been moving beneficiaries to managed care programs in an effort to reduce costs.
Each individual state Medicaid program represents less than 5% of our consolidated revenue for the three months and six months ended June 30, 2017, and no individual state Medicaid reimbursement reduction is expected to have a material effect on our Consolidated Financial Statements. We are continually assessing the impact of the state Medicaid reimbursement cuts as states propose, finalize and implement various cost-saving measures.
Given the reimbursement pressures, we continue to improve operational efficiencies and reduce costs to mitigate the impact on results of operations where possible. In some cases, reimbursement rate reductions may result in negative operating results, and we would likely exit some or all services where rate reductions result in unacceptable returns to our stockholders.
States are also in the process of determining whether to expand their Medicaid programs as permitted by the Patient Protection and Affordable Care Act, or PPACA. We cannot predict the impact of these decisions, but they may have a material impact on net revenues or income from continuing operations.
Medicare
Federal efforts to reduce Medicare spending continued in 2016. Congress first passed the PPACA, followed by the Health Care and Education Reconciliation Act of 2010, which amended PPACA. In August 2011, Congress passed a deficit reduction agreement that created a committee tasked with proposing legislation to reduce the federal deficit by November 23, 2011. Because the committee did not act, automatic Medicare cuts were scheduled to go into effect January 1, 2013. However, Congress passed legislation extending the time for such cuts by three months. Thus, Medicare reimbursement to providers was reduced overall by 2% (as part of sequestration) beginning April 1, 2013. In addition, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 established requirements for a competitive bidding program for determining Medicare reimbursement rates for certain items of durable medical equipment, prosthetics, orthotics and supplies (“DMEPOS”), including enteral nutrients, supplies and equipment, certain respiratory therapy and home medical equipment products and external infusion pumps and supplies.

24

We are contract suppliers under the Round 1 Recompete, which included nine competitive bidding areas (“CBAs”) and six product categories, including external infusion pumps, and expired on December 31, 2016, and Round 2 of competitive bidding, which was conducted in 100 additional CBAs for eight product categories, including enteral nutrition, and expired on June 30, 2016. We have entered into strategic relationships in the CBAs in which we were not awarded contracts for such periods. We were not awarded any contracts in Round 2 Recompete, which went into effect July 1, 2016 and includes 117 CBAs, comprising the same geographic area as the second round of competitive bidding, and seven product categories, including enteral nutrition. Our revenue may decrease unless and until we are able to provide Medicare beneficiaries with competitively bid items in the applicable CBAs but any negative impact has been immaterial.
Medicare currently covers home infusion therapy for selected therapies primarily through the durable medical equipment benefit. The Cures Act, enacted by Congress in December of 2016, creates a new payment system for certain home infusion therapy services paid under Medicare Part B. The Cures Act significantly reduces the amount paid by Medicare for the drug costs, and also provides for the implementation of a clinical services payment. That services payment does not take effect until 2021.
Approximately 7.1% and 7.0% of revenue for the three months and six months ended June 30, 2017 was derived from Medicare, respectively.
Critical Accounting Estimates
Our Unaudited Consolidated Financial Statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”). In preparing our financial statements, we are required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. As a result, actual results could differ from these estimates.
We evaluate our estimates and judgments on an ongoing basis. We base our estimates and judgments on historical experience and on various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the period presented. Our actual results may differ from these estimates, and different assumptions or conditions may yield different estimates. There have been no changes to critical accounting estimates in the six months ended June 30, 2017. For a full description of our accounting policies please refer to Management’s Discussion and Analysis of Financial Condition and Results of Operations in the Annual Report.
Collectability of Accounts Receivable
The following table sets forth the aging of our net accounts receivable (net of allowance for contractual adjustments, and prior to allowance for doubtful accounts), aged based on date of service and categorized based on the three primary overall types of accounts receivable characteristics (in thousands):
 
 
June 30, 2017
 
December 31, 2016
 
 
0 - 180 days
 
Over 180 days
 
Total
 
0 - 180 days
 
Over 180 days
 
Total
Government
 
$
18,714

 
$
7,512

 
$
26,226

 
$
19,891

 
$
8,278

 
$
28,169

Commercial
 
84,190

 
23,589

 
107,779

 
97,744

 
19,848

 
117,592

Patient
 
5,195

 
9,540

 
14,735

 
3,955

 
6,825

 
10,780

Gross accounts receivable
 
$
108,099

 
$
40,641

 
148,740

 
$
121,590

 
$
34,951

 
156,541

Allowance for doubtful accounts
 
 
 
 
 
(45,651
)
 
 
 
 
 
(44,730
)
Net accounts receivable
 
 
 
 
 
$
103,089

 
 
 
 
 
$
111,811


25

Results of Operations
The following consolidated statements have been derived from our unaudited consolidated financial statements included in this Quarterly Report on Form 10-Q. The discussion set forth below compares our results of operations for the three months and six months ended June 30, 2017 with the results of operations for the corresponding periods in 2016.
Three months ended June 30, 2017 compared to three months ended June 30, 2016
 
Three Months Ended June 30,
 
As a Percentage of Revenue
 
(in thousands)
 
 
 
 
 
2017
 
2016
 
2017
 
2016
Net revenue
$
218,106

 
$
232,462

 
100.0
 %
 
100.0
 %
Gross profit
68,310

 
64,164

 
31.3
 %
 
27.6
 %
Other operating expenses
42,486

 
40,619

 
19.5
 %
 
17.5
 %
Bad debt expense
6,223

 
4,279

 
2.9
 %
 
1.8
 %
General and administrative expenses
10,025

 
9,414

 
4.6
 %
 
4.0
 %
Restructuring, acquisition, integration, and other expenses, net
3,911

 
4,291

 
1.8
 %
 
1.8
 %
Depreciation and amortization expense
6,789

 
4,252

 
3.1
 %
 
1.8
 %
Interest expense
12,715

 
9,469

 
5.8
 %
 
4.1
 %
Loss on extinguishment of debt
13,453

 
—

 
6.2
 %
 
—
 %
Loss on dispositions
685

 
—

 
0.3
 %
 
—
 %
Loss from continuing operations, before income taxes
(27,977
)
 
(8,160
)
 
(12.8
)%
 
(3.5
)%
Income tax expense
718

 
149

 
0.3
 %
 
0.1
 %
Loss from continuing operations, net of income taxes
(28,695
)
 
(8,309
)
 
(13.2
)%
 
(3.6
)%
(Loss) income from discontinued operations, net of income taxes
(503
)
 
75

 
(0.2
)%
 
—
 %
Net loss
$
(29,198
)
 
$
(8,234
)
 
(13.4
)%
 
(3.5
)%
Net Revenue. Net revenue for the three months ended June 30, 2017 decreased $14.4 million, or 6.2%, to $218.1 million, compared to net revenue of $232.5 million for the same period in 2016. The decrease in net revenue primarily reflects the Company’s shift in strategy to focus on growing its core revenue mix coupled with the impact of the Cures Act.
Gross Profit. Gross profit consists of revenue less cost of revenue (excluding depreciation expense). The cost of revenue (excluding depreciation expense) primarily includes the costs of prescription medications, supplies, nursing services, shipping and other direct and indirect costs. The increase in gross profit of $4.1 million or 6.5% for the three months ended June 30, 2017 as compared to the same period in 2016 was driven by an improved mix of higher margin core therapy revenues versus lower margin non-core therapy revenues, coupled with improved product costs. Gross profit as a percentage of revenue improved by 3.7% for the three months ended June 30, 2017 as compared to the same period in 2016.
Other Operating Expenses. Other operating expenses consist primarily of wages and benefits, travel expenses, professional service and field office expenses for our healthcare professionals engaged in providing infusion services to our patients. Other operating expenses for the three months ended June 30, 2017 increased $1.9 million or 4.6% compared to the same period in 2016 as a result of increased wage, benefit, and other employee costs associated with the acquisition of Home Solutions on September 9, 2016.
Bad Debt Expense. The $1.9 million increase in bad expense during the three months ended June 30, 2017 as compared to the same period in 2016 results from our estimation process that incorporates historical write-offs, the aging of accounts receivable balances, and our mix of payers.
General and Administrative Expenses. General and administrative expenses consist of wages and benefits for corporate overhead personnel, and certain corporate level professional service fees, including legal, accounting, and IT fees. The increase of $0.6 million or 6.5% in general and administrative expenses during the three months ended June 30, 2017 as compared to the same period in 2016, resulted from increases in variable compensation expenses, partially offset by decreases in professional service fees.

26

Loss on Extinguishment of Debt. The loss on extinguishment of debt of $13.5 million during the three months ended June 30, 2017 is attributable to the Company’s entry into the Notes Facilities and the associated extinguishment of the Prior Credit Agreements (each term as defined below, see Note 6 - Debt).
Restructuring, Acquisition, Integration, and Other Expenses, Net. The restructuring, acquisition, integration, and other expenses, net decreased by $0.4 million or 8.9% during the three months ended June 30, 2017 as compared to the same period in 2016. The restructuring, acquisition, integration, and other expenses consist primarily of employee severance and other benefit-related costs, third-party consulting costs, redundant facility and personnel-related costs and certain other costs associated with our restructuring, acquisition, and integration activities specific to the Home Solutions Transaction and ongoing cost management initiatives.
Depreciation and Amortization Expense. Depreciation and amortization expense includes the depreciation of property and equipment and the amortization of intangible assets such as customer relationships, trademarks, and non-compete agreements with estimable lives. During the three months ended June 30, 2017 and 2016, we recorded depreciation expense of $3.6 million and $3.5 million, respectively, and amortization expense of intangibles of $3.2 million and $0.8 million, respectively.
The increase in depreciation expense in the three months ended June 30, 2017 as compared to the same period in 2016 is the result of a lower property and equipment net balance at the beginning of the three month period ended June 30, 2017. The increase in amortization expense is attributable to the corresponding increase in intangible assets associated with the acquisition of Home Solutions, Inc. in the third quarter of 2016.
Interest Expense. Interest expense consists of interest expense and deferred financing costs reduced by an immaterial amount of interest income. During the three months ended June 30, 2017 and 2016, we recorded interest expense of $12.7 million and $9.5 million, respectively, including $1.6 million and $0.9 million of amortization of deferred financing costs, respectively. The increase in interest expense during the three months ended June 30, 2017 as compared to the same period in 2016 is the result of the changes in debt structure attributable to the now extinguished Sixth Amendment to the Senior Credit Facilities (see Note 6 - Debt).
Loss on Dispositions. Loss on dispositions of $0.7 million during three months ended June 30, 2017 is the result of the Company’s write-off of certain assets associated with a software system no longer used in operations.
Income Tax Expense (Benefit). The 2017 income tax expense includes a federal tax benefit of $9.8 million and transaction costs and other permanent items of $0.1 million, offset by a $10.3 million adjustment related to deferred tax asset valuation allowances and state tax expense of $0.2 million. The income tax benefit of $0.1 million for the three months ended June 30, 2016 includes a federal tax benefit of $2.8 million and transaction costs and other permanent items of $1.1 million, partially offset by a $1.9 million adjustment to deferred tax asset valuation allowances and insignificant state tax expense.

27

Six months ended June 30, 2017 compared to six months ended June 30, 2016
 
Six Months Ended June 30,
 
As a Percentage of Revenue
 
(in thousands)
 
 
 
 
 
2017
 
2016
 
2017
 
2016
Net revenue
$
435,916

 
$
470,924

 
100.0
 %
 
100.0
 %
Gross profit
133,894

 
128,396

 
30.7
 %
 
27.3
 %
Other operating expenses
86,844

 
80,277

 
19.9
 %
 
17.0
 %
Bad debt expense
13,387

 
11,871

 
3.1
 %
 
2.5
 %
General and administrative expenses
19,504

 
20,465

 
4.5
 %
 
4.3
 %
Restructuring, acquisition, integration, and other expenses, net
7,134

 
6,958

 
1.6
 %
 
1.5
 %
Depreciation and amortization expense
13,777

 
8,790

 
3.2
 %
 
1.9
 %
Interest expense
25,459

 
18,881

 
5.8
 %
 
4.0
 %
Loss on extinguishment of debt
13,453

 
—

 
3.1
 %
 
—
 %
Loss (gain) on dispositions
685

 
(939
)
 
0.2
 %
 
(0.2
)%
Loss from continuing operations, before income taxes
(46,349
)
 
(17,907
)
 
(10.6
)%
 
(3.8
)%
Income tax expense
1,337

 
172

 
0.3
 %
 
—
 %
Loss from continuing operations, net of income taxes
(47,686
)
 
(18,079
)
 
(10.9
)%
 
(3.8
)%
(Loss) income from discontinued operations, net of income taxes
(940
)
 
308

 
(0.2
)%
 
0.1
 %
Net loss
$
(48,626
)
 
$
(17,771
)
 
(11.2
)%
 
(3.8
)%
Net Revenue. Net revenue for the six months ended June 30, 2017 decreased $35.0 million, or 7.4%, to $435.9 million, compared to net revenue of $470.9 million for the same period in 2016. The decrease in net revenue primarily reflects the Company’s shift in strategy to focus on growing its core revenue mix coupled with the impact of the Cures Act.
Gross Profit. Gross profit consists of revenue less cost of revenue (excluding depreciation expense). The cost of revenue (excluding depreciation expense) primarily includes the costs of prescription medications, supplies, nursing services, shipping and other direct and indirect costs. The increase in gross profit of $5.5 million or 4.3% for the six months ended June 30, 2017 as compared to the same period in 2016 was driven by an improved mix of higher margin core therapy revenues versus lower margin non-core therapy revenues, coupled with improved product costs. Gross profit as a percentage of revenue improved by 3.4% for the six months ended June 30, 2017 as compared to the same period in 2016.
Other Operating Expenses. Other operating expenses consist primarily of wages and benefits, travel expenses, professional service and field office expenses for our healthcare professionals engaged in providing infusion services to our patients. Other operating expenses for the six months ended June 30, 2017 increased $6.6 million or 8.2% compared to the same period in 2016 due to increased wage, benefit, and other employee costs associated with the Home Solutions Transaction on September 9, 2016.
Bad Debt Expense. The $1.5 million increase in bad expense during the six months ended June 30, 2017 as compared to the same period in 2016 results from our estimation process that incorporates historical write-offs, the aging of accounts receivable balances, and our mix of payers.
General and Administrative Expenses. General and administrative expenses consist of wages and benefits for corporate overhead personnel and certain corporate level professional service fees, including legal, accounting, and IT fees. The decrease in general and administrative expenses of $1.0 million or 4.7% resulted from reductions in the number of corporate personnel and their associated wage and benefits costs, as well as decreases in professional service fees.
Loss on Extinguishment of Debt. The loss on extinguishment of debt of $13.5 million during the six months ended June 30, 2017 is attributable to the Company’s entry into the Notes Facilities and the associated extinguishment of the Senior Credit Facilities and the Prior Credit Agreements (see Note 6 - Debt).
Restructuring, Acquisition, Integration, and Other Expenses, Net. The restructuring, acquisition, integration, and other expenses, net increased by $0.2 million or 2.5% during the six months ended June 30, 2017. The restructuring, acquisition, integration, and other expenses consist primarily of employee severance and other benefit-related costs, third-party consulting costs, redundant facility and personnel-related costs and certain other costs associated with our restructuring, acquisition, and integration activities specific to the Home Solutions Transaction and ongoing cost management initiatives.

28

Depreciation and Amortization Expense. Depreciation and amortization expense includes the depreciation of property and equipment and the amortization of intangible assets such as customer relationships, trademarks, and non-compete agreements with estimable lives. During the six months ended June 30, 2017 and 2016, we recorded depreciation expense of $7.4 million and $7.1 million, respectively, and amortization expense of intangibles of $6.4 million and $1.6 million, respectively. The increase in depreciation expense during the six months ended June 30, 2017 as compared to the same period in 2016 is attributable to increases in property and equipment associated with the Home Solutions Transaction. The increase in amortization expense of intangibles is a result of increased net intangible asset balances at the beginning of the current period due to the Home Solutions Transaction in 2016.
Interest Expense. Interest expense consists of interest expense and amortization of deferred financing costs, reduced by an immaterial amount of interest income. During the six months ended June 30, 2017 and 2016, we recorded interest expense of $25.5 million and $18.9 million, respectively, including $2.9 million and $0.9 million of amortization of deferred financing costs, respectively. The increase in interest expense during the six months ended June 30, 2017 as compared to the same period in 2016 is the result of the changes in debt structure attributable to the now extinguished Sixth Amendment to the Senior Credit Facilities (see Note 6 - Debt).
Loss (Gain) on Dispositions. Loss on dispositions of $0.7 million during the six months ended June 30, 2016 is the result of the Company’s write-off of certain assets certain assets associated with a software system no longer used in operations. Gain on dispositions during the six months ended June 30, 2016 consists of $0.9 million related to the sale of the Infusion Services center in Pittsburgh, Pennsylvania in the first quarter of 2016.
Income Tax Expense (Benefit). The 2017 income tax expense includes a federal tax benefit of $16.2 million, offset by $0.2 million state tax expense, a $17.2 million adjustment related to deferred tax asset valuation allowances, and transaction costs and other permanent items of $0.1 million. The nominal income tax expense for the six months ended June 30, 2016 includes a federal tax benefit of $6.3 million and an insignificant state tax benefit, partially offset by a $5.3 million adjustment to deferred tax asset valuation allowances and transaction costs of $1.1 million.

29

Non-GAAP Measures
The following table reconciles GAAP loss from continuing operations, net of income taxes to consolidated Adjusted EBITDA. Adjusted EBITDA is net income (loss) adjusted for interest expense, income tax expense (benefit), depreciation and amortization, impairments, loss on extinguishment of debt, and stock-based compensation expense. Adjusted EBITDA also excludes restructuring, acquisition, integration and other expenses including non-operating costs associated with restructuring, acquisition and integration initiatives such as employee severance costs, certain legal and professional fees, training costs, redundant wage costs, impacts recorded from the change in contingent consideration obligations, and other costs related to contract terminations and closed branches/offices.
Consolidated Adjusted EBITDA is a measure of earnings that management monitors as an important indicator of financial performance, particularly future earnings potential and recurring cash flow. Adjusted EBITDA is also a primary objective of the management bonus plan. Inclusion of Adjusted EBITDA is intended to provide investors insight into the manner in which management views the performance of the Company.
Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for our financial results prepared in accordance with GAAP. Our calculation of Non-GAAP Adjusted EBITDA, as presented, may differ from similarly titled measures reported by other companies. We encourage investors to review these reconciliations and we qualify our use of non-GAAP financial measures with cautionary statements as to their limitations.
 
Three Months Ended 
 June 30,
 
Six Months Ended 
 June 30,
 
2017
 
2016
 
2017
 
2016
 
(in thousands)
 
(in thousands)
Infusion services Adjusted EBITDA
$
19,601

 
$
19,266

 
$
33,663

 
$
36,248

Corporate overhead Adjusted EBITDA
(9,592
)
 
(8,895
)
 
(18,477
)
 
(18,472
)
 
 
 
 
 
 
 
 
Consolidated Adjusted EBITDA
10,009

 
10,371

 
15,186

 
17,776

 
 
 
 
 
 
 
 
Interest expense
(12,715
)
 
(9,469
)
 
(25,459
)
 
(18,881
)
Gain (loss) on dispositions
(685
)
 
—

 
(685
)
 
939

Loss on extinguishment of debt
(13,453
)
 
—

 
(13,453
)
 
—

Income tax expense
(718
)
 
(149
)
 
(1,337
)
 
(172
)
Depreciation and amortization expense
(6,789
)
 
(4,252
)
 
(13,777
)
 
(8,790
)
Stock-based compensation expense
(433
)
 
(519
)
 
(1,027
)
 
(1,993
)
Restructuring, acquisition, integration, and other expenses, net
(3,911
)
 
(4,291
)
 
(7,134
)
 
(6,958
)
Loss from continuing operations, net of income taxes
$
(28,695
)
 
$
(8,309
)
 
$
(47,686
)
 
$
(18,079
)
Consolidated Adjusted EBITDA decreased during the three months and six months ended June 30, 2017 compared to the same period of the prior year primarily due to the impact of the Cures Act on revenues, partially offset by the Company’s shift in strategy to focus on growing its core revenue mix and the Company’s restructuring efforts to cut costs.
Liquidity and Capital Resources
Sources and Uses of Funds
Net cash used in operating activities from continuing operations totaled $4.1 million during the six months ended June 30, 2017 compared to $15.7 million during the six months ended June 30, 2016, a decrease of $11.6 million. The decreased cash usage was primarily driven by improved operating performance and favorable changes from working capital management, which provided $16.9 million more in cash during the six months ended June 30, 2017 as compared to the same period in 2016, partially offset by a $5.3 million increase in cash paid for interest.
Net cash used in investing activities from continuing operations during the six months ended June 30, 2017 was $9.3 million compared to $4.3 million in cash used during the same period in 2016. The increase was the result of restrictions on cash to collateralize letters of credit issued under the Senior Credit Facilities totaling $5.1 million.

30

Net cash provided by financing activities from continuing operations during the six months ended June 30, 2017 was $45.3 million compared to $61.8 million in cash provided by financing activities during the same period in 2016. The cash provided by financing activities during the six months ended June 30, 2017, includes the net proceeds of approximately $20.8 million from the Second Quarter 2017 Private Placement, $23.1 million from the Priming Credit Agreement, $294.4 million from the Notes Facilities, and advances of $0.6 million offset by repayments of $55.9 million on our Revolving Credit Facility and by $236.8 million of principal payments made on the Term Loan Facility and the Priming Credit Agreement.
At June 30, 2017, we had working capital of $87.6 million, including $40.5 million of cash on hand, compared to working capital of $45.7 million at December 31, 2016. The $41.9 million increase in working capital results primarily from the increase in our cash and cash equivalents and restricted cash of $36.0 million attributable to the net proceeds received from the Notes Facilities and the First Quarter 2017 Private Placement and the Second Quarter 2017 Private Placement. Additional liquidity of $10.0 million is provided by the delayed draw capacity in our Second Lien Note Facility described below. At June 30, 2017, we had outstanding letters of credit totaling $4.8 million, collateralized by restricted cash of $5.1 million.
Debt Facilities
The Company was previously obligated under (i) a senior secured first-lien revolving credit facility in an aggregate principal amount of $75.0 million (the “Revolving Credit Facility”), (ii) a senior secured first-lien term loan B in an aggregate principal amount of $250.0 million (the “Term Loan B Facility”) and (iii) a senior secured first-lien delayed draw term loan B in an aggregate principal amount of $150.0 million (the “Delayed Draw Term Loan Facility” and, together with the Revolving Credit Facility and the Term Loan B Facility, the “Senior Credit Facilities”) with SunTrust Bank, Jefferies Finance LLC and Morgan Stanley Senior Funding, Inc., originally entered on July 31, 2013 and amended from time to time.
On January 6, 2017, the Company entered into a credit agreement (the “Priming Credit Agreement” and, together with the Senior Credit Facilities, the “Prior Credit Agreements”) with certain existing lenders under the Senior Credit Facilities and SunTrust, as administrative agent for itself and the lenders. The Priming Credit Agreement provides an aggregate borrowing commitment of $25.0 million, which was fully drawn at closing.
On June 29, 2017, the Company entered into (i) a first lien note purchase agreement (the “First Lien Note Facility”), among the Company, which is the issuer under the agreement, the financial institutions and note purchasers from time to time party to the agreement (the “First Lien Note Purchasers”), and Wells Fargo Bank, National Association, in its capacity as collateral agent for itself and the First Lien Note Purchasers (the “First Lien Collateral Agent”), pursuant to which the Company issued first lien senior secured notes in an aggregate principal amount of $200.0 million (the “First Lien Notes”); and (ii) a second lien note purchase agreement (the “Second Lien Note Facility” and, together with the First Lien Note Facility, the “Notes Facilities”) among the Company, which is the issuer under the agreement, the financial institutions and note purchasers from time to time party to the agreement (the “Second Lien Note Purchasers”), and Wells Fargo Bank, National Association, in its capacity as collateral agent for itself and the Second Lien Note Purchasers (the “Second Lien Collateral Agent” and, together with the First Lien Collateral Agent, the “Collateral Agent”), pursuant to which the Company (a) issued second lien senior secured notes in an aggregate initial principal amount of $100.0 million (the “Initial Second Lien Notes”) and (b) has the ability to draw upon the Second Lien Note Facility and issue second lien delayed draw senior secured notes in an aggregate initial principal amount of $10.0 million for a period of 18 months after the Closing Date, subject to certain terms and conditions (the “Second Lien Delayed Draw Notes” and, together with the Initial Second Lien Notes, the “Second Lien Notes”; the Second Lien Notes, together with the First Lien Notes, the “Notes”). Funds managed by Ares are acting as lead purchasers for the Notes Facilities.
The Company used the proceeds of the sale of the First Lien Notes and the Initial Second Lien Notes pursuant to the Note Facilities to repay in full all amounts outstanding under the Prior Credit Agreements. Each of the Prior Credit Agreements was terminated following such repayment. The Company used the remaining proceeds of $15.9 million of the Notes Facilities, net of $0.2 million in associated costs, and the Second Quarter 2017 Private Placement for working capital and general corporate purposes.
The First Lien Notes accrue interest, payable monthly in arrears, at a floating rate or rates equal to, at the option of the Company, (i) the base rate (defined as the highest of the Federal Funds Rate plus 0.5% per annum, the Prime Rate as published by The Wall Street Journal and the one-month London Interbank Offered Rate (“LIBOR”) (subject to a 1.0% floor) plus 1.0%), or (ii) the one-month LIBOR rate (subject to a 1.0% floor), plus a margin of 6.0% if the base rate is selected or 7.0% if the LIBOR Option is selected. The First Lien Notes mature on August 15, 2020, provided that if the Company’s existing 8.875% Senior Notes due 2021 (the “2021 Notes”) are refinanced prior to August 15, 2020, then the scheduled maturity date of the First Lien Notes shall be June 30, 2022.
The First Lien Notes will amortize in equal quarterly installments equal to 0.625% of the aggregate principal amount of the First Lien Note Facility, commencing on September 30, 2019, and on the last day of each third month thereafter, with the balance payable at maturity. The First Lien Notes are pre-payable at the Company’s option at specified premiums to the principal amount

31

that will decline over the term of the First Lien Note Facility. If the First Lien Notes are prepaid prior to the second anniversary of the Closing Date, the Company will be required to pay a make-whole premium based on the present value (using a discount rate based on the specified treasury rate plus 50 basis points) of all remaining interest payments on the First Lien Notes being prepaid prior to the second anniversary of the Closing Date, plus 4.0% of the principal amount of First Lien Notes being prepaid. On or after the second anniversary of the Closing Date, the prepayment premium is 4.0%, which declines to 2.0% on or after the third anniversary of the Closing Date, and declines to 0.0% on or after the fourth anniversary of the Closing Date. At any time, the Company may pre-pay up to $50.0 million in aggregate principal amount of the First Lien Notes from internally generated cash without incurring any make-whole or prepayment premium. The occurrence of certain events of default may increase the applicable rate of interest by 2.0% and could result in the acceleration of the Company’s obligations under the First Lien Note Facility prior to stated maturity and an obligation of the Company to pay the full amount of its obligations under the First Lien Note Facility.
The First Lien Note Facility contains customary events of default that include, among others, non-payment of principal, interest or fees, violation of covenants, inaccuracy of representations and warranties, bankruptcy and insolvency events, material judgments, cross-defaults to material indebtedness and events constituting a change of control. In addition, the obligations under the First Lien Note Facility will be guaranteed by joint and several guarantees from the Company’s subsidiaries.
In connection with the First Lien Note Facility, the Company, its subsidiaries and the First Lien Collateral Agent entered into a First Lien Guaranty and Security Agreement, dated as of June 29, 2017 (the “First Lien Guaranty and Security Agreement”). Pursuant to the First Lien Guaranty and Security Agreement, the obligations under the First Lien Notes will be secured by first priority liens on, and security interests in, substantially all of the assets of the Company and its subsidiaries.
The Second Lien Notes accrue interest, payable monthly in arrears, at a floating rate or rates equal to, at the option of the Company, (i) one-month LIBOR (subject to a 1.25% floor) plus 9.25% per annum in cash, (ii) one-month LIBOR (subject to a 1.25% floor) plus 11.25% per annum, which amount will be capitalized on each interest payment date, or (iii) one-month LIBOR (subject to a 1.25% floor) plus 10.25% per annum, of which one-half LIBOR plus 4.625% per annum will be payable in cash and one-half LIBOR plus 5.625% per annum will be capitalized on each interest payment date, provided that, in each case, if any permitted refinancing indebtedness with which the 2021 Notes are refinanced requires or permits the payment of cash interest, all of the interest on the Second Lien Notes shall be paid in cash. The Second Lien Notes mature on August 15, 2020, provided that if the 2021 Notes are refinanced prior to August 15, 2020, then the scheduled maturity date of the Second Lien Notes shall be June 30, 2022.
The Second Lien Notes are not subject to scheduled amortization installments. The Second Lien Notes are pre-payable at the Company’s option at specified premiums to the principal amount that will decline over the term of the Second Lien Note Facility. If the Second Lien Notes are prepaid prior to the third anniversary of the Closing Date, the Company will need to pay a make-whole premium based on the present value (using a discount rate based on the specified treasury rate plus 50 basis points) of all remaining interest payments on the Second Lien Notes being prepaid prior to the third anniversary of the Closing Date, plus 4.0% of the principal amount of Second Lien Notes being prepaid. On or after the third anniversary of the Closing Date, the prepayment premium is 4.0%, which declines to 2.0% on or after the fourth anniversary of the Closing Date, and declines to 0.0% on or after the fifth anniversary of the Closing Date. The occurrence of certain events of default may increase the applicable rate of interest by 2.0% and could result in the acceleration of the Company’s obligations under the Second Lien Note Facility prior to stated maturity and an obligation of the Company to pay the full amount of its obligations under the Second Lien Note Facility.
The Second Lien Note Facility contains customary events of default that include, among others, non-payment of principal, interest or fees, violation of covenants, inaccuracy of representations and warranties, bankruptcy and insolvency events, material judgments, cross-defaults to material indebtedness and events constituting a change of control. In addition, the obligations under the Second Lien Note Facility will be guaranteed by joint and several guarantees from the Company’s subsidiaries.
In connection with the Second Lien Note Facility, the Company, its subsidiaries and the Second Lien Collateral Agent entered into a Second Lien Guaranty and Security Agreement, dated as of June 29, 2017 (the “Second Lien Guaranty and Security Agreement”). Pursuant to the Second Lien Guaranty and Security Agreement, the obligations under the Second Lien Notes will be secured by second priority liens on, and security interests in, substantially all of the assets of the Company and its subsidies.
In connection with the First Lien Note Facility and the Second Lien Note Facility, the Company, the First Lien Collateral Agent and the Second Lien Collateral Agent, entered into an intercreditor agreement containing customary provisions to, among other things, subordinate the lien priority of the liens granted under the Second Lien Note Facility to the liens granted under the First Lien Note Facility.

32

2021 Notes
On February 11, 2014, the Company issued $200.0 million aggregate principal amount of 8.875% senior notes due in 2021 (the “2021 Notes”). The 2021 Notes are senior unsecured obligations of the Company and are fully and unconditionally guaranteed by all existing and future subsidiaries of the Company.
Interest on the 2021 Notes accrues at a fixed rate of 8.875% per annum and is payable in cash semi-annually on February 15 and August 15 of each year. The debt discount of $5.0 million at issuance is being amortized as interest expense through maturity which will result in the accretion over time of the outstanding debt balance to the principal amount. The 2021 Notes are the Company’s senior unsecured obligations and rank equally in right of payment with all of its other existing and future senior unsecured indebtedness and senior in right of payment to all of its existing and future subordinated indebtedness.
The 2021 Notes are guaranteed on a full, joint and several basis by each of the Company’s existing and future domestic restricted subsidiaries that is a borrower under any of the Company’s credit facilities or that guarantees any of the Company’s debt or that of any of its restricted subsidiaries, in each case incurred under the Company’s credit facilities. As of June 30, 2017, the Company does not have any independent assets or operations, and as a result, its direct and indirect subsidiaries (other than minor subsidiaries), each being 100% owned by the Company, are fully and unconditionally, jointly and severally, providing guarantees on a senior unsecured basis to the 2021 Notes.
Securities Purchase Agreement
On March 9, 2015, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with Coliseum Capital Partners L.P., a Delaware limited partnership, Coliseum Capital Partners II, L.P., a Delaware limited partnership, and Blackwell Partners, LLC, Series A, a Georgia limited liability company (collectively, the “PIPE Investors”). Pursuant to the terms of the Purchase Agreement, the Company issued and sold to the PIPE Investors in a private placement (the “PIPE Transaction”) an aggregate of (a) 625,000 shares of Series A Preferred Stock at a purchase price per share of $100.00, (b) 1,800,000 Class A warrants (the “Class A Warrants”), and (c) 1,800,000 Class B warrants (the “Class B Warrants” and, together with Class A Warrants, the “PIPE Warrants”), for gross proceeds of $62.5 million. The initial conversion price for the PIPE Preferred Shares is $5.17. The PIPE Warrants may be exercised to acquire shares of Common Stock. Pursuant to an addendum (the “Warrant Addendum”), dated as of March 23, 2015, to the Warrant Agreement, dated as of March 9, 2015 (together with the Warrant Addendum, the “Warrant Agreement”), with the PIPE Investors, the PIPE Investors paid the Company $0.5 million in the aggregate, and the per share exercise price of the Class A Warrants and Class B Warrants was set at $5.17 and $6.45, respectively, reduced from $5.295 to $5.17 and from $6.595 to $6.45, respectively.
Series A, Series B, and Series C Convertible Preferred Stock
In connection with the PIPE Transaction, the Company authorized 825,000 shares and issued to the PIPE Investors 625,000 shares of Series A Preferred Stock at $100.00 per share. We are required, pursuant to the terms of the Certificate of Designations governing the Series A Preferred Stock and the Warrant Agreement governing the PIPE Warrants, to at all times reserve sufficient shares of common stock to allow for the conversion of the Series A Preferred Stock and exercise of the PIPE Warrants.
The Series A Preferred Stock may, at the option of the holder, be converted into Common Stock and receive a Liquidation Preference upon voluntary or involuntary liquidation, dissolution, or winding up of the Company as described in the Company’s Annual Report. The Company may pay a noncumulative cash dividend on each share of the Series A Preferred Stock. In the event the Company does not declare and pay a cash dividend, the Liquidation Preference of the Series A Preferred Stock will be increased to an amount equal to the Liquidation Preference in effect at the start of the applicable quarterly dividend period, plus an amount equal to such then applicable Liquidation Preference multiplied by 11.5% per annum.
On June 10, 2016, in order to allow the shares of common stock reserved for issuance for the conversion of the Series A Preferred Stock and exercise of the PIPE Warrants to be released from reservation and sold pursuant to the 2016 Equity Offering (see below), we entered into an Exchange Agreement with the PIPE Investors (the “Series B Exchange Agreement”) pursuant to which the PIPE Investors agreed:
i)
to exchange 614,177 shares of the existing Series A Preferred Stock for an identical number of shares of Series B Convertible Preferred Stock (the “Series B Preferred Stock”), which have the same terms as the Series A Preferred Stock, except that the terms of the Series B Preferred Stock include the authority of the holders of the Series B Preferred Stock to waive the requirement that the Company reserve a sufficient number of shares of common stock reserved at all times to allow for the conversion of the Series B Preferred Stock; and

33

ii)
to waive the requirement under the Warrant Agreement governing the PIPE Warrants to reserve 3,600,000 shares of our common stock for the exercise of the PIPE Warrants.
On June 14, 2016, the Company entered into another Exchange Agreement (the “Series C Exchange Agreement”) with the PIPE Investors, pursuant to which the PIPE Investors agreed to exchange their shares of Series B Preferred Stock issued pursuant to the Series B Exchange Agreement on a one for one basis for shares of a new series of preferred stock of the Company (the “Series C Preferred Stock” and, together with the Series A Preferred Stock and the Series B Preferred Stock, the “Preferred Stock”), designated “Series C Convertible Preferred Stock.”
Under the terms of the Series C Exchange Agreement, the PIPE Investors agreed to exchange 614,177 shares of the Series B Preferred Stock for an identical number of shares of Series C Preferred Stock, which have the same terms as the Series B Preferred Stock, except that the terms of the Series C Preferred Stock provide that the 11.5% per annum rate of non-cash dividends payable on the shares of the Series C Preferred Stock will be reduced based on the achievement by the Company of specified “Consolidated EBITDA” as defined in the Senior Credit Facilities. In addition, pursuant to the Series C Exchange Agreement, the PIPE Investors agreed to waive the requirement under the Warrant Agreement governing the PIPE Warrants held by the PIPE Investors to reserve 3,600,000 shares of our common stock for the exercise of the PIPE Warrants.
The transactions effected pursuant to the Series C Exchange Agreement ensured there were a sufficient number of authorized shares of common stock to undertake the 2016 Equity Offering. In the Series C Exchange Agreement, we agreed that within four months of the date of the Series C Exchange Agreement, a special meeting of our stockholders would be called to seek approval to the Charter Amendment so as to allow us to reserve sufficient shares for the conversion of the Series C Preferred Stock and the exercise of the PIPE Warrants. This approval was obtained at a special meeting of our stockholders held on November 30, 2016.
As a result of the exchanges discussed above, there are, as of June 30, 2017 (a) 21,645 shares of Series A Preferred Stock outstanding, of which 10,823 shares are owned by the PIPE Investors, (b) no shares of Series B Preferred Stock outstanding, and (c) 614,177 shares of Series C Preferred Stock outstanding, all of which are owned by the PIPE Investors.
Rights Offering
On June 30, 2015, the Company commenced a rights offering (the “Rights Offering”) pursuant to which the Company distributed subscription rights to purchase units consisting of (1) Series A Preferred Stock, each share convertible into shares of Common Stock at a conversion price of $5.17 per share, (2) Class A warrants to purchase one share of Common Stock at a price of $5.17 per share (the “Public Class A Warrants”), and (3) Class B warrants to purchase one share of Common Stock at a price of $6.45 per share (the “Public Class B Warrants” and, together with the Public Class A Warrants, the “Public Warrants”). The Rights Offering was completed on July 31, 2015. Stockholders of the Company exercised subscription rights to purchase 10,822 units, consisting of an aggregate of 10,822 shares of the Series A Preferred Stock, 31,025 Public Class A Warrants, and 31,025 Public Class B Warrants, at a subscription price of $100.00 per unit. Pursuant to the Rights Offering, the Company raised gross proceeds of approximately $1.1 million.
With the exception of the expiration date, the Class A Warrants issued pursuant to the PIPE Transaction, as amended by the Warrant Addendum, have the same terms as the Public Class A Warrants issued pursuant to the Rights Offering. Similarly, with the exception of the expiration date, the Class B Warrants issued pursuant to the PIPE Transaction, as amended by the Warrant Addendum, have the same terms as the Public Class B Warrants issued pursuant to the Rights Offering.
2016 Shelf Registration
We filed a shelf registration statement on Form S-3 under the Securities Act on April 1, 2016, which was declared effective May 2, 2016 (the “2016 Shelf”). Under the 2016 Shelf at the time of effectiveness, we had the ability to raise up to $200.0 million, in one or more transactions, by selling common stock, preferred stock, debt securities, warrants, units and rights.
2016 Equity Offering
On June 22, 2016, pursuant to our effective shelf registration statement on Form S-3, we completed an underwritten public offering of 45,200,000 shares of our common stock, including 5,200,000 shares of common stock issued upon the underwriters’ full exercise of the over-allotment option, at a public offering price of 2.00 per share, less underwriting discounts and commissions and offering expenses payable by us (the “2016 Equity Offering”). We received net proceeds of approximately $83.3 million from the 2016 Equity Offering, after deducting underwriting discounts and commissions and offering expenses.
A portion of the net proceeds from the 2016 Equity Offering was used to temporarily repay our outstanding borrowings under the Revolving Credit Facility. We then drew from the Revolving Credit Facility and used the remainder of the 2016 Equity Offering

34

net proceeds to fund the Cash Consideration and pay fees and expenses in connection with the closing of the Home Solutions Transaction.
Home Solutions Transaction
On September 9, 2016, the Company acquired substantially all of the assets and assumed certain liabilities of Home Solutions and its subsidiaries pursuant to the Home Solutions Agreement dated June 11, 2016, by and among Home Solutions, a Delaware corporation, certain subsidiaries of Home Solutions, the Company and HomeChoice Partners, Inc., a Delaware corporation. Home Solutions, a privately held company, provides home infusion and home nursing products and services to patients suffering from chronic and acute medical conditions. On June 16, 2016, the Company, HomeChoice Partners, Inc. and Home Solutions entered into an amendment to the Home Solutions Agreement (the “First Amendment”), which modified the terms of the consideration payable by the Company to Home Solutions thereunder. On September 2, 2016, the same parties entered into a second amendment to the Home Solutions Agreement (the “HS Second Amendment”), which amended the Home Solutions Agreement to eliminate the condition to closing that the Company receive stockholder approval to increase its authorized share capital (the “Charter Amendment”) and facilitated the timely consummation of the Transaction. The HS Second Amendment instead provided that the Company will hold a stockholder meeting after the closing of the Transaction to seek stockholder approval of the Charter Amendment, and if the approval is not obtained at the first special meeting, the Company will submit the proposal on a twice per year basis beginning in 2017, at either the annual meeting or a special meeting of stockholders. This approval was obtained at a special meeting held on November 30, 2016. On September 9, 2016, in connection with the consummation of the Transaction, the parties entered into a third amendment (the “Third Amendment”) to the Home Solutions Agreement, which provided for non-material amendments to the closing mechanics, defined terms, acquired and excluded assets, and covenants of the Home Solutions Agreement.
Under the Home Solutions Agreement, the Company did not purchase, among other things, (a) any accounts receivable associated with governmental payors, (b) cash assets, (c) certain non-transferable assets (e.g., state licenses and Medicare and Medicaid certifications and personnel and employment records), (d) the equity of Home Solutions and its subsidiaries; (e) certain tax assets, (f) causes of actions related to any of the items specified as excluded assets or excluded liabilities in the Home Solutions Agreement, (g) any privileged materials, documents or records of Home Solutions related to such excluded assets or excluded liabilities, or (h) intercompany receivables.
The aggregate consideration paid by the Company in the Home Solutions Transaction was equal to (i) the Cash Consideration; plus (ii)(a) the Transaction Closing Equity Consideration and (b) the RSUs, issuable in two tranches, Tranche A and Tranche B, with different vesting conditions. The number of shares of Company common stock in Tranche A will be approximately 3.1 million. The number of shares of Company common stock in Tranche B will be approximately 4.0 million. Upon close of the Transaction the RSUs had no intrinsic value, but are reported in our consolidated financial statements at their estimated fair value at the date of issuance. The Home Solutions Agreement provides Home Solutions with certain customary registration rights that required us, within 30 days following the closing of the Home Solutions Transaction, to file a registration statement for the selling stockholder’s resale of the Transaction Closing Equity Consideration and the Contingent Shares pursuant to the Securities Act. The Company filed the registration statement on October 7, 2016 and it was declared effective on October 27, 2016.
The Company will issue the shares of our Common Stock issuable to Home Solutions pursuant to the RSUs in Tranche A promptly, and in any event within five business days, following the earlier of (a) the closing price of our Common Stock, as reported by NASDAQ, averaging $4.00 per share or above over 20 consecutive trading days during the period beginning on September 9, 2016 and ending December 31, 2019, or (b) a change of control that occurs on or prior to December 31, 2017 or a change of control thereafter but on or prior to December 31, 2019, pursuant to which the consideration payable per share equals or exceeds $4.00 per share. The Company will issue the shares of our Common Stock issuable to Home Solutions pursuant to the RSUs in Tranche B promptly, and in any event within five business days, following the earlier of (a) the closing price of our Common Stock, as reported by NASDAQ, averaging $5.00 per share or above over 20 consecutive trading days during the period beginning on September 9, 2016 and ending December 31, 2019, or (b) a change of control that occurs on or prior to December 31, 2017, or a change of control thereafter but on or prior to December 31, 2019, pursuant to which the consideration payable per share equals or exceeds $5.00 per share. The Home Solutions Agreement provides for a cash settlement option related to the RSUs, effective June 15, 2021, if, and only if, authorized shares are unavailable when the vesting conditions of Tranche A and Tranche B are met. The Cash Consideration and the Transaction Closing Equity Consideration were paid at closing and were funded by cash on-hand and borrowings from our Revolving Credit Facility.
First Quarter 2017 Private Placement
On March 1, 2017, the Company entered into a Stock Purchase Agreement (the “First Quarter Stock Purchase Agreement”) with Venor Capital Master Fund Ltd., Map 139 Segregated Portfolio of LMA SPC, Venor Special Situations Fund II LP and Trevithick LP (the “First Quarter Stockholders”). Pursuant to the First Quarter Stock Purchase Agreement, the Company sold an

35

aggregate of 3.3 million shares of its common stock (the “First Quarter Shares”) for aggregate gross proceeds of approximately $5.1 million in a private placement transaction (the “First Quarter 2017 Private Placement”). The purchase price for each Share was $1.5366, which was negotiated between the Company and the Stockholders based on the volume-weighted average price of the Company’s common stock on the NASDAQ Global Market on March 1, 2017. Proceeds from the First Quarter 2017 Private Placement will be used for working capital and general corporate purposes.
2017 Warrants
In connection with the Second Lien Note Facility (as defined below), the Company will also issue warrants (the “2017 Warrants”) to the purchasers of the Second Lien Notes (as defined below) pursuant to a Warrant Purchase Agreement dated as of June 29, 2017 (the “2017 Warrant Purchase Agreement”). The 2017 Warrants entitle the purchasers of the 2017 Warrants to purchase shares of Common Stock, representing at the time of any exercise of the 2017 Warrants an equivalent number of shares equal to 4.99% of the Common Stock of the Company on a fully diluted basis, subject to the terms of the Warrant Agreement governing the Warrants, dated as of June 29, 2017 (the “2017 Warrant Agreement”); provided, however, the Warrants may not be converted to the extent that, after giving effect to such conversion, the holders of the 2017 Warrants would beneficially own, in the aggregate, in excess of (i) 19.99% of the shares of Common Stock outstanding as of June 29, 2017 (the “Closing Date”) minus (ii) the shares of Common Stock that were sold pursuant to the Second Quarter 2017 Private Placement (as defined below) (the “Conversion Cap”). The Conversion Cap will not apply to the 2017 Warrants if the Company obtains the approval of its stockholders for the removal of the Conversion Cap, which the Company is required to take certain steps to attempt to obtain, subject to the terms of the Warrant Agreement.
The 2017 Warrants have a 10-year term and an initial exercise price of $2.00 per share, and may be exercised by payment of the exercise price in cash or surrender of shares of Common Stock into which the Warrants are being converted in an aggregate amount sufficient to pay the exercise price.  The exercise price and the number of shares that may be acquired upon exercise of the 2017 Warrants is subject to adjustments in certain situations, including price based anti-dilution protection whereby, subject to certain exceptions, if the Company later issues Common Stock or certain Common Stock Equivalents (as defined in the Warrant Agreement) at a price less than either the then-current market price per share or exercise price of the 2017 Warrant, then the exercise price will be decreased and the percentage of shares of Common Stock issuable upon exercise of the Warrants will remain the same, giving effect to such issuance. Additionally, the 2017 Warrants have standard anti-dilution protections if the Company effects a stock split, subdivision, reclassification or combination of its Common Stock or fixes a record date for the making of a dividend or distribution to stockholders of cash or certain assets. Upon the occurrence of certain business combinations the 2017 Warrants will be converted into the right to acquire shares of stock or other securities or property (including cash) of the successor entity.
Second Quarter 2017 Private Placement
On June 29, 2017, the Company entered into a Stock Purchase Agreement (the “Second Quarter Stock Purchase Agreement”) with a fund managed by Ares Management L.P. (“Ares” or the “Second Quarter Stock Purchaser”). Pursuant to the terms of the Second Quarter Stock Purchase Agreement, the Company issued and sold to the Second Quarter Stock Purchaser in a private placement (the “Second Quarter 2017 Private Placement”) 6,359,350 shares of Common Stock (the “Second Quarter Shares”) at a price of $2.50 per share, for proceeds of approximately $15.9 million, net of $0.2 million in associated costs.
Second Quarter Registration Rights Agreement
In connection with the 2017 Warrants and the Second Quarter 2017 Private Placement, the Company entered into a Registration Rights Agreement (the “Second Quarter 2017 Registration Rights Agreement”) with the holders of the 2017 Warrants and the Second Quarter Stock Purchaser. Pursuant to the Second Quarter 2017 Registration Rights Agreement, subject to certain exceptions, the Company is required, upon the request of the Second Quarter Stock Purchaser and holders of the 2017 Warrants, to register the resale of the Second Quarter Shares and the shares of Common Stock issuable upon exercise of the 2017 Warrants. Pursuant to the terms of the Second Quarter 2017 Registration Rights Agreement, these registration rights will not become effective until twelve months after the Closing Date, and the costs incurred in connection with such registrations will be borne by the Company.
Income Taxes
At June 30, 2017, we had Federal net operating loss (“NOL”) carry forwards of approximately $373.8 million, of which $14.3 million is subject to an annual limitation, which will begin expiring in 2026 and later. We have post-apportioned state NOL carry forwards of approximately $414.4 million, the majority of which will begin expiring in 2017 and later.

36

Future Cash Requirements
Net cash used in operating activities from continuing operations totaled $4.1 million during the six months ended June 30, 2017. Our working capital increased $41.9 million as of June 30, 2017 compared to December 31, 2016, primarily as a result of an increase in our cash and cash equivalents of $31.0 million attributable to the net proceeds received from the 2017 Private Placement and the Priming Credit Agreement. At June 30, 2017, we had $40.5 million of unrestricted cash on hand and, until December 2018, $10.0 million of delayed draw capacity under the Second Lien Notes Facility to supplement our working capital needs.
If we cannot successfully execute our strategic plans we will likely require additional or alternative sources of liquidity, including additional borrowings.
On June 29, 2017, we entered into the Notes Facilities pursuant to which we issued new senior secured notes and refinanced our existing senior secured credit facilities. Please refer to “Debt Facilities” in this section.
We regularly evaluate market conditions and financing options to improve our current liquidity profile and enhance our financial flexibility. These options may include opportunities to raise additional funds through the issuance of various forms of equity and/or debt securities or other instruments, the sale of assets or refinancing all or a portion of our indebtedness. However, there is no assurance that, if necessary, we would be able to raise capital to provide required liquidity.
Additionally, we will pursue our operational and strategic plan and will also review a range of strategic alternatives, which could include, among other things, transitioning chronic therapies to alliance partners, a potential sale or merger of our company, or continuing to pursue our operational and strategic plan. Additionally, we may pursue joint venture arrangements, additional business acquisitions and other transactions designed to expand our business.
As of the filing of this Quarterly Report, we expect that our cash on hand and cash from operations will be sufficient to fund our anticipated working capital, scheduled interest repayments and other cash needs for at least the next 12 months. Principal payments on the Notes Facilities are not required until September 30, 2018.
The accompanying unaudited consolidated financial statements have been prepared on a going concern basis, which contemplates realization of assets and satisfaction of liabilities in the ordinary course of business. As such, they do not include any adjustments to the recoverability and reclassification of recorded amounts that might be necessary should we be unable to continue as a going concern.
The UnitedHealthcare contract will terminate effective on September 30, 2017. Following a negotiation process it became apparent our business demands do not align, and UnitedHealthcare and the Company were unable to find an agreement that was beneficial to both parties. The termination of this agreement is consistent with our CORE initiative, which focuses on growth of our profitable business segments. We anticipate that the UnitedHealthcare contract termination, exclusive of certain provisions, will have a negative impact to 2017 revenue and a neutral impact to 2017 adjusted EBITDA. Because the UnitedHealthcare contract was not profitable, its termination is expected to have a negative impact on revenues but a positive impact on adjusted EBITDA outlook going forward (see Note 8 - Concentration of Risk).
Item 3.
Quantitative and Qualitative Disclosures About Market Risks
There have been no material changes to our exposure to market risk since the Annual Report.
Item 4.
Controls and Procedures
Evaluation of Disclosure Controls and Procedures
The Company maintains disclosure controls and procedures (as such term is defined under Rule 13a-15(e) promulgated under the Exchange Act) that are designed to ensure that information required to be disclosed by the Company in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the Company’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Under the supervision and with the participation of the Company’s management, including its Chief Executive Officer and Chief Financial Officer, management evaluated the effectiveness of the Company’s disclosure controls and procedures as of June 30, 2017. Based on that evaluation, the Company’s Chief Executive Officer and its Chief Financial Officer concluded that the Company’s disclosure controls and procedures were effective as of June 30, 2017.

37

Changes in Internal Control Over Financial Reporting
There have been no changes in our internal control over financial reporting that occurred during the three months ended June 30, 2017 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II
OTHER INFORMATION
Item 1.
Legal Proceedings
 
For a summary of legal proceedings please refer to Note 7 within the financial statements section of this document.
Item 1A.
Risk Factors
The risk factors disclosed in “Item 1A. Risk Factors” included in our Annual Report on Form 10-K for the year ended December 31, 2016 are hereby incorporated by reference.
Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds
The information disclosed in Part I Item 2 under the headings “2017 Warrants” and “Second Quarter 2017 Private Placement” is hereby incorporated by reference. The Company relied on Section 4(a)(2) of the Securities Act for both the issuance of the 2017 Warrants and the Common Shares in the Second Quarter 2017 Private Placement.
Item 5.
Other Information
None.

38

Item 6.
Exhibits
(a) Exhibits.
Exhibit Number 
Description
2.1+
Asset Purchase Agreement, dated June 11, 2016, by and among HS Infusion Holdings, Inc., the direct and indirect subsidiaries of HS Infusion Holdings, Inc. set forth on the signature pages, the Company and HomeChoice Partners, Inc. (the “Home Solutions Agreement”) (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed on June 13, 2016, SEC File Number 000-28740).
2.2
First Amendment, dated June 16, 2016, to the Home Solutions Agreement (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K/A filed on June 20, 2016, SEC File Number 000-28740).
2.3
Second Amendment, dated September 2, 2016, to the Home Solutions Agreement (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed on September 7, 2016, SEC File Number 001-11993).
2.4
Third Amendment, dated September 9, 2016, to the Home Solutions Agreement (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed on September 12, 2016, SEC File Number 001-11993).
3.1
Second Amended and Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.2 to the Company’s Registration Statement on Form S-4 (File No. 333-119098) declared effective on January 26, 2005).
3.2
Amendment to the Second Amended and Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on June 10, 2010, SEC File Number 000-28740).
3.3
Certificate of Designations for Series A Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on March 10, 2015, SEC File Number 000-28740).
3.4
Certificate of Designations for Series B Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on June 13, 2016, SEC File Number 000-28740).
3.5
Certificate of Designations for Series C Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on June 14, 2016, SEC File Number 000-28740).
3.6
Certificate of Designations, Preferences, and Rights for Series D Junior Participating Preferred Stock (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on August 12, 2016, SEC File Number 000-28740).
3.7
Amended and Restated By-Laws of the Company (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed on April 28, 2011, SEC File Number 000-28740).
4.1
Registration Rights Agreement, dated June 29, 2017, by and among the Company and the parties signatory thereto (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed on June 29, 2017, SEC File Number 001-11993).
4.2
Warrant Agreement, dated June 29, 2017, by and among the Company and the subscribers signatory thereto (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on June 29, 2017, SEC File Number 001-11993).
10.1
Offer Letter, dated April 10, 2017, by and between the Company and Stephen M. Deitsch (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on April 20, 2017, SEC File Number 001-11993).
10.2
First Lien Note Purchase Agreement, dated as of June 29, 2017, by and among the Company, the financial institutions and note purchasers from time to time party thereto, and Wells Fargo Bank, National Association, as Collateral Agent (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on June 29, 2017, SEC File Number 001-11993).
10.3
First Lien Guaranty and Security Agreement, dated as of June 29, 2017, by and the Company, the subsidiaries of the Company signatory thereto and Wells Fargo Bank, National Association as Collateral Agent (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on June 29, 2017, SEC File Number 001-11993).
10.4
Second Lien Note Purchase Agreement, dated as of June 29, 2017, by and among the Company, the financial institutions and note purchasers from time to time party thereto, and Wells Fargo Bank, National Association as Collateral Agent (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed on June 29, 2017, SEC File Number 001-11993).
10.5
Second Lien Guaranty and Security Agreement, dated as of June 29, 2017, by and the Company, the subsidiaries of the Company signatory thereto and Wells Fargo Bank, National Association as Collateral Agent (incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K filed on June 29, 2017, SEC File Number 001-11993).
10.6
Warrant Purchase Agreement, dated as of June 29, 2017, by and among the Company and the subscribers signatory thereto (incorporated by reference to Exhibit 10.5 to the Company’s Current Report on Form 8-K filed on June 29, 2017, SEC File Number 001-11993).
10.7
Stock Purchase Agreement, dated as of June 29, 2017, by and among the Company and the purchaser signatory thereto (incorporated by reference to Exhibit 10.6 to the Company’s Current Report on Form 8-K filed on June 29, 2017, SEC File Number 001-11993).
31.1
Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2
Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

39

32.1
Certification of Chief Executive Officer pursuant to 18 U.S. C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2
Certification of Chief Financial Officer pursuant to 18 U.S. C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101 *
The following financial information from BioScrip, Inc.’s Quarterly Report on Form 10-Q for the period ended September 30, 2016, formatted in XBRL (eXtensible Business Reporting Language): (i) Unaudited Consolidated Statements of Operations for the three and nine months ended September 30, 2016 and 2015, (ii) Consolidated Balance Sheets as of September 30, 2016 and December 31, 2015, (iii) Unaudited Consolidated Statements of Cash Flows for the nine months ended September 30, 2016 and 2015, and (iv) Notes to Unaudited Consolidated Financial Statements.
*
Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933 or Section 18 of the Securities Exchange Act of 1934 and otherwise are not subject to liability under those sections.
+
Certain schedules attached to the Home Solutions Agreement have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company will furnish the omitted schedules to the Securities and Exchange Commission upon request by the Commission.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on August 8, 2017.


                                                          BIOSCRIP INC.
 
                                                         /s/  C. Britt Jeffcoat
                                                          C. Britt Jeffcoat
                                                          Vice President, Controller
and Chief Accounting Officer


40
 EX-31.1 2 bios-ex311x20170630x10q.htm EXHIBIT 31.1 Exhibit


EXHIBIT 31.1 

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Daniel E. Greenleaf, certify that:
1.     I have reviewed this Quarterly Report on Form 10-Q of BioScrip, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))for the registrant and have:
(a) 
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) 
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) 
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) 
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a) 
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b) 
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: August 8, 2017


/s/ Daniel E. Greenleaf
Daniel E. Greenleaf, President, Chief Executive Officer
and Principal Executive Officer



 EX-31.2 3 bios-ex312x20170630x10q.htm EXHIBIT 31.2 Exhibit


EXHIBIT 31.2

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Stephen M. Deitsch, certify that:
1.     I have reviewed this Quarterly Report on Form 10-Q of BioScrip, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))for the registrant and have:
(a) 
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) 
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) 
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) 
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a) 
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b) 
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 8, 2017


/s/ Stephen M. Deitsch
Stephen M. Deitsch, Chief Financial Officer,
Treasurer and Principal Financial Officer



 EX-32.1 4 bios-ex321x20170630x10q.htm EXHIBIT 32.1 Exhibit


EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of BioScrip, Inc. (the “Company”) on Form 10-Q for the quarter ended June 30, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Daniel E. Greenleaf, Chief Executive Officer of the Company, do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
(1)     The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 8, 2017



/s/ Daniel E. Greenleaf
Daniel E. Greenleaf, President, Chief Executive Officer
and Principal Executive Officer
    



 EX-32.2 5 bios-ex322x20170630x10q.htm EXHIBIT 32.2 Exhibit


EXHIBIT 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of BioScrip, Inc. (the “Company”) on Form 10-Q for the quarter ended June 30, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Stephen M. Deitsch, Chief Financial Officer of the Company, do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
(1)     The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 8, 2017



/s/ Stephen M. Deitsch _________________
Stephen M. Deitsch, Chief Financial Officer,
Treasurer and Principal Financial Officer
   





 EX-101.INS 6 bios-20170630.xml XBRL INSTANCE DOCUMENT 0001014739 2017-01-01 2017-06-30 0001014739 2017-08-07 0001014739 2016-12-31 0001014739 2017-06-30 0001014739 us-gaap:SeriesAPreferredStockMember 2016-12-31 0001014739 us-gaap:SeriesCPreferredStockMember 2016-12-31 0001014739 us-gaap:SeriesAPreferredStockMember 2017-06-30 0001014739 us-gaap:SeriesCPreferredStockMember 2017-06-30 0001014739 2017-04-01 2017-06-30 0001014739 2016-01-01 2016-06-30 0001014739 2016-04-01 2016-06-30 0001014739 2015-12-31 0001014739 2016-06-30 0001014739 bios:PatientMember bios:FinancingReceivables.Greaterthan180DaysPastDueMember 2017-06-30 0001014739 bios:FinancingReceivables.1to180DaysPastDueMember 2017-06-30 0001014739 bios:PatientMember 2017-06-30 0001014739 us-gaap:CommercialAndIndustrialSectorMember 2016-12-31 0001014739 us-gaap:GovernmentSectorMember bios:FinancingReceivables.1to180DaysPastDueMember 2016-12-31 0001014739 bios:PatientMember 2016-12-31 0001014739 bios:PatientMember bios:FinancingReceivables.1to180DaysPastDueMember 2016-12-31 0001014739 us-gaap:GovernmentSectorMember 2017-06-30 0001014739 us-gaap:GovernmentSectorMember bios:FinancingReceivables.1to180DaysPastDueMember 2017-06-30 0001014739 us-gaap:CommercialAndIndustrialSectorMember bios:FinancingReceivables.Greaterthan180DaysPastDueMember 2016-12-31 0001014739 us-gaap:GovernmentSectorMember bios:FinancingReceivables.Greaterthan180DaysPastDueMember 2016-12-31 0001014739 bios:PatientMember bios:FinancingReceivables.Greaterthan180DaysPastDueMember 2016-12-31 0001014739 bios:FinancingReceivables.Greaterthan180DaysPastDueMember 2016-12-31 0001014739 us-gaap:CommercialAndIndustrialSectorMember 2017-06-30 0001014739 bios:FinancingReceivables.1to180DaysPastDueMember 2016-12-31 0001014739 us-gaap:CommercialAndIndustrialSectorMember bios:FinancingReceivables.1to180DaysPastDueMember 2017-06-30 0001014739 bios:FinancingReceivables.Greaterthan180DaysPastDueMember 2017-06-30 0001014739 us-gaap:CommercialAndIndustrialSectorMember bios:FinancingReceivables.Greaterthan180DaysPastDueMember 2017-06-30 0001014739 us-gaap:GovernmentSectorMember 2016-12-31 0001014739 us-gaap:CommercialAndIndustrialSectorMember bios:FinancingReceivables.1to180DaysPastDueMember 2016-12-31 0001014739 us-gaap:GovernmentSectorMember bios:FinancingReceivables.Greaterthan180DaysPastDueMember 2017-06-30 0001014739 bios:PatientMember bios:FinancingReceivables.1to180DaysPastDueMember 2017-06-30 0001014739 us-gaap:SeriesCPreferredStockMember 2017-01-01 2017-06-30 0001014739 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2017-06-29 2017-06-29 0001014739 bios:ClassAWarrantsMember 2015-07-31 0001014739 bios:TwoThousandFifteenWarrantsMember 2015-03-09 2015-03-09 0001014739 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2017-03-01 2017-03-01 0001014739 us-gaap:SeriesAPreferredStockMember 2015-03-09 0001014739 us-gaap:RestrictedStockUnitsRSUMember bios:HSInfusionHoldingsIncMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2016-09-09 2016-09-09 0001014739 bios:ClassBWarrantsMember 2015-07-31 0001014739 bios:ClassAWarrantsMember 2015-06-30 0001014739 us-gaap:RestrictedStockUnitsRSUMember bios:HSInfusionHoldingsIncMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2016-09-09 0001014739 bios:ClassBWarrantsMember 2015-03-09 0001014739 bios:ClassBWarrantsPriortoAddendumMember 2015-03-09 0001014739 us-gaap:CommonStockMember bios:SecondaryOfferingMember 2016-06-22 2016-06-22 0001014739 us-gaap:SeriesAPreferredStockMember 2015-07-31 0001014739 us-gaap:RestrictedStockUnitsRSUMember bios:HSInfusionHoldingsIncMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2016-09-09 0001014739 bios:TwoThousandFifteenWarrantsMember us-gaap:CommonStockMember 2017-06-30 0001014739 bios:A2017WarrantsMember us-gaap:CommonStockMember 2017-06-30 0001014739 2015-07-31 2015-07-31 0001014739 bios:ClassAWarrantsPriortoAddendumMember 2015-03-09 0001014739 us-gaap:SeriesBPreferredStockMember 2017-06-30 0001014739 bios:ClassAWarrantsMember 2015-03-09 0001014739 us-gaap:SeriesAPreferredStockMember 2015-03-09 2015-03-09 0001014739 us-gaap:CommonStockMember us-gaap:OverAllotmentOptionMember 2016-06-22 2016-06-22 0001014739 bios:HSInfusionHoldingsIncMember 2016-09-09 2016-09-09 0001014739 us-gaap:RestrictedStockUnitsRSUMember bios:HSInfusionHoldingsIncMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2016-09-09 2016-09-09 0001014739 2016-05-02 0001014739 us-gaap:SeriesAPreferredStockMember 2017-01-01 2017-06-30 0001014739 bios:ClassBWarrantsMember 2015-06-30 0001014739 us-gaap:SeriesBPreferredStockMember 2016-06-14 2016-06-14 0001014739 bios:TwoThousandFifteenWarrantsMember us-gaap:SeriesAPreferredStockMember 2017-06-30 0001014739 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2017-03-01 0001014739 bios:A2017WarrantsMember us-gaap:CommonStockMember 2017-06-29 0001014739 us-gaap:CommonStockMember bios:SecondaryOfferingMember 2016-06-22 0001014739 us-gaap:SeriesAPreferredStockMember 2015-06-30 0001014739 bios:A2017WarrantsMember us-gaap:CommonStockMember 2017-06-29 2017-06-29 0001014739 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2017-06-29 0001014739 us-gaap:SeriesCPreferredStockMember 2016-06-14 2016-06-14 0001014739 bios:HSInfusionHoldingsIncMember 2016-09-09 0001014739 bios:HSInfusionHoldingsIncMember us-gaap:NoncompeteAgreementsMember 2016-09-09 0001014739 bios:HSInfusionHoldingsIncMember us-gaap:TradeNamesMember 2016-09-09 0001014739 bios:HSInfusionHoldingsIncMember bios:LicensesMember 2016-09-09 0001014739 bios:HSInfusionHoldingsIncMember us-gaap:CustomerContractsMember 2016-09-09 0001014739 bios:SeniorSecuredRevolvingCreditFacilityMember 2016-12-31 0001014739 bios:SecondLienNoteMaturingAugust152020Member 2016-12-31 0001014739 bios:FirstLienNoteMaturingJune302022Member 2016-12-31 0001014739 bios:SeniorUnsecured8.875NotesMember 2016-12-31 0001014739 bios:SeniorUnsecured8.875NotesMember 2017-06-30 0001014739 bios:FirstLienNoteMaturingJune302022Member 2017-06-30 0001014739 bios:SecondLienNoteMaturingAugust152020Member 2017-06-30 0001014739 us-gaap:CapitalLeaseObligationsMember 2016-12-31 0001014739 us-gaap:CapitalLeaseObligationsMember 2017-06-30 0001014739 bios:SeniorSecuredRevolvingCreditFacilityMember 2017-06-30 0001014739 us-gaap:FairValueInputsLevel2Member 2017-06-30 0001014739 bios:FirstLienNoteMaturingJune302022Member us-gaap:FairValueInputsLevel1Member 2017-06-30 0001014739 bios:SecondLienNoteMaturingAugust152020Member us-gaap:FairValueInputsLevel3Member 2017-06-30 0001014739 us-gaap:FairValueInputsLevel3Member 2017-06-30 0001014739 us-gaap:FairValueInputsLevel1Member 2017-06-30 0001014739 bios:SeniorUnsecured8.875NotesMember us-gaap:FairValueInputsLevel1Member 2017-06-30 0001014739 bios:SeniorUnsecured8.875NotesMember us-gaap:FairValueInputsLevel3Member 2017-06-30 0001014739 bios:FirstLienNoteMaturingJune302022Member us-gaap:FairValueInputsLevel2Member 2017-06-30 0001014739 bios:SecondLienNoteMaturingAugust152020Member us-gaap:FairValueInputsLevel1Member 2017-06-30 0001014739 bios:SeniorUnsecured8.875NotesMember us-gaap:FairValueInputsLevel2Member 2017-06-30 0001014739 bios:SecondLienNoteMaturingAugust152020Member us-gaap:FairValueInputsLevel2Member 2017-06-30 0001014739 bios:FirstLienNoteMaturingJune302022Member us-gaap:FairValueInputsLevel3Member 2017-06-30 0001014739 bios:FirstLienNoteMaturingJune302022Member us-gaap:SeniorNotesMember us-gaap:MinimumMember us-gaap:LondonInterbankOfferedRateLIBORMember 2017-01-01 2017-06-30 0001014739 bios:FirstLienNoteMaturingJune302022Member us-gaap:DebtInstrumentRedemptionPeriodTwoMember us-gaap:SeniorNotesMember 2017-01-01 2017-06-30 0001014739 bios:OptionThreeMember bios:SecondLienNoteMaturingAugust152020Member us-gaap:SeniorNotesMember 2017-01-01 2017-06-30 0001014739 bios:TermLoanBFacilityMember us-gaap:SeniorNotesMember 2013-07-31 0001014739 bios:FirstLienNoteMaturingJune302022Member us-gaap:SeniorNotesMember 2017-06-29 0001014739 bios:FirstLienNoteMaturingJune302022Member us-gaap:SeniorNotesMember 2017-01-01 2017-06-30 0001014739 bios:SecondLienNoteMaturingAugust152020Member us-gaap:SeniorNotesMember 2017-01-01 2017-06-30 0001014739 bios:OptionThreeHalfCashMember bios:SecondLienNoteMaturingAugust152020Member us-gaap:SeniorNotesMember 2017-01-01 2017-06-30 0001014739 us-gaap:RevolvingCreditFacilityMember bios:SeniorSecuredRevolvingCreditFacilityMember us-gaap:SeniorNotesMember 2013-07-31 0001014739 bios:SecondLienNoteMaturingAugust152020Member us-gaap:DebtInstrumentRedemptionPeriodOneMember us-gaap:SeniorNotesMember 2017-01-01 2017-06-30 0001014739 bios:SecondLienNoteMaturingAugust152020Member us-gaap:DebtInstrumentRedemptionPeriodThreeMember us-gaap:SeniorNotesMember 2017-01-01 2017-06-30 0001014739 bios:FirstLienNoteMaturingJune302022Member us-gaap:DebtInstrumentRedemptionPeriodThreeMember us-gaap:SeniorNotesMember 2017-01-01 2017-06-30 0001014739 bios:DelayedDrawTermLoanBFacilityMember us-gaap:SeniorNotesMember 2013-07-31 0001014739 bios:OptionOneMember bios:SecondLienNoteMaturingAugust152020Member us-gaap:SeniorNotesMember 2017-01-01 2017-06-30 0001014739 bios:OptionTwoMember bios:SecondLienNoteMaturingAugust152020Member us-gaap:SeniorNotesMember 2017-01-01 2017-06-30 0001014739 bios:FirstLienNoteMaturingJune302022Member us-gaap:SeniorNotesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2017-01-01 2017-06-30 0001014739 bios:OptionOneMember bios:SecondLienNoteMaturingAugust152020Member us-gaap:SeniorNotesMember us-gaap:MinimumMember us-gaap:LondonInterbankOfferedRateLIBORMember 2017-01-01 2017-06-30 0001014739 bios:FirstLienNoteMaturingJune302022Member us-gaap:DebtInstrumentRedemptionPeriodOneMember us-gaap:SeniorNotesMember 2017-01-01 2017-06-30 0001014739 bios:SecondLienNoteMaturingAugust152020Member us-gaap:DebtInstrumentRedemptionPeriodTwoMember us-gaap:SeniorNotesMember 2017-01-01 2017-06-30 0001014739 bios:FirstLienNoteMaturingJune302022Member us-gaap:SeniorNotesMember us-gaap:PrimeRateMember 2017-01-01 2017-06-30 0001014739 bios:FirstLienNoteMaturingJune302022Member us-gaap:SeniorNotesMember us-gaap:BaseRateMember 2017-01-01 2017-06-30 0001014739 bios:SeniorUnsecured8.875NotesMember 2014-02-11 0001014739 bios:OptionThreeHalfCapitalizedInterestMember bios:SecondLienNoteMaturingAugust152020Member us-gaap:SeniorNotesMember 2017-01-01 2017-06-30 0001014739 bios:PrimingCreditAgreementMember us-gaap:LineOfCreditMember 2017-01-06 0001014739 bios:FirstLienNoteMaturingJune302022Member us-gaap:SeniorNotesMember us-gaap:MinimumMember us-gaap:BaseRateMember 2017-01-01 2017-06-30 0001014739 bios:SecondLienDelayedDrawNotesMember us-gaap:SeniorNotesMember 2017-06-29 0001014739 bios:SecondLienNoteMaturingAugust152020Member us-gaap:SeniorNotesMember 2017-06-29 0001014739 bios:SecondLienDelayedDrawNotesMember us-gaap:SeniorNotesMember 2017-06-29 2017-06-29 0001014739 bios:PharmacyServicesAssetsSaleMember bios:WalgreensMember us-gaap:SettledLitigationMember 2016-12-28 2016-12-28 0001014739 us-gaap:CustomerConcentrationRiskMember bios:MedicareMember 2016-01-01 2016-06-30 0001014739 us-gaap:CustomerConcentrationRiskMember bios:UnitedHealthcareMember 2017-01-01 2017-06-30 0001014739 us-gaap:ProductConcentrationRiskMember bios:ImmuneGlobulinMember 2017-04-01 2017-06-30 0001014739 us-gaap:CustomerConcentrationRiskMember bios:MedicareMember 2016-04-01 2016-06-30 0001014739 us-gaap:ProductConcentrationRiskMember bios:ImmuneGlobulinMember 2016-04-01 2016-06-30 0001014739 us-gaap:ProductConcentrationRiskMember bios:ImmuneGlobulinMember 2017-01-01 2017-06-30 0001014739 us-gaap:ProductConcentrationRiskMember bios:ImmuneGlobulinMember 2016-01-01 2016-06-30 0001014739 us-gaap:CustomerConcentrationRiskMember bios:UnitedHealthcareMember 2016-01-01 2016-06-30 0001014739 us-gaap:CustomerConcentrationRiskMember bios:MedicareMember 2017-01-01 2017-06-30 0001014739 us-gaap:CustomerConcentrationRiskMember bios:UnitedHealthcareMember 2016-04-01 2016-06-30 0001014739 us-gaap:CustomerConcentrationRiskMember bios:UnitedHealthcareMember 2017-04-01 2017-06-30 0001014739 us-gaap:CustomerConcentrationRiskMember bios:MedicareMember 2017-04-01 2017-06-30 0001014739 us-gaap:DomesticCountryMember 2017-06-30 0001014739 us-gaap:StateAndLocalJurisdictionMember 2017-06-30 0001014739 us-gaap:RestrictedStockMember 2017-01-01 2017-06-30 0001014739 us-gaap:EmployeeStockMember 2013-05-07 0001014739 bios:A2008PlanMember us-gaap:CommonStockMember 2016-11-30 0001014739 bios:A2008PlanMember 2016-11-30 0001014739 bios:A2008PlanMember us-gaap:CommonStockMember 2016-11-30 2016-11-30 0001014739 us-gaap:StockOptionMember 2016-01-01 2016-06-30 0001014739 us-gaap:StockAppreciationRightsSARSMember 2017-01-01 2017-06-30 0001014739 us-gaap:EmployeeStockMember 2017-06-30 0001014739 us-gaap:RestrictedStockMember 2017-04-01 2017-06-30 0001014739 us-gaap:StockAppreciationRightsSARSMember bios:A2008PlanMember 2016-11-29 0001014739 us-gaap:StockOptionMember 2017-01-01 2017-06-30 0001014739 bios:A2008PlanMember 2017-06-30 0001014739 us-gaap:StockOptionMember bios:A2008PlanMember 2016-11-29 0001014739 bios:CharterAmendmentMember 2016-11-29 0001014739 us-gaap:EmployeeStockMember 2013-05-07 2013-05-07 0001014739 bios:A2008PlanMember us-gaap:CommonStockMember 2016-11-29 0001014739 us-gaap:StockOptionMember 2017-04-01 2017-06-30 0001014739 us-gaap:EmployeeStockMember 2017-04-01 2017-06-30 0001014739 bios:MarketBasedCashAwardsMember 2016-04-01 2016-06-30 0001014739 us-gaap:RestrictedStockMember bios:A2008PlanMember 2016-11-29 0001014739 us-gaap:StockOptionMember 2016-04-01 2016-06-30 0001014739 bios:CharterAmendmentMember 2016-11-30 0001014739 us-gaap:EmployeeStockMember 2017-01-01 2017-06-30 0001014739 bios:MarketBasedCashAwardsMember 2016-01-01 2016-06-30 0001014739 us-gaap:EmployeeStockMember 2016-04-01 2016-06-30 0001014739 us-gaap:EmployeeStockMember 2016-01-01 2016-06-30 xbrli:shares bios:Days iso4217:USD xbrli:shares iso4217:USD xbrli:pure 42191000 43209000 4291000 6958000 3911000 7134000 3799000 4825000 15400000 3136000 0.0499 494847000 0.00625 0.02 0.02 0.05 0.05 0.04 0 0.02 0.04 0 0.02 10000000 P18M 50000000 -51000 -102000 0 0 939000 -685000 62000 1027000 -102000 0 0.03 0.20 14300000 0.115 62500000 1100000 500000 200000000 false --12-31 Q2 2017 2017-06-30 10-Q 0001014739 127475226 Accelerated Filer BioScrip, Inc. 59134000 46381000 156541000 10780000 3955000 6825000 117592000 97744000 19848000 28169000 19891000 8278000 121590000 34951000 148740000 14735000 5195000 9540000 107779000 84190000 23589000 26226000 18714000 7512000 108099000 40641000 111811000 103089000 611844000 628545000 200000 -200000 100000 700000 100000 300000 1700000 100000 100000 300000 300000 300000 100000 600000 44730000 45651000 44730000 45651000 1987000 2875000 4252000 8790000 6789000 13777000 14000000 15500000 18300000 18400000 607740000 613383000 176052000 190497000 3100000 4000000 3750000 4.00 5.00 93155000 9938000 301000 2924000 2924000 263000 280000 110867000 16007000 852000 11956000 17712000 14576000 5400000 24700000 200000 1800000 3199000 93155000 891000 4651000 2209000 3134000 0 1327000 15577000 51425000 9569000 40533000 35848000 30964000 -5913000 -940000 5.17 6.45 5.17 2.00 5.17 5.295 6.45 6.595 1800000 1800000 31025 31025 3600000 0.0001 0.0001 0.0001 250000000 250000000 117682543 127441893 117682543 127441893 12000 13000 0.083 0.244 0.172 0.078 0.252 0.172 0.071 0.219 0.211 0.070 0.224 0.216 614177 614177 168298000 342528000 149796000 302022000 0 0 0 0 25000 25000 190000 226000 25000 25000 190000 226000 0.0925 0.0125 0.05625 0.04625 0.1025 0.1125 0.005 0.010 0.06 0.07 0.01 20 20 75000000.0 150000000.0 250000000.0 200000000.0 25000000 200000000 100000000 0.08875 0.08875 5000000 108000 125000 437000 932000 12452000 3668000 124000 147000 528000 1111000 16000 22000 91000 179000 2281000 3504000 8790000 13777000 -0.14 -0.32 -0.26 -0.45 0 475948000 0 31043000 24672000 0 939000 -685000 -685000 0 0 -13453000 -13453000 9414000 20465000 10025000 19504000 365947000 365947000 57218000 64164000 128396000 68310000 133894000 232462000 470924000 218106000 435916000 -8309000 -18079000 -28695000 -47686000 -8160000 -17907000 -27977000 -46349000 -0.14 -0.32 -0.26 -0.44 75000 308000 -503000 -940000 0.00 0.00 0.00 -0.01 149000 172000 718000 1337000 1926000 5314000 10266000 17242000 -2844000 -6271000 -9790000 -16236000 1064000 1126000 52000 105000 3000 3000 190000 226000 229000 249000 -16190000 -12753000 -352000 -1223000 -192000 31000 -10537000 -7343000 -3140000 714000 -322000 -5469000 1281000 -8721000 0 5055000 -9469000 -18881000 -12715000 -25459000 17325000 22613000 6705000 6736000 36165000 28822000 567301000 600002000 607740000 613383000 130350000 102882000 0 0 265507000 196670000 198000000 82931000 0 197008000 433413000 475674000 18521000 1731000 451934000 477405000 0 198000000 0 0 82931000 0 0 178109000 0 5800000 0.1999 61771000 45345000 -4334000 -9347000 -21589000 -5034000 -15676000 -4094000 -8234000 -17771000 -29198000 -48626000 -10463000 -22170000 -31676000 -53492000 373800000 414400000 2163000 2204000 1257000 17942000 40619000 80277000 42486000 86844000 0 311000 67516000 67500000 5466000 4292000 0.115 0.0001 0.0001 5000000 5000000 0 0 0 0 0 0 18507000 12998000 0 23060000 83300000 5100000 15900000 83267000 20776000 0 294446000 45000000 563000 -93000 -155000 1132000 0 32535000 30063000 4279000 11871000 6223000 13387000 111811000 103089000 129000 401000 60000000 55863000 6274000 236770000 0 5055000 1316000 3932000 3648000 6854000 -643419000 -692045000 1993000 1027000 5250000 750000 350000 500000 500000 9355000 125000000 3000000 14605000 250000000 136713 4360887 613287 0.85 100.00 100 100.00 2.00 1.5366 2.50 45200000 5200000 3300000.0 6359350 -31563000 -63487000 151000 4366000 26000 323000 173000 345000 175000 349000 2462000 69540000 2639000 74229000 2056000 4054000 2303000 4517000 2603000 75491000 2754000 2800000 79900000 79858000 0.0001 0.0001 0.0001 0.0001 5.17 825000 625000 825000 625000 825000 21645 614177 10823 21645 614177 625000 10822 21645 614177 21645 0 614177 16908000 16900000 0 16908000 0 73186000 70978000 121189000 119993000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These Unaudited Consolidated Financial Statements should be read in conjunction with the Audited Consolidated Financial Statements, including the notes thereto, and other information included in the Annual Report on Form 10-K of BioScrip, Inc. and its wholly-owned subsidiaries (the &#8220;Company&#8221;) for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> (the &#8220;Annual Report&#8221;) filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;). These Unaudited Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial information, and the instructions to Form 10-Q and Article 10 of Regulation S-X promulgated under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information furnished in these Unaudited Consolidated Financial Statements reflects all adjustments, including normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the results for the interim periods presented. Operating results for the </font><font style="font-family:inherit;font-size:10pt;">three months and six months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> require management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes and are not necessarily indicative of the results that may be expected for the full year ending </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RESTRUCTURING, ACQUISITION, INTEGRATION, AND OTHER EXPENSES, NET</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restructuring, acquisition, integration and other expenses include non-operating costs associated with restructuring, acquisition, and integration initiatives such as employee severance costs, certain legal and professional fees, training costs, redundant wage costs, impacts recorded from the change in contingent consideration obligations, and other costs related to contract terminations and closed branches/offices.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restructuring, acquisition, integration, and other expenses, net in the Unaudited Consolidated Statements of Operations for the </font><font style="font-family:inherit;font-size:10pt;">three months and six months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> consisted of the following (in thousands):</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.484375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended&#160;<br clear="none"/>&#160;June&#160;30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended&#160;<br clear="none"/>&#160;June&#160;30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restructuring expense </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,648</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,316</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,854</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,932</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Acquisition and integration expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">263</font></div></td><td style="vertical-align:bottom;background-color:;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,924</font></div></td><td style="vertical-align:bottom;background-color:;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">280</font></div></td><td style="vertical-align:bottom;background-color:;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,924</font></div></td><td style="vertical-align:bottom;background-color:;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Change in fair value of contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">102</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total restructuring, acquisition, integration, and other expense, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">3,911</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">4,291</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">7,134</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">6,958</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ACQUISITIONS</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 9, 2016, the Company completed the Home Solutions Transaction pursuant to the Home Solutions Agreement. The aggregate consideration paid by the Company in the Home Solutions Transaction was equal to (i) the Cash Consideration; plus (ii)(a) the Transaction Closing Equity Consideration and (b) the RSUs, issuable in two tranches, Tranche A and Tranche B, with different vesting conditions. The number of shares of Company common stock in Tranche A is </font><font style="font-family:inherit;font-size:10pt;">3.1 million</font><font style="font-family:inherit;font-size:10pt;"> and the number of shares of Company common stock in Tranche B is </font><font style="font-family:inherit;font-size:10pt;">4.0 million</font><font style="font-family:inherit;font-size:10pt;">, each subject to vesting conditions (see Note 3 - Stockholders&#8217; Deficit). Upon close of the Home Solutions Transaction the RSUs had no intrinsic value, but are reported in our consolidated financial statements at their estimated fair value at the date of issuance. Upon approval of the Charter Amendment on November 30, 2016, the date at which sufficient shares were available should the RSUs vest and become issuable, the liability was remeasured to its then-current fair value and reclassified to equity.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the consideration transferred in connection with the acquisition of Home Solutions as of September 9, 2016 (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:499px;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:405px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:82px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">67,516</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Equity issued at closing</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,938</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Capital lease obligation assumed</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">301</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Fair value of contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,400</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total consideration</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">93,155</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the preliminary estimate of fair value of the assets acquired and liabilities assumed upon acquisition of Home Solutions (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:499px;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:405px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:82px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,956</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Inventories</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,199</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaids and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">852</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">16,007</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">57,218</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Managed care contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">24,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Licenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,400</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Trade name</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Non-compete agreements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other non-current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">891</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">110,867</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,576</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,136</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Current liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">17,712</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total fair value of cash and contingent consideration</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">93,155</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The excess of the purchase price over the fair value of the tangible and identifiable intangible assets acquired and liabilities assumed in the acquisition was allocated to goodwill. The value of the goodwill represents the value the Company expects to be created by combining the operations of the companies, including the ability to cross-sell its services on a national basis with an expanded footprint in home infusion and the opportunity to focus on higher margin therapies.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with ASC Topic 805&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Business Combinations</font><font style="font-family:inherit;font-size:10pt;">&#160;(&#8220;ASC 805&#8221;), the allocation of the purchase price is subject to adjustment during the measurement period after the closing date (September 9, 2016) when additional information on assets and liability valuations becomes available. The Company has not finalized its valuation of certain assets and liabilities recorded pursuant to the acquisition including intangible assets and contingent consideration. Thus, the provisional measurements recorded are subject to change. Any changes will be recorded as adjustments to the fair value of the assets and liabilities with residual amounts allocated to goodwill.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Home Solutions Agreement, the Company did not purchase, among other things, any accounts receivable associated with governmental payors. However, the Home Solutions Agreement stipulates that collections of government receivables, as of the first anniversary of the closing date, in an amount less than the amount estimated as government receivables in the Closing Certificate, must be paid to the seller. The Company continues to evaluate the collectability of the government receivables and will record a liability in the event collections fall short of the guarantee.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Business Combinations</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Business combinations are accounted for using the acquisition method as of the acquisition date, the date on which control is transferred to the Company. Goodwill is measured at the acquisition date as the fair value of the consideration transferred, plus the fair value of the identifiable assets acquired and liabilities assumed. Transaction costs are expensed as incurred. Contingent consideration payable is measured at fair value at the acquisition date. Contingent consideration classified as equity is not re-measured and settlement is accounted for within equity.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">BASIS OF PRESENTATION</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These Unaudited Consolidated Financial Statements should be read in conjunction with the Audited Consolidated Financial Statements, including the notes thereto, and other information included in the Annual Report on Form 10-K of BioScrip, Inc. and its wholly-owned subsidiaries (the &#8220;Company&#8221;) for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> (the &#8220;Annual Report&#8221;) filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;). These Unaudited Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial information, and the instructions to Form 10-Q and Article 10 of Regulation S-X promulgated under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information furnished in these Unaudited Consolidated Financial Statements reflects all adjustments, including normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the results for the interim periods presented. Operating results for the </font><font style="font-family:inherit;font-size:10pt;">three months and six months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> require management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes and are not necessarily indicative of the results that may be expected for the full year ending </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Unaudited Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Business Combinations</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Business combinations are accounted for using the acquisition method as of the acquisition date, the date on which control is transferred to the Company. Goodwill is measured at the acquisition date as the fair value of the consideration transferred, plus the fair value of the identifiable assets acquired and liabilities assumed. Transaction costs are expensed as incurred. Contingent consideration payable is measured at fair value at the acquisition date. Contingent consideration classified as equity is not re-measured and settlement is accounted for within equity.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reclassifications</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior period financial statement amounts have been reclassified to conform to current period presentation.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents and Restricted Cash</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Highly liquid investments with a maturity of three months or less when purchased are classified as cash equivalents. Restricted cash consists of cash balances held by financial institutions as collateral for letters of credit. These balances are reclassified to cash and cash equivalents when the underlying obligation is satisfied, or in accordance with the governing agreement. Restricted cash balances expected to become unrestricted during the next twelve months are recorded as current assets. As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had a restricted cash balance, in a money market account, of $</font><font style="font-family:inherit;font-size:10pt;">5.1 million</font><font style="font-family:inherit;font-size:10pt;"> to cash collateralize outstanding letters of credit.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Collectability of Accounts Receivable</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the aging of our net accounts receivable (net of allowance for contractual adjustments, and prior to allowance for doubtful accounts), aged based on date of service and categorized based on the three primary overall types of accounts receivable characteristics (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td style="width:38%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June&#160;30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">0 - 180 days</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Over 180 days</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">0 - 180 days</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Over 180 days</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,714</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,512</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">26,226</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19,891</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,278</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">28,169</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">84,190</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">23,589</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">107,779</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">97,744</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19,848</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">117,592</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Patient</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,195</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,540</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,735</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,955</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,825</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,780</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">108,099</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">40,641</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">148,740</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">121,590</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">34,951</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">156,541</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Allowance for doubtful accounts</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(45,651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(44,730</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Net accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">103,089</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">111,811</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2017, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2017-11&#8212;Earnings Per Share (Topic 260), Distinguishing Liabilities From Equity (Topic 480), and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features and II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. ASU 2017-11 eliminates the requirement that a down round feature precludes equity classification when assessing whether an instrument is indexed to an entity&#8217;s own stock. A freestanding equity-linked financial instrument no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. The effective date for ASU 2017-11 is for annual or any interim periods beginning after December 15, 2018. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, the FASB issued ASU 2017-09&#8212;Compensation&#8211;Stock Compensation (Topic 718): Scope of Modification Accounting. ASU 2017-09 modifies when a change to the terms or conditions of a share-based payment award must be accounted for as a modification. The new guidance requires modification accounting if the fair value, vesting condition or the classification of the award is not the same immediately before and after a change to the terms and conditions of the award. The effective date for ASU 2017-09 is for annual or any interim periods beginning after December 15, 2017. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU 2017-04&#8212;Intangibles&#8211;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. ASU 2017-04 modifies the accounting for goodwill impairment. The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit&#8217;s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The effective date for ASU 2017-04 is for annual or any interim periods beginning after December 15, 2019. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2016, the FASB issued ASU 2016-18&#8212;Statement of Cash Flows (Topic 230): Restricted Cash. ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The effective date for ASU 2016-18 is for annual or any interim periods beginning after December 15, 2017. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU 2016-15&#8212;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 provides guidance for eight specific cash flow issues with respect to how cash receipts and cash payments are classified in the statements of cash flows, with the objective of reducing diversity in practice.&#160;The effective date for ASU 2016-15 is for annual periods beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02&#8212;Leases (Topic 842), requiring lessees to recognize a right-of-use asset and a lease liability on the balance sheet for all leases with the exception of short-term leases. For lessees, leases will continue to be classified as either operating or finance leases in the income statement. The effective date of the new standard for public companies is for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition and requires application of the new guidance at the beginning of the earliest comparative period presented. The Company is evaluating the effect that the updated standard will have on its consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU 2014-09&#8212;Revenue from Contracts with Customers (Topic 606). The guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The FASB delayed the effective date to annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period.&#160;In addition, in March and April 2016, the FASB issued new guidance intended to improve the operability and understandability of the implementation guidance on principal versus agent considerations. Both amendments permit the use of either a retrospective or cumulative effect transition method and are effective for fiscal years, and interim periods within those fiscal years, beginning after December&#160;15, 2017, with early application permitted. The Company has not elected early adoption and will apply the modified retrospective approach upon adoption. The Company continues to evaluate the impact of the adoption of the new revenue standard on its consolidated financial statements.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents and Restricted Cash</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Highly liquid investments with a maturity of three months or less when purchased are classified as cash equivalents. Restricted cash consists of cash balances held by financial institutions as collateral for letters of credit. These balances are reclassified to cash and cash equivalents when the underlying obligation is satisfied, or in accordance with the governing agreement. Restricted cash balances expected to become unrestricted during the next twelve months are recorded as current assets.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">COMMITMENTS AND CONTINGENCIES</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Legal Proceedings</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Breach of Contract Litigation in the Delaware Court of Chancery</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 3, 2015, Walgreen Co. and various affiliates (&#8220;Walgreens&#8221;) filed a lawsuit in the Delaware Court of Chancery against the Company and certain of its subsidiaries (collectively, the &#8220;Defendants&#8221;). The complaint alleges that the Company breached certain non-compete provisions contained in the Community Pharmacy and Mail Business Purchase Agreement dated as of February 1, 2012, by and among Walgreens and certain subsidiaries and the Company and certain subsidiaries. The complaint seeks both money damages and injunctive relief. On December 7, 2015, the Defendants filed a motion to dismiss the case. Walgreens filed an answering brief on January 11, 2016 and the Defendants filed a reply on January 25, 2016. On March 11, 2016, the Court held oral argument on the Company&#8217;s motion to dismiss and granted the motion, holding that Walgreens&#8217; breach of contract claims for money damages must be resolved in accordance with the 2012 Purchase Agreement&#8217;s alternative dispute resolution procedure. On March 15, 2016, Walgreens informed the Court that it would not be pursuing any claims for injunctive relief in the Court at that time, but instead would engage in the required alternative dispute resolution procedure. Walgreens requested that the Court keep the case open pending the results of that process. On March 16, 2016, the Court stayed the lawsuit and removed the trial from its calendar, but did not grant Walgreens any other relief or enjoin the Company from taking any action. On December 8, 2016, the parties submitted the dispute to an arbitrator. On December 28, 2016, the arbitrator rendered its decision, finding that the Company had not violated the non-compete, except for certain limited sales of oral oncology, HIV and transplant pharmaceuticals, constituting approximately </font><font style="font-family:inherit;font-size:10pt;">3 percent</font><font style="font-family:inherit;font-size:10pt;"> of the total sales that Walgreens claimed were made in violation of the agreement. The arbitrator also concluded that Walgreens was not entitled to recover its lost profits or lost revenues as a result of any such sales. Despite that ruling, the arbitrator awarded Walgreens </font><font style="font-family:inherit;font-size:10pt;">$5.8 million</font><font style="font-family:inherit;font-size:10pt;"> in damages, or approximately </font><font style="font-family:inherit;font-size:10pt;">20 percent</font><font style="font-family:inherit;font-size:10pt;"> of the total amount requested. Such amount is included as a component of Accrued expenses and other current liabilities within the Consolidated Balance Sheets as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> (unaudited) and December 31, 2016. The Company believes that arbitrator&#8217;s damages award ignored applicable law, contradicted the arbitrator&#8217;s liability findings and exceeded the scope of the arbitrator&#8217;s authority in light of both parties&#8217; arbitration submissions. Accordingly, on January 13, 2017, the Company filed a motion to vacate the arbitration award. On February 10, 2017, Walgreens opposed the Company&#8217;s motion and filed a motion to confirm the arbitration award and for other relief. On July 19, 2017, the Court confirmed the arbitration award and denied Walgreens&#8217; request for injunctive relief. The Company intends to continue to vigorously defend itself, but the Company can provide no assurance that any continued challenge to the award will be successful.</font></div><div style="line-height:120%;padding-bottom:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Derivative Lawsuit in the Delaware Court of Chancery</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 7, 2015, a derivative complaint was filed in the Delaware Court of Chancery (the &#8220;Derivative Complaint&#8221;) by the Park Employees&#8217; &amp; Retirement Board Employees&#8217; Annuity &amp; Benefit Fund of Chicago (the &#8220;Derivative Plaintiff&#8221;). The Derivative Complaint names as defendants certain current and former directors of the Company, consisting of Richard M. Smith, Myron Holubiak, Charlotte Collins, Samuel Frieder, David Hubers, Richard Robbins, Stuart Samuels and Gordon Woodward (collectively, the &#8220;Director Defendants&#8221;), certain current and former officers of the Company, consisting of Kimberlee Seah, Hai Tran and Patricia Bogusz (collectively the &#8220;Officer Defendants&#8221;), Kohlberg &amp; Co., L.L.C., Kohlberg Management V, L.L.C., Kohlberg Investors V, L.P., Kohlberg Partners V, L.P., Kohlberg TE Investors V, L.P., KOCO Investors V, L.P., and Jefferies LLC. The Company is also named as a nominal defendant in the Derivative Complaint. The Derivative Complaint was filed in the Delaware Court of Chancery as </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Park Employees and Retirement Board Employees&#8217; Annuity and Benefit Fund of Chicago v. Richard M. Smith, Myron Z. Holubiak, Charlotte W. Collins, Samuel P. Frieder, David R. Huber, Richard L. Robbins, Stuart A. Samuels, Gordon H. Woodward, Kimberlee C. Seah, Hai V.Tran, Patricia Bogusz, Kohlberg &amp; Co., L.L.C., Kohlberg Management V, L.L.C., Kohlberg Investors V, L.P., Kohlberg Partners V, L.P., Kohlberg TE Investors V, L.P., KOCO Investors V, L.P., Jefferies LLC and BioScrip, Inc., C.A. No. 11000-VCG (Del. Ch. Ct., May 7, 2015).</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Derivative Complaint alleges generally that certain defendants breached their fiduciary duties with respect to the Company&#8217;s public disclosures, oversight of Company operations, secondary stock offerings and stock sales. The Derivative Complaint also contends that certain defendants aided and abetted those alleged breaches. The damages sought are not quantified but include, among other things, claims for money damages, restitution, disgorgement, equitable relief, reasonable attorneys&#8217; fees, costs and expenses, and interest. The Derivative Complaint incorporates the same factual allegations from </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">In re BioScrip, Inc., Securities Litigation </font><font style="font-family:inherit;font-size:10pt;">(described below). On June 16, 2015, all defendants moved to dismiss the case. Briefing for the motion to dismiss was completed on November 30, 2015, and the court heard oral argument on the motion to dismiss on January 12, 2016. During the hearing, the court requested additional briefing, which was completed on February 12, 2016. On May 31, 2016, the court determined that the Derivative Plaintiff&#8217;s claims could not proceed as pled but granted the Derivative Plaintiff thirty days in which to make a motion to amend the Derivative Complaint. The court reserved decision on the motion to dismiss and on June 29, 2016, the Derivative Plaintiff filed a motion for leave to file an amended complaint. On October 10, 2016, all defendants moved to dismiss the amended complaint and the Court heard oral argument on January 19, 2017. On April 18, 2017, the Court granted the defendants&#8217; motion to dismiss. Plaintiffs filed a notice of appeal on May 12, 2017.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company, Director Defendants and the Officer Defendants deny any allegations of wrongdoing in this lawsuit. The Company and those persons believe all of the claims in this lawsuit are without merit and intend to vigorously defend against these claims. However, there is no assurance that the defense will be successful or that insurance will be available or adequate to fund any settlement, judgment or litigation costs associated with this action. Certain of the defendants have sought indemnification from the Company pursuant to certain indemnification agreements, for which there may be no insurance coverage. Additional similar lawsuits may be filed. The Company is unable to predict the outcome or reasonably estimate a range of possible loss at this time. While no assurance can be given as to the ultimate outcome of this matter, the Company believes that the final resolution of this action is not likely to have a material adverse effect on results of operations, financial position, liquidity or capital resources.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Government Regulation</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various federal and state laws and regulations affecting the healthcare industry do or may impact the Company&#8217;s current and planned operations, including, without limitation, federal and state laws prohibiting kickbacks in government health programs, federal and state antitrust and drug distribution laws, and a wide variety of consumer protection, insurance and other state laws and regulations. While management believes the Company is in substantial compliance with all existing laws and regulations material to the operation of its business, such laws and regulations are often uncertain in their application to our business practices as they evolve and are subject to rapid change. As controversies continue to arise in the healthcare industry, federal and state regulation and enforcement priorities in this area can be expected to increase, the impact of which cannot be predicted.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, the Company responds to investigatory subpoenas and requests for information from governmental agencies and private parties. The Company cannot predict with certainty what the outcome of any of the foregoing might be. While the Company believes it is in substantial compliance with all laws, rules and regulations that affects its business and operations, there can be no assurance that the Company will not be subject to scrutiny or challenge under one or more existing laws or that any such challenge would not be successful. Any such challenge, whether or not successful, could have a material effect upon the Company&#8217;s Consolidated Financial Statements. A violation of the Federal anti-kickback statute, for example, may result in substantial criminal penalties, as well as suspension or exclusion from the Medicare and Medicaid programs. Moreover, the costs and expenses associated with defending these actions, even where successful, can be significant.</font><font style="font-family:inherit;font-size:10pt;color:#1f497d;"> </font><font style="font-family:inherit;font-size:10pt;">Further, there can be no assurance the Company will be able to obtain or maintain any of the regulatory approvals that may be required to operate its business, and the failure to do so could have a material effect on the Company&#8217;s Consolidated Financial Statements.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONCENTRATION OF RISK</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Customer and Credit Concentration Risk</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company provides trade credit to its customers in the normal course of business.&#160;One commercial payor, United Healthcare, accounted for approximately </font><font style="font-family:inherit;font-size:10pt;">21.9%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">24.4%</font><font style="font-family:inherit;font-size:10pt;"> of revenue during the </font><font style="font-family:inherit;font-size:10pt;">three months ended June&#160;30, 2017 and 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, and approximately&#160;</font><font style="font-family:inherit;font-size:10pt;">22.4%</font><font style="font-family:inherit;font-size:10pt;">&#160;and&#160;</font><font style="font-family:inherit;font-size:10pt;">25.2%</font><font style="font-family:inherit;font-size:10pt;">&#160;of revenue during the&#160;</font><font style="font-family:inherit;font-size:10pt;">six months ended June&#160;30, 2017 and 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively. This contract, exclusive of certain provisions, will terminate effective September 30, 2017. In addition, Medicare accounted for approximately </font><font style="font-family:inherit;font-size:10pt;">7.1%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">8.3%</font><font style="font-family:inherit;font-size:10pt;"> of revenue during the </font><font style="font-family:inherit;font-size:10pt;">three months ended June&#160;30, 2017 and 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, and </font><font style="font-family:inherit;font-size:10pt;">7.0%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">7.8%</font><font style="font-family:inherit;font-size:10pt;"> of revenue during the </font><font style="font-family:inherit;font-size:10pt;">six months ended June&#160;30, 2017 and 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Therapy Revenue Concentration Risk</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company sells products related to the Immune Globulin therapy, which represented </font><font style="font-family:inherit;font-size:10pt;">21.1%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">17.2%</font><font style="font-family:inherit;font-size:10pt;"> of revenue for the </font><font style="font-family:inherit;font-size:10pt;">three months ended June&#160;30, 2017 and 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, and </font><font style="font-family:inherit;font-size:10pt;">21.6%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">17.2%</font><font style="font-family:inherit;font-size:10pt;"> of revenue for the </font><font style="font-family:inherit;font-size:10pt;">six months ended June&#160;30, 2017 and 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Unaudited Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DEBT</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company&#8217;s debt consisted of the following (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:83.51219512195122%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Senior Credit Facilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">265,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">First Lien Note Facility, net of unamortized discount</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">198,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Second Lien Note Facility, net of unamortized discount</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">82,931</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2021 Notes, net of unamortized discount</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">197,008</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">196,670</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Capital leases</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,134</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,209</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less: Deferred financing costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,668</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(12,452</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total Debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">477,405</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">451,934</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less: Current portion</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,731</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(18,521</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Long-term debt, net of current portion</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">475,674</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">433,413</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Debt Facilities</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company was previously obligated under (i) a senior secured first-lien revolving credit facility in an aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;"> (the &#8220;Revolving Credit Facility&#8221;), (ii) a senior secured first-lien term loan B in an aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">$250.0 million</font><font style="font-family:inherit;font-size:10pt;"> (the &#8220;Term Loan B Facility&#8221;) and (iii) a senior secured first-lien delayed draw term loan B in an aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">$150.0 million</font><font style="font-family:inherit;font-size:10pt;"> (the &#8220;Delayed Draw Term Loan Facility&#8221; and, together with the Revolving Credit Facility and the Term Loan B Facility, the &#8220;Senior Credit Facilities&#8221;) with SunTrust Bank (&#8220;SunTrust&#8221;), Jefferies Finance LLC and Morgan Stanley Senior Funding, Inc., originally entered on July 31, 2013 and amended from time to time.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 6, 2017, the Company entered into a credit agreement (the &#8220;Priming Credit Agreement&#8221; and, together with the Senior Credit Facilities, the &#8220;Prior Credit Agreements&#8221;) with certain existing lenders under the Senior Credit Facilities and SunTrust, as administrative agent for itself and the lenders. The Priming Credit Agreement provided an aggregate borrowing commitment of </font><font style="font-family:inherit;font-size:10pt;">$25.0 million</font><font style="font-family:inherit;font-size:10pt;">, which was fully drawn at closing.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 29, 2017 (the &#8220;Closing Date&#8221;), the Company entered into (i) a first lien note purchase agreement (the &#8220;First Lien Note Facility&#8221;), among the Company, which is the issuer under the agreement, the financial institutions and note purchasers from time to time party to the agreement (the &#8220;First Lien Note Purchasers&#8221;), and Wells Fargo Bank, National Association, in its capacity as collateral agent for itself and the First Lien Note Purchasers (the &#8220;First Lien Collateral Agent&#8221;), pursuant to which the Company issued first lien senior secured notes in an aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">$200.0 million</font><font style="font-family:inherit;font-size:10pt;"> (the &#8220;First Lien Notes&#8221;); and (ii) a second lien note purchase agreement (the &#8220;Second Lien Note Facility&#8221; and, together with the First Lien Note Facility, the &#8220;Notes Facilities&#8221;) among the Company, which is the issuer under the agreement, the financial institutions and note purchasers from time to time party to the agreement (the &#8220;Second Lien Note Purchasers&#8221;), and Wells Fargo Bank, National Association, in its capacity as collateral agent for itself and the Second Lien Note Purchasers (the &#8220;Second Lien Collateral Agent&#8221; and, together with the First Lien Collateral Agent, the &#8220;Collateral Agent&#8221;), pursuant to which the Company (a) issued second lien senior secured notes in an aggregate initial principal amount of </font><font style="font-family:inherit;font-size:10pt;">$100.0 million</font><font style="font-family:inherit;font-size:10pt;"> (the &#8220;Initial Second Lien Notes&#8221;) and (b) has the ability to draw upon the Second Lien Note Facility and issue second lien delayed draw senior secured notes in an aggregate initial principal amount of </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> for a period of </font><font style="font-family:inherit;font-size:10pt;">18</font><font style="font-family:inherit;font-size:10pt;"> months after the Closing Date, subject to certain terms and conditions (the &#8220;Second Lien Delayed Draw Notes&#8221; and, together with the Initial Second Lien Notes, the &#8220;Second Lien Notes&#8221;; the Second Lien Notes, together with the First Lien Notes, the &#8220;Notes&#8221;). Funds managed by Ares are acting as lead purchasers for the Notes Facilities.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company used the proceeds of the sale of the First Lien Notes and the Initial Second Lien Notes to repay in full all amounts outstanding under the Prior Credit Agreements and extinguished the liability. Each of the Prior Credit Agreements was terminated following such repayment. The Company used the remaining proceeds of </font><font style="font-family:inherit;font-size:10pt;">$15.9 million</font><font style="font-family:inherit;font-size:10pt;">, net of </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> in issuance costs, from the Notes Facilities and the Second Quarter 2017 Private Placement for working capital and general corporate purposes.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The First Lien Notes accrue interest, payable monthly in arrears, at a floating rate or rates equal to, at the option of the Company, (i) the base rate (defined as the highest of the Federal Funds Rate plus </font><font style="font-family:inherit;font-size:10pt;">0.5%</font><font style="font-family:inherit;font-size:10pt;"> per annum, the Prime Rate as published by The Wall Street Journal and the one-month London Interbank Offered Rate (&#8220;LIBOR&#8221;) (subject to a </font><font style="font-family:inherit;font-size:10pt;">1.0%</font><font style="font-family:inherit;font-size:10pt;"> floor) plus </font><font style="font-family:inherit;font-size:10pt;">1.0%</font><font style="font-family:inherit;font-size:10pt;">), or (ii) the one-month LIBOR rate (subject to a </font><font style="font-family:inherit;font-size:10pt;">1.0%</font><font style="font-family:inherit;font-size:10pt;"> floor), plus a margin of </font><font style="font-family:inherit;font-size:10pt;">6.0%</font><font style="font-family:inherit;font-size:10pt;"> if the base rate is selected or </font><font style="font-family:inherit;font-size:10pt;">7.0%</font><font style="font-family:inherit;font-size:10pt;"> if the LIBOR Option is selected. The First Lien Notes mature on August 15, 2020, provided that if the Company&#8217;s existing </font><font style="font-family:inherit;font-size:10pt;">8.875%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes due 2021 (the &#8220;2021 Notes&#8221;) are refinanced prior to August 15, 2020, then the scheduled maturity date of the First Lien Notes shall be June 30, 2022.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The First Lien Notes will amortize in equal quarterly installments equal to </font><font style="font-family:inherit;font-size:10pt;">0.625%</font><font style="font-family:inherit;font-size:10pt;"> of the aggregate principal amount of the First Lien Note Facility, commencing on September 30, 2019, and on the last day of each third month thereafter, with the balance payable at maturity. The First Lien Notes are pre-payable at the Company&#8217;s option at specified premiums to the principal amount that will decline over the term of the First Lien Note Facility. If the First Lien Notes are prepaid prior to the second anniversary of the Closing Date, the Company will be required to pay a make-whole premium based on the present value (using a discount rate based on the specified treasury rate plus </font><font style="font-family:inherit;font-size:10pt;">50</font><font style="font-family:inherit;font-size:10pt;"> basis points) of all remaining interest payments on the First Lien Notes being prepaid prior to the second anniversary of the Closing Date, plus </font><font style="font-family:inherit;font-size:10pt;">4.0%</font><font style="font-family:inherit;font-size:10pt;"> of the principal amount of First Lien Notes being prepaid. On or after the second anniversary of the Closing Date, the prepayment premium is </font><font style="font-family:inherit;font-size:10pt;">4.0%</font><font style="font-family:inherit;font-size:10pt;">, which declines to </font><font style="font-family:inherit;font-size:10pt;">2.0%</font><font style="font-family:inherit;font-size:10pt;"> on or after the third anniversary of the Closing Date, and declines to </font><font style="font-family:inherit;font-size:10pt;">0.0%</font><font style="font-family:inherit;font-size:10pt;"> on or after the fourth anniversary of the Closing Date. At any time, the Company may pre-pay up to </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;"> in aggregate principal amount of the First Lien Notes from internally generated cash without incurring any make-whole or prepayment premium. The occurrence of certain events of default may increase the applicable rate of interest by </font><font style="font-family:inherit;font-size:10pt;">2.0%</font><font style="font-family:inherit;font-size:10pt;"> and could result in the acceleration of the Company&#8217;s obligations under the First Lien Note Facility prior to stated maturity and an obligation of the Company to pay the full amount of its obligations under the First Lien Note Facility.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The First Lien Note Facility contains customary events of default that include, among others, non-payment of principal, interest or fees, violation of covenants, inaccuracy of representations and warranties, bankruptcy and insolvency events, material judgments, cross-defaults to material indebtedness and events constituting a change of control. In addition, the obligations under the First Lien Note Facility will be guaranteed by joint and several guarantees from the Company&#8217;s subsidiaries.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the First Lien Note Facility, the Company, its subsidiaries and the First Lien Collateral Agent entered into a First Lien Guaranty and Security Agreement, dated as of June 29, 2017 (the &#8220;First Lien Guaranty and Security Agreement&#8221;). Pursuant to the First Lien Guaranty and Security Agreement, the obligations under the First Lien Notes will be secured by first priority liens on, and security interests in, substantially all of the assets of the Company and its subsidiaries.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Second Lien Notes accrue interest, payable monthly in arrears, at a floating rate or rates equal to, at the option of the Company, (i) one-month LIBOR (subject to a </font><font style="font-family:inherit;font-size:10pt;">1.25%</font><font style="font-family:inherit;font-size:10pt;"> floor) plus </font><font style="font-family:inherit;font-size:10pt;">9.25%</font><font style="font-family:inherit;font-size:10pt;"> per annum in cash, (ii) one-month LIBOR (subject to a </font><font style="font-family:inherit;font-size:10pt;">1.25%</font><font style="font-family:inherit;font-size:10pt;"> floor) plus </font><font style="font-family:inherit;font-size:10pt;">11.25%</font><font style="font-family:inherit;font-size:10pt;"> per annum, which amount will be capitalized on each interest payment date, or (iii) one-month LIBOR (subject to a </font><font style="font-family:inherit;font-size:10pt;">1.25%</font><font style="font-family:inherit;font-size:10pt;"> floor) plus </font><font style="font-family:inherit;font-size:10pt;">10.25%</font><font style="font-family:inherit;font-size:10pt;"> per annum, of which one-half LIBOR plus </font><font style="font-family:inherit;font-size:10pt;">4.625%</font><font style="font-family:inherit;font-size:10pt;"> per annum will be payable in cash and one-half LIBOR plus </font><font style="font-family:inherit;font-size:10pt;">5.625%</font><font style="font-family:inherit;font-size:10pt;"> per annum will be capitalized on each interest payment date, provided that, in each case, if any permitted refinancing indebtedness with which the 2021 Notes are refinanced requires or permits the payment of cash interest, all of the interest on the Second Lien Notes shall be paid in cash. The Second Lien Notes mature on August 15, 2020, provided that if the 2021 Notes are refinanced prior to August 15, 2020, then the scheduled maturity date of the Second Lien Notes shall be June 30, 2022.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Second Lien Note Facility, the Company also issued warrants (the &#8220;2017 Warrants&#8221;) to the purchasers of the Second Lien Notes pursuant to a Warrant Purchase Agreement dated as of June 29, 2017 (the &#8220;Warrant Purchase Agreement&#8221;). The 2017 Warrants entitle the purchasers of the Warrants to purchase shares of Common Stock, representing at the time of any exercise of the 2017 Warrants an equivalent number of shares equal to </font><font style="font-family:inherit;font-size:10pt;">4.99%</font><font style="font-family:inherit;font-size:10pt;"> of the Common Stock of the Company on a fully diluted basis, subject to the terms of the Warrant Agreement governing the Warrants, dated as of June 29, 2017 (the &#8220;Warrant Agreement&#8221;). The 2017 Warrants, considered a derivative and subject to remeasurement at each reporting period, are reflected in other non-current liabilities at a fair value of </font><font style="font-family:inherit;font-size:10pt;">$16.9 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Second Lien Notes are not subject to scheduled amortization installments. The Second Lien Notes are pre-payable at the Company&#8217;s option at specified premiums to the principal amount that will decline over the term of the Second Lien Note Facility. If the Second Lien Notes are prepaid prior to the third anniversary of the Closing Date, the Company will need to pay a make-whole premium based on the present value (using a discount rate based on the specified treasury rate plus </font><font style="font-family:inherit;font-size:10pt;">50</font><font style="font-family:inherit;font-size:10pt;"> basis points) of all remaining interest payments on the Second Lien Notes being prepaid prior to the third anniversary of the Closing Date, plus </font><font style="font-family:inherit;font-size:10pt;">4.0%</font><font style="font-family:inherit;font-size:10pt;"> of the principal amount of Second Lien Notes being prepaid. On or after the third anniversary of the Closing Date, the prepayment premium is </font><font style="font-family:inherit;font-size:10pt;">4.0%</font><font style="font-family:inherit;font-size:10pt;">, which declines to </font><font style="font-family:inherit;font-size:10pt;">2.0%</font><font style="font-family:inherit;font-size:10pt;"> on or after the fourth anniversary of the Closing Date, and declines to </font><font style="font-family:inherit;font-size:10pt;">0.0%</font><font style="font-family:inherit;font-size:10pt;"> on or after the fifth anniversary of the Closing Date. The occurrence of certain events of default may increase the applicable rate of interest by </font><font style="font-family:inherit;font-size:10pt;">2.0%</font><font style="font-family:inherit;font-size:10pt;"> and could result in the acceleration of the Company&#8217;s obligations under the Second Lien Note Facility prior to stated maturity and an obligation of the Company to pay the full amount of its obligations under the Second Lien Note Facility.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Second Lien Note Facility contains customary events of default that include, among others, non-payment of principal, interest or fees, violation of covenants, inaccuracy of representations and warranties, bankruptcy and insolvency events, material judgments, cross-defaults to material indebtedness and events constituting a change of control. In addition, the obligations under the Second Lien Note Facility will be guaranteed by joint and several guarantees from the Company&#8217;s subsidiaries.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Second Lien Note Facility, the Company, its subsidiaries and the Second Lien Collateral Agent entered into a Second Lien Guaranty and Security Agreement, dated as of June 29, 2017 (the &#8220;Second Lien Guaranty and Security Agreement&#8221;). Pursuant to the Second Lien Guaranty and Security Agreement, the obligations under the Second Lien Notes will be secured by second priority liens on, and security interests in, substantially all of the assets of the Company and its subsidies.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the First Lien Note Facility and the Second Lien Note Facility, the Company, the First Lien Collateral Agent and the Second Lien Collateral Agent, entered into an intercreditor agreement containing customary provisions to, among other things, subordinate the lien priority of the liens granted under the Second Lien Note Facility to the liens granted under the First Lien Note Facility.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2021 Notes</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 11, 2014, the Company issued </font><font style="font-family:inherit;font-size:10pt;">$200.0 million</font><font style="font-family:inherit;font-size:10pt;"> aggregate principal amount of the 2021 Notes. The 2021 Notes are senior unsecured obligations of the Company and are fully and unconditionally guaranteed by all existing and future subsidiaries of the Company.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest on the 2021 Notes accrues at a fixed rate of </font><font style="font-family:inherit;font-size:10pt;">8.875%</font><font style="font-family:inherit;font-size:10pt;"> per annum and is payable in cash semi-annually on February 15 and August 15 of each year. The debt discount of </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> at issuance is being amortized as interest expense through maturity which will result in the accretion over time of the outstanding debt balance to the principal amount. The 2021 Notes are the Company&#8217;s senior unsecured obligations and rank equally in right of payment with all of its other existing and future senior unsecured indebtedness and senior in right of payment to all of its existing and future subordinated indebtedness.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2021 Notes are guaranteed on a full, joint and several basis by each of the Company&#8217;s existing and future domestic restricted subsidiaries that is a borrower under any of the Company&#8217;s credit facilities or that guarantees any of the Company&#8217;s debt or that of any of its restricted subsidiaries, in each case incurred under the Company&#8217;s credit facilities. As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company does not have any independent assets or operations, and as a result, its direct and indirect subsidiaries (other than minor subsidiaries), each being 100% owned by the Company, are fully and unconditionally, jointly and severally, providing guarantees on a senior unsecured basis to the 2021 Notes.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following details our financial instruments where the carrying value and the fair value differ (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.95121951219512%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:32%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Financial Instrument</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Carrying Value as of June 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Markets for Identical Item (Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Significant Other Observable Inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Significant Unobservable Inputs (Level 3)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">First Lien Note Facility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">198,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">198,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Second Lien Note Facility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">82,931</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">82,931</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2017 Warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">16,908</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">16,908</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2021 Notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">197,008</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">178,109</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">494,847</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">475,948</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value hierarchy for disclosure of fair value measurements is as follows:</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Level 1</font><font style="font-family:inherit;font-size:10pt;">:&#160; Quoted prices (unadjusted) in active markets for identical assets or liabilities.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Level 2</font><font style="font-family:inherit;font-size:10pt;">:&#160; Quoted prices, other than quoted prices included in Level 1, which are observable for the assets or liabilities, either directly or indirectly.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Level 3</font><font style="font-family:inherit;font-size:10pt;">:&#160; Inputs that are unobservable for the assets or liabilities. Financial assets with carrying values approximating fair value include cash and cash equivalents and accounts receivable. Financial liabilities with carrying values approximating fair value include accounts payable and capital leases. The carrying value of these financial assets and liabilities approximates fair value due to their short maturities.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">STOCK-BASED COMPENSATION</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">BioScrip Equity Incentive Plans</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Company&#8217;s Amended and Restated 2008 Equity Incentive Plan (the &#8220;2008 Plan&#8221;), the Company may issue, among other things, incentive stock options, non-qualified stock options, stock appreciation rights (&#8220;SARs&#8221;), restricted stock grants, restricted stock units, performance shares and performance units to key employees and directors. While SARs are authorized under the 2008 Plan, they may also be issued outside of the plan. The 2008 Plan is administered by the Company&#8217;s Management Development and Compensation Committee (the &#8220;Compensation Committee&#8221;), a standing committee of the Board of Directors.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 30, 2016, at a special meeting, the stockholders approved (i) an amendment to the Company&#8217;s Second Amended and Restated Certificate of Incorporation to increase the number of shares of Common Stock that the Company is authorized to issue from </font><font style="font-family:inherit;font-size:10pt;">125 million</font><font style="font-family:inherit;font-size:10pt;"> shares to </font><font style="font-family:inherit;font-size:10pt;">250 million</font><font style="font-family:inherit;font-size:10pt;"> shares (the &#8220;Charter Amendment&#8221;); (ii) an amendment to the 2008 Plan to (a) increase the number of shares of Common Stock in the aggregate that may be subject to awards by </font><font style="font-family:inherit;font-size:10pt;">5,250,000</font><font style="font-family:inherit;font-size:10pt;"> shares, from </font><font style="font-family:inherit;font-size:10pt;">9,355,000</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">14,605,000</font><font style="font-family:inherit;font-size:10pt;"> shares and (b) increase the annual grant caps under the Company&#8217;s 2008 Plan from </font><font style="font-family:inherit;font-size:10pt;">500,000</font><font style="font-family:inherit;font-size:10pt;"> Options, </font><font style="font-family:inherit;font-size:10pt;">500,000</font><font style="font-family:inherit;font-size:10pt;"> Stock Appreciation Rights and </font><font style="font-family:inherit;font-size:10pt;">350,000</font><font style="font-family:inherit;font-size:10pt;"> Stock Grants and Restricted Stock Units that are intended to comply with the requirements of Section 162(m) of the Code to a cap of no more than a total of </font><font style="font-family:inherit;font-size:10pt;">3,000,000</font><font style="font-family:inherit;font-size:10pt;"> Options, Stock Appreciation Rights, Stock Grants and Restricted Stock Units that are intended to comply with the requirements of Section 162(m) of the Code combined; and (iii) if necessary, an adjournment of the Stockholders&#8217; Meeting if there were insufficient votes in favor of the Charter Amendment.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">4,360,887</font><font style="font-family:inherit;font-size:10pt;"> shares remain available for grant under the 2008 Plan.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Options</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognized compensation expense related to stock options of </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> during the </font><font style="font-family:inherit;font-size:10pt;">three months ended June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, and </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;"> during the </font><font style="font-family:inherit;font-size:10pt;">six months ended June&#160;30, 2017 and 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognized </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> and a nominal amount of compensation expense related to restricted stock awards during the </font><font style="font-family:inherit;font-size:10pt;">three months ended June&#160;30, 2017 and 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, and </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> and a nominal amount of compensation expense during the </font><font style="font-family:inherit;font-size:10pt;">six months ended June&#160;30, 2017 and 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Appreciation Rights and Market Based Cash Awards</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognized nominal amounts of compensation expense related to stock appreciation rights awards during the </font><font style="font-family:inherit;font-size:10pt;">three months ended June&#160;30, 2017 and 2016</font><font style="font-family:inherit;font-size:10pt;">, and nominal and </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#160;of compensation expense during the&#160;</font><font style="font-family:inherit;font-size:10pt;">six months ended June&#160;30, 2017 and 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognized&#160;nominal compensation expense and </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#160;compensation benefit related to market based cash awards during the </font><font style="font-family:inherit;font-size:10pt;">three months ended June&#160;30, 2017 and 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, and&#160;nominal and </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#160;compensation expense during&#160;</font><font style="font-family:inherit;font-size:10pt;">six months ended June&#160;30, 2017 and 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Employee Stock Purchase Plan</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 7, 2013, the Company&#8217;s stockholders approved the BioScrip, Inc. Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The ESPP is administered by the Compensation Committee. The ESPP provides all eligible employees, as defined under the ESPP, the opportunity to purchase up to a maximum number of shares of Common Stock of the Company as determined by the Compensation Committee. Participants in the ESPP may acquire the Common Stock at a cost of </font><font style="font-family:inherit;font-size:10pt;">85%</font><font style="font-family:inherit;font-size:10pt;"> of the lower of the fair market value on the first or last day of the quarterly offering period. The Company filed a Registration Statement on Form S-8 to register </font><font style="font-family:inherit;font-size:10pt;">750,000</font><font style="font-family:inherit;font-size:10pt;"> shares of Common Stock, par value </font><font style="font-family:inherit;font-size:10pt;">$0.0001</font><font style="font-family:inherit;font-size:10pt;"> per share, for issuance under the ESPP.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">136,713</font><font style="font-family:inherit;font-size:10pt;"> shares remained available for grant under the ESPP. Since inception, the ESPP&#8217;s third-party service provider has purchased </font><font style="font-family:inherit;font-size:10pt;">613,287</font><font style="font-family:inherit;font-size:10pt;"> shares on the open market and delivered these shares to the Company&#8217;s employees pursuant to the ESPP. During the </font><font style="font-family:inherit;font-size:10pt;">three months ended June&#160;30, 2017 and 2016</font><font style="font-family:inherit;font-size:10pt;">, and the </font><font style="font-family:inherit;font-size:10pt;">six months ended June&#160;30, 2017 and 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company incurred less than </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> of expense related to the ESPP.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">LOSS PER SHARE</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company presents basic and diluted loss per share for its common stock, par value </font><font style="font-family:inherit;font-size:10pt;">$0.0001</font><font style="font-family:inherit;font-size:10pt;"> per share (&#8220;Common Stock&#8221;). Basic loss per share is calculated by dividing the net loss attributable to common stockholders of the Company by the weighted average number of shares of Common Stock outstanding during the period. Diluted loss per share is determined by adjusting the profit or loss attributable to stockholders and the weighted average number of shares of Common Stock outstanding adjusted for the effects of all dilutive potential common shares comprised of options granted, unvested restricted stocks, stock appreciation rights, warrants and Series A and Series C Preferred Stock (as defined below). Potential Common Stock equivalents that have been issued by the Company related to outstanding stock options, unvested restricted stock and warrants are determined using the treasury stock method, while potential common shares related to Series A and Series C Preferred Stock are determined using the &#8220;if converted&#8221; method.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's Series A Convertible Preferred Stock, par value </font><font style="font-family:inherit;font-size:10pt;">$0.0001</font><font style="font-family:inherit;font-size:10pt;"> per share (the &#8220;Series A Preferred Stock&#8221;), and Series C Convertible Preferred Stock, par value </font><font style="font-family:inherit;font-size:10pt;">$0.0001</font><font style="font-family:inherit;font-size:10pt;"> per share (the &#8220;Series C Preferred Stock&#8221; and, together with the Series A Preferred Stock, the &#8220;Preferred Stock&#8221;), is considered a participating security, which means the security may participate in undistributed earnings with Common Stock. The holders of the Preferred Stock would be entitled to share in dividends, on an as-converted basis, if the holders of Common Stock were to receive dividends. The Company is required to use the two-class method when computing loss per share when it has a security that qualifies as a participating security. The two-class method is an earnings allocation formula that determines loss per share for each class of common stock and participating security according to dividends declared (or accumulated) and participation rights in undistributed earnings. In determining the amount of net earnings to allocate to common stockholders, earnings are allocated to both common and participating securities based on their respective weighted-average shares outstanding during the period. Diluted loss per share for the Company&#8217;s Common Stock is computed using the more dilutive of the two-class method or the if-converted method.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the computation of basic and diluted loss per common share (in thousands, except for per share amounts):</font></div><div style="line-height:120%;padding-bottom:13px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended&#160;<br clear="none"/>&#160;June&#160;30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended&#160;<br clear="none"/>&#160;June&#160;30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Loss from continuing operations, net of income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(28,695</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(8,309</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(47,686</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(18,079</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Income (loss) from discontinued operations, net of income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(503</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(940</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">308</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(29,198</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(8,234</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(48,626</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(17,771</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accrued dividends on preferred stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,303</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,056</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,517</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,054</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Deemed dividend on preferred stock</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(175</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(173</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(349</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(345</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Loss attributable to common stockholders</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(31,676</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(10,463</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(53,492</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(22,170</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Denominator - Basic and Diluted:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted average common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">121,189</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">73,186</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">119,993</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">70,978</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Loss per Common Share:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Loss from continuing operations, basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Loss from discontinued operations, basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.01</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Loss per common share, basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(0.26</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(0.14</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(0.45</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(0.32</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The loss attributable to common stockholders is used as the basis of determining whether the inclusion of common stock equivalents would be anti-dilutive. Accordingly, the computation of diluted shares for the </font><font style="font-family:inherit;font-size:10pt;">three months ended June&#160;30, 2017 and 2016</font><font style="font-family:inherit;font-size:10pt;"> excludes the effect of </font><font style="font-family:inherit;font-size:10pt;">18.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">14.0 million</font><font style="font-family:inherit;font-size:10pt;"> shares, respectively, and the computation of the diluted shares for the </font><font style="font-family:inherit;font-size:10pt;">six months ended June&#160;30, 2017 and 2016</font><font style="font-family:inherit;font-size:10pt;"> excludes the effect of </font><font style="font-family:inherit;font-size:10pt;">18.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">15.5 million</font><font style="font-family:inherit;font-size:10pt;"> shares, respectively, issued in connection with the PIPE Transaction and the Rights Offering, as well as the 2017 Warrants (see Note 3 - Stockholders&#8217; Deficit), stock options and restricted stock awards, as their inclusion would be anti-dilutive to loss attributable to common stockholders.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INCOME TAXES</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s federal and state income tax provision from continuing operations for the </font><font style="font-family:inherit;font-size:10pt;">three months and six months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> is summarized in the following table (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended&#160;<br clear="none"/>&#160;June&#160;30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended&#160;<br clear="none"/>&#160;June&#160;30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Current</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">190</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">226</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">190</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">25</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">226</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">25</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Deferred</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Federal</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">437</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">108</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">932</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">125</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">179</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total deferred</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">528</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">124</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">1,111</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">147</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total income tax expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">718</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">149</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">1,337</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">172</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The income tax expense recognized for the </font><font style="font-family:inherit;font-size:10pt;">three months and six months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> is a result of an increase in the deferred tax liability.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s reconciliation of the statutory rate from continuing operations to the effective income tax rate for the </font><font style="font-family:inherit;font-size:10pt;">three months and six months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> is summarized as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended&#160;<br clear="none"/>&#160;June&#160;30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended&#160;<br clear="none"/>&#160;June&#160;30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Tax benefit at statutory rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(9,790</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,844</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(16,236</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(6,271</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">State tax expense, net of federal taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">190</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">226</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Valuation allowance changes affecting income tax provision</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,266</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,926</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">17,242</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,314</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Non-deductible transaction costs and other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">52</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,064</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">105</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,126</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Income tax expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">718</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">149</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">1,337</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">172</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had Federal net operating loss (&#8220;NOL&#8221;) carry forwards of approximately </font><font style="font-family:inherit;font-size:10pt;">$373.8 million</font><font style="font-family:inherit;font-size:10pt;">, of which </font><font style="font-family:inherit;font-size:10pt;">$14.3 million</font><font style="font-family:inherit;font-size:10pt;"> is subject to an annual limitation, which will begin expiring in 2026 and later.&#160;The Company has post-apportioned state NOL carry forwards of approximately </font><font style="font-family:inherit;font-size:10pt;">$414.4 million</font><font style="font-family:inherit;font-size:10pt;">, the majority of which will begin expiring in 2017 and later.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2017, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2017-11&#8212;Earnings Per Share (Topic 260), Distinguishing Liabilities From Equity (Topic 480), and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features and II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. ASU 2017-11 eliminates the requirement that a down round feature precludes equity classification when assessing whether an instrument is indexed to an entity&#8217;s own stock. A freestanding equity-linked financial instrument no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. The effective date for ASU 2017-11 is for annual or any interim periods beginning after December 15, 2018. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, the FASB issued ASU 2017-09&#8212;Compensation&#8211;Stock Compensation (Topic 718): Scope of Modification Accounting. ASU 2017-09 modifies when a change to the terms or conditions of a share-based payment award must be accounted for as a modification. The new guidance requires modification accounting if the fair value, vesting condition or the classification of the award is not the same immediately before and after a change to the terms and conditions of the award. The effective date for ASU 2017-09 is for annual or any interim periods beginning after December 15, 2017. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU 2017-04&#8212;Intangibles&#8211;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. ASU 2017-04 modifies the accounting for goodwill impairment. The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit&#8217;s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The effective date for ASU 2017-04 is for annual or any interim periods beginning after December 15, 2019. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2016, the FASB issued ASU 2016-18&#8212;Statement of Cash Flows (Topic 230): Restricted Cash. ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The effective date for ASU 2016-18 is for annual or any interim periods beginning after December 15, 2017. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU 2016-15&#8212;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 provides guidance for eight specific cash flow issues with respect to how cash receipts and cash payments are classified in the statements of cash flows, with the objective of reducing diversity in practice.&#160;The effective date for ASU 2016-15 is for annual periods beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02&#8212;Leases (Topic 842), requiring lessees to recognize a right-of-use asset and a lease liability on the balance sheet for all leases with the exception of short-term leases. For lessees, leases will continue to be classified as either operating or finance leases in the income statement. The effective date of the new standard for public companies is for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition and requires application of the new guidance at the beginning of the earliest comparative period presented. The Company is evaluating the effect that the updated standard will have on its consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU 2014-09&#8212;Revenue from Contracts with Customers (Topic 606). The guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The FASB delayed the effective date to annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period.&#160;In addition, in March and April 2016, the FASB issued new guidance intended to improve the operability and understandability of the implementation guidance on principal versus agent considerations. Both amendments permit the use of either a retrospective or cumulative effect transition method and are effective for fiscal years, and interim periods within those fiscal years, beginning after December&#160;15, 2017, with early application permitted. The Company has not elected early adoption and will apply the modified retrospective approach upon adoption. The Company continues to evaluate the impact of the adoption of the new revenue standard on its consolidated financial statements.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the aging of our net accounts receivable (net of allowance for contractual adjustments, and prior to allowance for doubtful accounts), aged based on date of service and categorized based on the three primary overall types of accounts receivable characteristics (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td style="width:38%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June&#160;30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">0 - 180 days</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Over 180 days</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">0 - 180 days</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Over 180 days</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,714</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,512</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">26,226</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19,891</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,278</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">28,169</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">84,190</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">23,589</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">107,779</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">97,744</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19,848</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">117,592</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Patient</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,195</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,540</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,735</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,955</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,825</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,780</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">108,099</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">40,641</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">148,740</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">121,590</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">34,951</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">156,541</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Allowance for doubtful accounts</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(45,651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(44,730</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Net accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">103,089</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">111,811</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the consideration transferred in connection with the acquisition of Home Solutions as of September 9, 2016 (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:499px;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:405px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:82px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">67,516</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Equity issued at closing</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,938</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Capital lease obligation assumed</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">301</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Fair value of contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,400</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total consideration</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">93,155</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following details our financial instruments where the carrying value and the fair value differ (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.95121951219512%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:32%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Financial Instrument</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Carrying Value as of June 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Markets for Identical Item (Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Significant Other Observable Inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Significant Unobservable Inputs (Level 3)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">First Lien Note Facility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">198,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">198,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Second Lien Note Facility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">82,931</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">82,931</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2017 Warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">16,908</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">16,908</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2021 Notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">197,008</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">178,109</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">494,847</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">475,948</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s federal and state income tax provision from continuing operations for the </font><font style="font-family:inherit;font-size:10pt;">three months and six months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> is summarized in the following table (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended&#160;<br clear="none"/>&#160;June&#160;30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended&#160;<br clear="none"/>&#160;June&#160;30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Current</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">190</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">226</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">190</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">25</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">226</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">25</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Deferred</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Federal</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">437</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">108</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">932</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">125</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">179</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total deferred</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">528</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">124</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">1,111</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">147</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total income tax expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">718</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">149</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">1,337</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">172</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company&#8217;s debt consisted of the following (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:83.51219512195122%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Senior Credit Facilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">265,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">First Lien Note Facility, net of unamortized discount</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">198,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Second Lien Note Facility, net of unamortized discount</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">82,931</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2021 Notes, net of unamortized discount</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">197,008</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">196,670</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Capital leases</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,134</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,209</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less: Deferred financing costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,668</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(12,452</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total Debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">477,405</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">451,934</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less: Current portion</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,731</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(18,521</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Long-term debt, net of current portion</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">475,674</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">433,413</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the computation of basic and diluted loss per common share (in thousands, except for per share amounts):</font></div><div style="line-height:120%;padding-bottom:13px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended&#160;<br clear="none"/>&#160;June&#160;30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended&#160;<br clear="none"/>&#160;June&#160;30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Loss from continuing operations, net of income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(28,695</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(8,309</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(47,686</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(18,079</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Income (loss) from discontinued operations, net of income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(503</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(940</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">308</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(29,198</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(8,234</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(48,626</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(17,771</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accrued dividends on preferred stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,303</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,056</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,517</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,054</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Deemed dividend on preferred stock</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(175</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(173</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(349</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(345</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Loss attributable to common stockholders</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(31,676</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(10,463</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(53,492</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(22,170</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Denominator - Basic and Diluted:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted average common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">121,189</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">73,186</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">119,993</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">70,978</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Loss per Common Share:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Loss from continuing operations, basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Loss from discontinued operations, basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.01</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Loss per common share, basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(0.26</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(0.14</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(0.45</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(0.32</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s reconciliation of the statutory rate from continuing operations to the effective income tax rate for the </font><font style="font-family:inherit;font-size:10pt;">three months and six months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> is summarized as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended&#160;<br clear="none"/>&#160;June&#160;30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended&#160;<br clear="none"/>&#160;June&#160;30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Tax benefit at statutory rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(9,790</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,844</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(16,236</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(6,271</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">State tax expense, net of federal taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">190</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">226</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Valuation allowance changes affecting income tax provision</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,266</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,926</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">17,242</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,314</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Non-deductible transaction costs and other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">52</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,064</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">105</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,126</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Income tax expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">718</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">149</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">1,337</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">172</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the preliminary estimate of fair value of the assets acquired and liabilities assumed upon acquisition of Home Solutions (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:499px;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:405px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:82px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,956</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Inventories</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,199</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaids and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">852</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">16,007</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">57,218</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Managed care contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">24,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Licenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,400</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Trade name</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Non-compete agreements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other non-current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">891</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">110,867</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,576</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,136</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Current liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">17,712</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total fair value of cash and contingent consideration</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">93,155</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restructuring, acquisition, integration, and other expenses, net in the Unaudited Consolidated Statements of Operations for the </font><font style="font-family:inherit;font-size:10pt;">three months and six months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> consisted of the following (in thousands):</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.484375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended&#160;<br clear="none"/>&#160;June&#160;30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended&#160;<br clear="none"/>&#160;June&#160;30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restructuring expense </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,648</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,316</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,854</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,932</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Acquisition and integration expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">263</font></div></td><td style="vertical-align:bottom;background-color:;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,924</font></div></td><td style="vertical-align:bottom;background-color:;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">280</font></div></td><td style="vertical-align:bottom;background-color:;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,924</font></div></td><td style="vertical-align:bottom;background-color:;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Change in fair value of contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">102</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total restructuring, acquisition, integration, and other expense, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">3,911</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">4,291</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">7,134</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">6,958</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">STOCKHOLDERS&#8217; DEFICIT</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Securities Purchase Agreement</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 9, 2015, the Company entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with Coliseum Capital Partners L.P., a Delaware limited partnership, Coliseum Capital Partners II, L.P., a Delaware limited partnership, and Blackwell Partners, LLC, Series A, a Georgia limited liability company (collectively, the &#8220;PIPE Investors&#8221;). Pursuant to the terms of the Purchase Agreement, the Company issued and sold to the PIPE Investors in a private placement (the &#8220;PIPE Transaction&#8221;) an aggregate of (a) </font><font style="font-family:inherit;font-size:10pt;">625,000</font><font style="font-family:inherit;font-size:10pt;"> shares of Series A Preferred Stock at a purchase price per share of </font><font style="font-family:inherit;font-size:10pt;">$100.00</font><font style="font-family:inherit;font-size:10pt;">, (b) </font><font style="font-family:inherit;font-size:10pt;">1,800,000</font><font style="font-family:inherit;font-size:10pt;"> Class A warrants (the &#8220;Class A Warrants&#8221;), and (c) </font><font style="font-family:inherit;font-size:10pt;">1,800,000</font><font style="font-family:inherit;font-size:10pt;"> Class B warrants (the &#8220;Class B Warrants&#8221; and, together with Class A Warrants, the &#8220;PIPE Warrants&#8221;), for gross proceeds of </font><font style="font-family:inherit;font-size:10pt;">$62.5 million</font><font style="font-family:inherit;font-size:10pt;">. The initial conversion price for the Series A Preferred Stock is </font><font style="font-family:inherit;font-size:10pt;">$5.17</font><font style="font-family:inherit;font-size:10pt;">. The PIPE Warrants may be exercised to acquire shares of Common Stock. Pursuant to an addendum (the &#8220;Warrant Addendum&#8221;), dated as of March 23, 2015, to the Warrant Agreement, dated as of March 9, 2015, with the PIPE Investors, the PIPE Investors paid the Company </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> in the aggregate, and the per share exercise price of the Class A Warrants and Class B Warrants was set at </font><font style="font-family:inherit;font-size:10pt;">$5.17</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$6.45</font><font style="font-family:inherit;font-size:10pt;">, respectively, reduced from </font><font style="font-family:inherit;font-size:10pt;">$5.295</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$5.17</font><font style="font-family:inherit;font-size:10pt;"> and from </font><font style="font-family:inherit;font-size:10pt;">$6.595</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$6.45</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Series A, Series B, and Series C Convertible Preferred Stock</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the PIPE Transaction, the Company authorized </font><font style="font-family:inherit;font-size:10pt;">825,000</font><font style="font-family:inherit;font-size:10pt;"> shares and issued </font><font style="font-family:inherit;font-size:10pt;">625,000</font><font style="font-family:inherit;font-size:10pt;"> shares of Series A Preferred Stock at </font><font style="font-family:inherit;font-size:10pt;">$100.00</font><font style="font-family:inherit;font-size:10pt;"> per share. In connection with the Rights Offering (as defined below), the Company issued an additional </font><font style="font-family:inherit;font-size:10pt;">10,822</font><font style="font-family:inherit;font-size:10pt;"> shares of Series A Preferred Stock at </font><font style="font-family:inherit;font-size:10pt;">$100.00</font><font style="font-family:inherit;font-size:10pt;"> per share. The Series A Preferred Stock may, at the option of the holder, be converted into Common Stock and receive a Liquidation Preference upon voluntary or involuntary liquidation, dissolution, or winding up of the Company as described in the Annual Report. The Company may pay a noncumulative cash dividend on each share of the Series A Preferred Stock as previously disclosed in the Annual Report. In the event the Company does not declare and pay a cash dividend, the Liquidation Preference of the Series A Preferred Stock will be increased to an amount equal to the Liquidation Preference in effect at the start of the applicable quarterly dividend period, plus an amount equal to such then applicable Liquidation Preference multiplied by </font><font style="font-family:inherit;font-size:10pt;">11.5%</font><font style="font-family:inherit;font-size:10pt;"> per annum.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 10, 2016, in order to allow the shares of Common Stock reserved for issuance for the conversion of the Series A Preferred Stock and exercise of the PIPE Warrants to be released from reservation and sold pursuant to the 2016 Equity Offering (see below), we entered into an Exchange Agreement with the PIPE Investors (the &#8220;Series B Exchange Agreement&#8221;) pursuant to which the PIPE Investors agreed:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">i)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to exchange </font><font style="font-family:inherit;font-size:10pt;">614,177</font><font style="font-family:inherit;font-size:10pt;"> shares of the existing Series A Preferred Stock for an identical number of shares of Series B Convertible Preferred Stock (the &#8220;Series B Preferred Stock&#8221;), which have the same terms as the Series A Preferred Stock previously described in the Company&#8217;s prior public filings, except that the terms of the Series B Preferred Stock include the authority of the holders of the Series B Preferred Stock to waive the requirement that the Company reserve a sufficient number of shares of Common Stock reserved at all times to allow for the conversion of the Series B Preferred Stock; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">ii)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to waive the requirement under the Warrant Agreement governing the PIPE Warrants to reserve </font><font style="font-family:inherit;font-size:10pt;">3,600,000</font><font style="font-family:inherit;font-size:10pt;"> shares of our Common Stock for the exercise of the PIPE Warrants.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 14, 2016, the Company entered into another Exchange Agreement (the &#8220;Series C Exchange Agreement&#8221;) with the PIPE Investors, pursuant to which the PIPE Investors agreed to exchange their shares of Series B Preferred Stock issued pursuant to the Series B Exchange Agreement on a one for one basis for shares of Series C Preferred Stock.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the Series C Exchange Agreement, the PIPE Investors agreed to exchange </font><font style="font-family:inherit;font-size:10pt;">614,177</font><font style="font-family:inherit;font-size:10pt;"> shares of the Series B Preferred Stock for an identical number of shares of Series C Preferred Stock, which have the same terms as the Series B Preferred Stock, except that the terms of the Series C Preferred Stock provide that the </font><font style="font-family:inherit;font-size:10pt;">11.5%</font><font style="font-family:inherit;font-size:10pt;"> per annum rate of non-cash dividends payable on the shares of the Series C Preferred Stock will be reduced based on the achievement by the Company of specified &#8220;Consolidated EBITDA&#8221; as defined in the Senior Credit Facilities. In addition, pursuant to the Series C Exchange Agreement, the PIPE Investors agreed to waive the requirement under the Warrant Agreement governing the PIPE Warrants held by the PIPE Investors to reserve </font><font style="font-family:inherit;font-size:10pt;">3,600,000</font><font style="font-family:inherit;font-size:10pt;"> shares of Common Stock for the exercise of the PIPE Warrants.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the exchanges discussed above, there are, as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, (a) </font><font style="font-family:inherit;font-size:10pt;">21,645</font><font style="font-family:inherit;font-size:10pt;"> shares of Series A Preferred Stock outstanding, of which </font><font style="font-family:inherit;font-size:10pt;">10,823</font><font style="font-family:inherit;font-size:10pt;"> shares are owned by the PIPE Investors, (b) </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> shares of Series B Preferred Stock outstanding, and (c) </font><font style="font-family:inherit;font-size:10pt;">614,177</font><font style="font-family:inherit;font-size:10pt;"> shares of Series C Preferred Stock outstanding, all of which are owned by the PIPE Investors.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Liquidation Preference of the Series A Preferred Stock and Series C Preferred Stock was </font><font style="font-family:inherit;font-size:10pt;">$2.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$79.9 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">PIPE Warrants</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the PIPE Transaction, the Company issued </font><font style="font-family:inherit;font-size:10pt;">1,800,000</font><font style="font-family:inherit;font-size:10pt;"> Class A Warrants and </font><font style="font-family:inherit;font-size:10pt;">1,800,000</font><font style="font-family:inherit;font-size:10pt;"> Class B Warrants which may be exercised to acquire shares of Common Stock. The rights and terms of the Class A Warrants and the Class B Warrants are identical except for the exercise price. Pursuant to the Warrant Addendum with the PIPE Investors, the PIPE Investors paid the Company </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> in the aggregate, and the per share exercise price of the Class A Warrants and Class B Warrants was set at </font><font style="font-family:inherit;font-size:10pt;">$5.17</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$6.45</font><font style="font-family:inherit;font-size:10pt;">, respectively, reduced from </font><font style="font-family:inherit;font-size:10pt;">$5.295</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$5.17</font><font style="font-family:inherit;font-size:10pt;"> and from </font><font style="font-family:inherit;font-size:10pt;">$6.595</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$6.45</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company entered into a registration rights agreement, as amended (the &#8220;Registration Rights Agreement&#8221;), with the PIPE Investors that, among other things and subject to certain exceptions, requires the Company, upon the request of the PIPE Investors, to register the Common Stock of the Company issuable upon conversion of the PIPE Investors&#8217; Series A Preferred Shares, the Series C Preferred Shares, or exercise of the PIPE Warrants. Pursuant to the terms of the Registration Rights Agreement, the costs incurred in connection with such registrations will be borne by the Company. As provided under the Registration Rights Agreement, the Company on April 1, 2016 filed a shelf registration statement on Form S-3 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), to register, among other things, the Common Stock of the Company issuable upon conversion of the PIPE Investors&#8217; Series A and Series C Preferred Shares.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Rights Offering</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 30, 2015, the Company commenced a rights offering (the &#8220;Rights Offering&#8221;) pursuant to which the Company distributed subscription rights to purchase units consisting of (1) Series A Preferred Stock, each share convertible into shares of Common Stock at a conversion price of </font><font style="font-family:inherit;font-size:10pt;">$5.17</font><font style="font-family:inherit;font-size:10pt;"> per share, (2) Class A warrants to purchase one share of Common Stock at a price of </font><font style="font-family:inherit;font-size:10pt;">$5.17</font><font style="font-family:inherit;font-size:10pt;"> per share (the &#8220;Public Class A Warrants&#8221;), and (3) Class B warrants to purchase one share of Common Stock at a price of </font><font style="font-family:inherit;font-size:10pt;">$6.45</font><font style="font-family:inherit;font-size:10pt;"> per share (the &#8220;Public Class B Warrants&#8221; and, together with the Public Class A Warrants, the &#8220;Public Warrants&#8221;). The Rights Offering expired on July 27, 2015 and was completed on July 31, 2015. Stockholders of the Company exercised subscription rights to purchase </font><font style="font-family:inherit;font-size:10pt;">10,822</font><font style="font-family:inherit;font-size:10pt;"> units, consisting of an aggregate of </font><font style="font-family:inherit;font-size:10pt;">10,822</font><font style="font-family:inherit;font-size:10pt;"> shares of the Series A Preferred Stock, </font><font style="font-family:inherit;font-size:10pt;">31,025</font><font style="font-family:inherit;font-size:10pt;"> Public Class A Warrants, and </font><font style="font-family:inherit;font-size:10pt;">31,025</font><font style="font-family:inherit;font-size:10pt;"> Public Class B Warrants, at a subscription price of </font><font style="font-family:inherit;font-size:10pt;">$100.00</font><font style="font-family:inherit;font-size:10pt;"> per unit. Pursuant to the Rights Offering, the Company raised gross proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With the exception of the expiration date, the Class A Warrants issued pursuant to the PIPE Transaction, as amended by the Warrant Addendum, have the same terms as the Public Class A Warrants issued pursuant to the Rights Offering. Similarly, with the exception of the expiration date, the Class B Warrants issued pursuant to the PIPE Transaction, as amended by the Warrant Addendum, have the same terms as the Public Class B Warrants issued pursuant to the Rights Offering.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Carrying Value of Series A Preferred Stock</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the following values were accreted pursuant to the terms of the Exchange Agreement, dated as of June 10, 2016, among the Company and the signatories thereto and recorded as a reduction of additional paid in capital in Stockholders&#8217; Deficit and a deemed dividend on the Unaudited Consolidated Statements of Operations. In addition, dividends were accrued at </font><font style="font-family:inherit;font-size:10pt;">11.5%</font><font style="font-family:inherit;font-size:10pt;"> from the date of issuance to </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">. The following table sets forth the activity recorded during the </font><font style="font-family:inherit;font-size:10pt;">six months ended June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> related to the Series A Preferred Stock (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.4765625%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Series A Preferred Stock carrying value at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2,462</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accretion of discount related to issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">26</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Dividends recorded through June 30, 2017</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#160;1</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">151</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Series A Preferred Stock carrying value June 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2,639</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1 </sup></font><font style="font-family:inherit;font-size:10pt;">Dividends recorded reflect the increase in the Liquidation Preference associated with unpaid dividends.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Carrying Value of Series C Preferred Stock</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the following values were accreted pursuant to the terms of the Exchange Agreement, dated as of June 16, 2016, among the Company and the signatories thereto and recorded as a reduction of additional paid in capital in Stockholders&#8217; Deficit and a deemed dividend on the Unaudited Consolidated Statements of Operations. In addition, dividends were accrued at </font><font style="font-family:inherit;font-size:10pt;">11.5%</font><font style="font-family:inherit;font-size:10pt;"> from the date of issuance to </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">. The following table sets forth the activity recorded during the </font><font style="font-family:inherit;font-size:10pt;">six months ended June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> related to the Series C Preferred Stock (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.4765625%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Series C Preferred Stock carrying value at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">69,540</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accretion of discount related to issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">323</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Dividends recorded through June 30, 2017</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#160;1</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,366</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Series C Preferred Stock carrying value June 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">74,229</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1 </sup></font><font style="font-family:inherit;font-size:10pt;">Dividends recorded reflect the increase in the Liquidation Preference associated with unpaid dividends.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Shelf Registration Statement</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company filed a shelf registration statement on Form S-3 under the Securities Act on April 1, 2016, which was declared effective May 2, 2016 (the &#8220;2016 Shelf&#8221;). Under the 2016 Shelf at the time of effectiveness, the Company had the ability to raise up to </font><font style="font-family:inherit;font-size:10pt;">$200.0 million</font><font style="font-family:inherit;font-size:10pt;">, in one or more transactions, by selling Common Stock, preferred stock, debt securities, warrants, units and rights.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2016 Equity Offering</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 22, 2016 the Company completed an underwritten public offering of </font><font style="font-family:inherit;font-size:10pt;">45,200,000</font><font style="font-family:inherit;font-size:10pt;"> shares of Common Stock, including </font><font style="font-family:inherit;font-size:10pt;">5,200,000</font><font style="font-family:inherit;font-size:10pt;"> shares of Common Stock issued upon the underwriters&#8217; full exercise of the over-allotment option, at a public offering price of </font><font style="font-family:inherit;font-size:10pt;">$2.00</font><font style="font-family:inherit;font-size:10pt;"> per share, less underwriting discounts and commissions and offering expenses payable by us (the &#8220;2016 Equity Offering&#8221;). The Company received net proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">$83.3 million</font><font style="font-family:inherit;font-size:10pt;"> from the 2016 Equity Offering, after deducting underwriting discounts and commissions and offering costs.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A portion of the net proceeds from the 2016 Equity Offering was used to fund the Cash Consideration (as defined below) and pay fees and expenses in connection with the closing of the Home Solutions Transaction (see below)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Home Solutions Transaction</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 9, 2016, the Company acquired substantially all of the assets and assumed certain liabilities of HS Infusion Holdings, Inc. (&#8220;Home Solutions&#8221;) and its subsidiaries (the &#8220;Home Solutions Transaction&#8221;) pursuant to an Asset Purchase Agreement dated June 11, 2016 (as amended, the &#8220;Home Solutions Agreement&#8221;), by and among Home Solutions, a Delaware corporation, certain subsidiaries of Home Solutions, the Company and HomeChoice Partners, Inc., a Delaware corporation. Home Solutions, a privately held company, provides home infusion and home nursing products and services to patients suffering from chronic and acute medical conditions. On June 16, 2016, the Company, HomeChoice Partners, Inc. and Home Solutions entered into an amendment to the Home Solutions Agreement (the &#8220;First Amendment&#8221;), which modified the terms of the consideration payable by the Company to Home Solutions thereunder. On September 2, 2016, the same parties entered into a second amendment to the Home Solutions Agreement (the &#8220;Second Amendment&#8221;), which amended the Home Solutions Agreement to eliminate the condition to closing that the Company receive stockholder approval to increase its authorized share capital (the &#8220;Charter Amendment&#8221;) and facilitated the timely consummation of the Home Solutions Transaction. The Second Amendment instead provided that the Company will hold a stockholder meeting after the closing of the Home Solutions Transaction to seek stockholder approval of the Charter Amendment, and if the approval is not obtained at the first special meeting, the Company will submit the proposal on a twice per year basis beginning in 2017, at either the annual meeting or a special meeting of stockholders. The Charter Amendment was approved at a special meeting of stockholders held on November 30, 2016.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The aggregate consideration paid by the Company in the Home Solutions Transaction was equal to (i) </font><font style="font-family:inherit;font-size:10pt;">$67.5 million</font><font style="font-family:inherit;font-size:10pt;"> in cash (the &#8220;Cash Consideration&#8221;); plus (ii) (a) </font><font style="font-family:inherit;font-size:10pt;">3,750,000</font><font style="font-family:inherit;font-size:10pt;"> shares of Company common stock (the &#8220;Transaction Closing Equity Consideration&#8221;) and (b) the right to receive contingent equity securities of the Company, in the form of restricted shares of Company common stock (the &#8220;RSUs&#8221;), issuable in two tranches, Tranche A and Tranche B, with different vesting conditions (collectively, the &#8220;Contingent Shares&#8221;). The number of shares of Company common stock in Tranche A is </font><font style="font-family:inherit;font-size:10pt;">3.1 million</font><font style="font-family:inherit;font-size:10pt;"> and the number of shares of Company common stock in Tranche B is </font><font style="font-family:inherit;font-size:10pt;">4.0 million</font><font style="font-family:inherit;font-size:10pt;">, each subject to certain vesting conditions. Upon close of the Home Solutions Transaction the RSUs had no intrinsic value, but are reported in our consolidated financial statements at their estimated fair value at the date of issuance. The Home Solutions Agreement provides Home Solutions with certain customary registration rights that required us, within 30 days following the closing of the Home Solutions Transaction, to file a registration statement for the selling stockholder&#8217;s resale of the Transaction Closing Equity Consideration and the Contingent Shares pursuant to the Securities Act. The Company filed the registration statement on October 7, 2016 and it was declared effective on October 27, 2016.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company will issue the shares of our Common Stock issuable to Home Solutions pursuant to the RSUs in Tranche A promptly, and in any event within five business days, following the earlier of (a) the closing price of our Common Stock, as reported by NASDAQ, averaging </font><font style="font-family:inherit;font-size:10pt;">$4.00</font><font style="font-family:inherit;font-size:10pt;"> per share or above over </font><font style="font-family:inherit;font-size:10pt;">20</font><font style="font-family:inherit;font-size:10pt;"> consecutive trading days during the period beginning on September 9, 2016 and ending December 31, 2019, or (b) a change of control that occurs on or prior to December 31, 2017 or a change of control thereafter but on or prior to December 31, 2019, pursuant to which the consideration payable per share equals or exceeds </font><font style="font-family:inherit;font-size:10pt;">$4.00</font><font style="font-family:inherit;font-size:10pt;"> per share. The Company will issue the shares of our Common Stock issuable to Home Solutions pursuant to the RSUs in Tranche B promptly, and in any event within five business days, following the earlier of (a) the closing price of our Common Stock, as reported by NASDAQ, averaging </font><font style="font-family:inherit;font-size:10pt;">$5.00</font><font style="font-family:inherit;font-size:10pt;"> per share or above over </font><font style="font-family:inherit;font-size:10pt;">20</font><font style="font-family:inherit;font-size:10pt;"> consecutive trading days during the period beginning on September 9, 2016 and ending December 31, 2019, or (b) a change of control that occurs on or prior to December 31, 2017, or a change of control thereafter but on or prior to December 31, 2019, pursuant to which the consideration payable per share equals or exceeds </font><font style="font-family:inherit;font-size:10pt;">$5.00</font><font style="font-family:inherit;font-size:10pt;"> per share. The Home Solutions Agreement provides for a cash settlement option related to the RSUs, effective June 15, 2021, if, and only if, authorized shares are unavailable when the vesting conditions of Tranche A and Tranche B are met. At the date of acquisition, the Company did not have sufficient authorized shares available to satisfy the issuance of Tranche A and Tranche B RSUs and, accordingly, recognized a liability for the fair value of the contingent consideration. As of November 30, 2016, upon approval of the Charter Amendment, the Company had sufficient authorized shares available should the vesting conditions be met and the RSUs become issuable. The liability was reclassified to equity and a gain on the change in the fair value of the RSUs was recognized as of November 30, 2016. On March 13, 2017, the Company filed with the SEC a Registration Statement on Form S-3 to register the Contingent Shares and it was declared effective on April 18, 2017.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Cash Consideration and the Transaction Closing Equity Consideration were paid at closing and were funded by cash on-hand and borrowings from our Revolving Credit Facility.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">First Quarter 2017 Private Placement</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 1, 2017, the Company entered into a Stock Purchase Agreement (the &#8220;First Quarter Stock Purchase Agreement&#8221;) with Venor Capital Master Fund Ltd., Map 139 Segregated Portfolio of LMA SPC, Venor Special Situations Fund II LP and Trevithick LP (the &#8220;First Quarter Stockholders&#8221;). Pursuant to the First Quarter Stock Purchase Agreement, the Company sold an aggregate of </font><font style="font-family:inherit;font-size:10pt;">3.3 million</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock (the &#8220;First Quarter Shares&#8221;) for aggregate gross proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">$5.1 million</font><font style="font-family:inherit;font-size:10pt;"> in a private placement transaction (the &#8220;First Quarter 2017 Private Placement&#8221;). The purchase price for each Share was </font><font style="font-family:inherit;font-size:10pt;">$1.5366</font><font style="font-family:inherit;font-size:10pt;">, which was negotiated between the Company and the First Quarter Stockholders based on the volume-weighted average price of the Company's common stock on the NASDAQ Global Market on March 1, 2017.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the First Quarter 2017 Private Placement, the Company entered into a Registration Rights Agreement (the &#8220;First Quarter 2017 Registration Rights Agreement&#8221;) with the First Quarter Stockholders. Pursuant to the First Quarter 2017 Registration Rights Agreement, the Company agreed to prepare and file a registration statement with the SEC within ten days of the date it files its annual report on Form 10-K for the fiscal year ended December 31, 2016, for purposes of registering the resale of the First Quarter Shares and any shares of common stock issued as a dividend or other distribution with respect to the First Quarter Shares.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As provided under the First Quarter 2017 Registration Rights Agreement, the Company, on March 13, 2017, filed a shelf registration statement on Form S-3 under the Securities Act to register the First Quarter Shares and it was declared effective April 18, 2017.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from the First Quarter 2017 Private Placement were used for working capital and general corporate purposes.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2017 Warrants</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Second Lien Note Facility (as defined below), the Company also issued warrants (the &#8220;2017 Warrants&#8221;) to the purchasers of the Second Lien Notes (as defined below) pursuant to a Warrant Purchase Agreement dated as of June 29, 2017 (the &#8220;Warrant Purchase Agreement&#8221;). The 2017 Warrants entitle the purchasers of the Warrants to purchase shares of Common Stock, representing at the time of any exercise of the 2017 Warrants an equivalent number of shares equal to </font><font style="font-family:inherit;font-size:10pt;">4.99%</font><font style="font-family:inherit;font-size:10pt;"> of the Common Stock of the Company on a fully diluted basis, subject to the terms of the Warrant Agreement governing the Warrants, dated as of June 29, 2017 (the &#8220;Warrant Agreement&#8221;); provided, however, the Warrants may not be converted to the extent that, after giving effect to such conversion, the holders of the 2017 Warrants would beneficially own, in the aggregate, in excess of (i) </font><font style="font-family:inherit;font-size:10pt;">19.99%</font><font style="font-family:inherit;font-size:10pt;"> of the shares of Common Stock outstanding as of June 29, 2017 (the &#8220;Closing Date&#8221;) minus (ii) the shares of Common Stock that were sold pursuant to the Second Quarter 2017 Private Placement (as defined below) (the &#8220;Conversion Cap&#8221;). The Conversion Cap will not apply to the 2017 Warrants if the Company obtains the approval of its stockholders for the removal of the Conversion Cap, which the Company is required to take certain steps to attempt to obtain, subject to the terms of the Warrant Agreement.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2017 Warrants have a 10-year term and an initial exercise price of </font><font style="font-family:inherit;font-size:10pt;">$2.00</font><font style="font-family:inherit;font-size:10pt;"> per share, and may be exercised by payment of the exercise price in cash or surrender of shares of Common Stock into which the Warrants are being converted in an aggregate amount sufficient to pay the exercise price.&#160; The exercise price and the number of shares that may be acquired upon exercise of the 2017 Warrants is subject to adjustment in certain situations, including price based anti-dilution protection whereby, subject to certain exceptions, if the Company later issues Common Stock or certain Common Stock Equivalents (as defined in the Warrant Agreement) at a price less than either the then-current market price per share or exercise price of the 2017 Warrants, then the exercise price will be decreased and the percentage of shares of Common Stock issuable upon exercise of the Warrants will remain the same, giving effect to such issuance. Additionally, the 2017 Warrants have standard anti-dilution protections if the Company effects a stock split, subdivision, reclassification or combination of its Common Stock or fixes a record date for the making of a dividend or distribution to stockholders of cash or certain assets. Upon the occurrence of certain business combinations the 2017 Warrants will be converted into the right to acquire shares of stock or other securities or property (including cash) of the successor entity.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Second Quarter 2017 Private Placement</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 29, 2017, the Company entered into a Stock Purchase Agreement (the &#8220;Second Quarter Stock Purchase Agreement&#8221;) with a fund managed by Ares Management L.P. (&#8220;Ares&#8221; or the &#8220;Second Quarter Stock Purchaser&#8221;). Pursuant to the terms of the Second Quarter Stock Purchase Agreement, the Company issued and sold to the Second Quarter Stock Purchaser in a private placement (the &#8220;Second Quarter 2017 Private Placement&#8221;) </font><font style="font-family:inherit;font-size:10pt;">6,359,350</font><font style="font-family:inherit;font-size:10pt;"> shares of Common Stock (the &#8220;Second Quarter Shares&#8221;) at a price of </font><font style="font-family:inherit;font-size:10pt;">$2.50</font><font style="font-family:inherit;font-size:10pt;"> per share, for proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">$15.9 million</font><font style="font-family:inherit;font-size:10pt;">, net of </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> in associated costs.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Second Quarter Registration Rights Agreement</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the 2017 Warrants and the Second Quarter 2017 Private Placement, the Company entered into a Registration Rights Agreement (the &#8220;Second Quarter 2017 Registration Rights Agreement&#8221;) with the holders of the 2017 Warrants and the Second Quarter Stock Purchaser. Pursuant to the Second Quarter 2017 Registration Rights Agreement, subject to certain exceptions, the Company is required, upon the request of the Second Quarter Stock Purchaser and holders of the 2017 Warrants, to register the resale of the Second Quarter Shares and the shares of Common Stock issuable upon exercise of the 2017 Warrants. Pursuant to the terms of the Second Quarter 2017 Registration Rights Agreement, these registration rights will not become effective until twelve months after the Closing Date, and the costs incurred in connection with such registrations will be borne by the Company.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the activity recorded during the </font><font style="font-family:inherit;font-size:10pt;">six months ended June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> related to the Series C Preferred Stock (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.4765625%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Series C Preferred Stock carrying value at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">69,540</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accretion of discount related to issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">323</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Dividends recorded through June 30, 2017</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#160;1</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,366</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Series C Preferred Stock carrying value June 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">74,229</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1 </sup></font><font style="font-family:inherit;font-size:10pt;">Dividends recorded reflect the increase in the Liquidation Preference associated with unpaid dividends.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the activity recorded during the </font><font style="font-family:inherit;font-size:10pt;">six months ended June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> related to the Series A Preferred Stock (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.4765625%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Series A Preferred Stock carrying value at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2,462</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accretion of discount related to issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">26</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Dividends recorded through June 30, 2017</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#160;1</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">151</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Series A Preferred Stock carrying value June 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2,639</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1 </sup></font><font style="font-family:inherit;font-size:10pt;">Dividends recorded reflect the increase in the Liquidation Preference associated with unpaid dividends.</font></div></div> EX-101.SCH 7 bios-20170630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2104100 - Disclosure - ACQUISITIONS link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - ACQUISITIONS - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2404404 - Disclosure - ACQUISITIONS - Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - ACQUISITIONS - Consideration Transferred in Acquisition (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - ACQUISITIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 2401404 - Disclosure - BASIS OF PRESENTATION - Accounts Receivable Aging (Details) link:presentationLink link:calculationLink link:definitionLink 2401403 - Disclosure - BASIS OF PRESENTATION - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - BASIS OF PRESENTATION (Policies) link:presentationLink link:calculationLink link:definitionLink 2301302 - Disclosure - BASIS OF PRESENTATION (Tables) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 2407401 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - CONCENTRATION OF RISK link:presentationLink link:calculationLink link:definitionLink 2408401 - Disclosure - CONCENTRATION OF RISK (Details) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1001001 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - DEBT - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2406404 - Disclosure - DEBT - Carrying and Estimated Fair Values of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - DEBT - Summary of Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - DEBT - Summary of Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 2409404 - Disclosure - INCOME TAXES - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - INCOME TAXES - Reconciliation of the Income Tax Rate (Details) link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - INCOME TAXES - Schedule of Federal and State Income Tax Provision (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - LOSS PER SHARE link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - LOSS PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 2302301 - Disclosure - LOSS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - RESTRUCTURING, ACQUISITION, INTERGRATION, AND OTHER EXPENSES, NET link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - RESTRUCTURING, ACQUISITION, INTERGRATION, AND OTHER EXPENSES, NET (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - RESTRUCTURING, ACQUISITION, INTERGRATION, AND OTHER EXPENSES, NET (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 2410401 - Disclosure - STOCK-BASED COMPENSATION (Details) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - STOCKHOLDERS' DEFICIT link:presentationLink link:calculationLink link:definitionLink 2403406 - Disclosure - STOCKHOLDERS' DEFICIT - 2017 Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - STOCKHOLDERS' DEFICIT - Activity Related to Series A and C Preferred Stock (Details) link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - STOCKHOLDERS' DEFICIT - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2403405 - Disclosure - STOCKHOLDERS' DEFICIT - First Quarter 2017 Private Placement (Details) link:presentationLink link:calculationLink link:definitionLink 2403404 - Disclosure - STOCKHOLDERS' DEFICIT - Home Solutions Transaction (Details) link:presentationLink link:calculationLink link:definitionLink 2403407 - Disclosure - STOCKHOLDERS' DEFICIT - Second Quarter 2017 Private Placement (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - STOCKHOLDERS' DEFICIT (Tables) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 bios-20170630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 bios-20170630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 bios-20170630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Business Combinations [Abstract] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Home Solutions HS Infusion Holdings, Inc [Member] HS Infusion Holdings, Inc [Member] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Managed care contracts Customer Contracts [Member] Licenses Licenses [Member] Licenses [Member] Trade name Trade Names [Member] Non-compete agreements Noncompete Agreements [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Accounts receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Inventories Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Prepaids and other assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Total current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets Property and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Goodwill Goodwill Intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Other non-current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Total assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Accounts payable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Accrued liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities Current liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities Total fair value of cash and contingent consideration Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table] Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table] Plan Name [Axis] Plan Name [Axis] Share-based Compensation Arrangements by Share-based Payment Award, Award Type and Plan Name [Domain] Plan Name [Domain] Charter Amendment Charter Amendment [Member] Charter Amendment [Member] 2008 Plan 2008 Plan [Member] 2008 Plan [Member] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock Common Stock [Member] Award Type [Axis] Award Type [Axis] Equity Award [Domain] Equity Award [Domain] Equity Option Equity Option [Member] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Restricted Stock Restricted Stock [Member] Market Based Cash Awards Market Based Cash Awards [Member] Market Based Cash Awards [Member] Employee Stock Employee Stock [Member] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Number of shares authorized (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Adjustment to number of shares authorized (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Number of shares available for grant (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Share-based compensation expense Allocated Share-based Compensation Expense Purchase price of common stock, percent Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent Par value of common stock (in dollars per share) Common Stock, Par or Stated Value Per Share Shares purchased on the open market for award (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award Equity [Abstract] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Sale of Stock [Axis] Sale of Stock [Axis] Sale of Stock [Domain] Sale of Stock [Domain] Private Placement Private Placement [Member] Class of Stock [Line Items] Class of Stock [Line Items] Stock issued (in shares) Stock Issued During Period, Shares, New Issues Stock offering price (in dollars per share) Shares Issued, Price Per Share Net proceeds from issuance of equity, net of issuance costs Proceeds from Issuance of Common Stock Associated costs with private placement Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Restructuring and Related Activities [Abstract] Restructuring expense Restructuring Charges Acquisition and integration expense Business Combination, Integration Related Costs Change in fair value of contingent consideration Gain (Loss) on Change in Fair Value of Contingent Consideration Gain (Loss) on Change in Fair Value of Contingent Consideration Total restructuring, acquisition, integration, and other expense, net Acquisition, Integration, Restructuring and Other Expenses Acquisition, Integration, Restructuring and Other Expenses Cash Payments to Acquire Businesses, Gross Equity issued at closing Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Capital lease obligation assumed Business Combination, Consideration Transferred, Liabilities Incurred Fair value of contingent consideration Business Combination, Consideration Transferred, Fair Value Business Combination, Consideration Transferred, Fair Value Total consideration Business Combination, Consideration Transferred Schedule of Restructuring, Acquisition, Integration, and Other Expenses, Net Restructuring and Related Costs [Table Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Income Tax Disclosure [Abstract] Schedule of Federal and State Income Tax Provision (Benefit) Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Reconciliation of the Income Tax Rate Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Earnings Per Share [Abstract] Schedule of Basic and Diluted Loss Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Income Statement [Abstract] Net revenue Health Care Organization, Revenue Cost of revenue (excluding depreciation expense) Cost of Revenue Gross profit Gross Profit Other operating expenses Other Selling, General and Administrative Expense Bad debt expense Provision for Doubtful Accounts General and administrative expenses General and Administrative Expense Restructuring, acquisition, integration, and other expenses, net Depreciation and amortization expense Amortization of Intangible Assets Interest expense Interest Income (Expense), Net Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt Loss (gain) on dispositions Gain (Loss) on Disposition of Property Plant Equipment Loss from continuing operations, before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Income tax expense Income Tax Expense (Benefit) Loss from continuing operations, net of income taxes Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent (Loss) income from discontinued operations, net of income taxes Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Net loss Net Income (Loss) Attributable to Parent Accrued dividends on preferred stock Temporary Equity, Dividends, Adjustment Deemed dividends on preferred stock Temporary Equity, Accretion to Redemption Value, Adjustment Loss attributable to common stockholders Net Income (Loss) Available to Common Stockholders, Basic Loss per common share: Loss from continuing operations, basic and diluted (in dollars per share) Income (Loss) from Continuing Operations, Per Basic and Diluted Share Loss from discontinued operations, basic and diluted (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share Loss per common share, basic and diluted (in dollars per share) Earnings Per Share, Basic and Diluted Weighted average common shares outstanding, basic and diluted (in shares) Weighted Average Number of Shares Outstanding, Basic and Diluted Tax benefit at statutory rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount State tax expense, net of federal taxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Valuation allowance changes affecting income tax provision Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Non-deductible transaction costs and other Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Total income tax expense Class of Warrant or Right [Table] Class of Warrant or Right [Table] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Series A Preferred Stock Series A Preferred Stock [Member] Series B Preferred Stock Series B Preferred Stock [Member] Series C Preferred Stock Series C Preferred Stock [Member] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] PIPE Warrants Two Thousand Fifteen Warrants [Member] Two Thousand Fifteen Warrants [Member] Class A Warrants Class A Warrants [Member] Class A Warrants [Member] Class B Warrants Class B Warrants [Member] Class B Warrants [Member] Class A Warrants Prior to Addendum Class A Warrants Prior to Addendum [Member] Class A Warrants Prior to Addendum [Member] Class B Warrants Prior to Addendum Class B Warrants Prior to Addendum [Member] Class B Warrants Prior to Addendum [Member] Secondary Offering Secondary Offering [Member] Secondary Offering [Member] Over-Allotment Option Over-Allotment Option [Member] Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Shares issued (in shares) Temporary Equity, Shares Issued Share price (in dollars per share) Warrants issued (in shares) Class of Warrant or Right, Outstanding Proceeds from issuance of equity and temporary equity Proceeds from Issuance of Equity and Temporary Equity Proceeds from Issuance of Equity and Temporary Equity Redemption price (in dollars per share) Temporary Equity, Redemption Price Per Share Additional contribution by investors Proceeds from Modification of Warrant Terms Proceeds from Modification of Warrant Terms Exercise price of warrants (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Series A convertible preferred stock, shares authorized (in shares) Temporary Equity, Shares Authorized Dividend accrual rate Preferred Stock, Dividend Accrual Rate, Percentage Preferred Stock, Dividend Accrual Rate, Percentage Shares converted (in shares) Conversion of Stock, Shares Converted Shares issued in conversion (in shares) Conversion of Stock, Shares Issued Common stock reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Dividend rate of non-cash dividend payable Preferred Stock, Dividend Rate, Percentage Convertible preferred stock series, shares outstanding (in shares) Temporary Equity, Shares Outstanding Convertible preferred stock series, liquidation preference Temporary Equity, Liquidation Preference Amount of equity able to raise Sale of Stock, Equity Issuable, Amount Sale of Stock, Equity Issuable, Amount Value of stock issued in secondary offering Restructuring, Acquisition, Integration, and Other Expenses, Net Business Acquisition, Integration, Restructuring and Other Related Costs [Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Financing Receivables, Period Past Due [Axis] Financing Receivables, Period Past Due [Axis] Financing Receivables, Period Past Due [Domain] Financing Receivables, Period Past Due [Domain] Receivables 0 to 180 Days Past Due Financing Receivables. 1 to 180 Days Past Due [Member] Financing Receivables. 1 to 180 Days Past Due [Member] Receivables Over 180 Days Past Due Financing Receivables. Greater than 180 Days Past Due [Member] Financing Receivables. Greater than 180 Days Past Due [Member] Industry Sector [Axis] Industry Sector [Axis] Industry Sector [Domain] Industry Sector [Domain] Government Government Sector [Member] Commercial Commercial and Industrial Sector [Member] Patient Patient [Member] Patient [Member] Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Gross accounts receivable Accounts Receivable, Gross Allowance for doubtful accounts Allowance for Doubtful Accounts Receivable Net accounts receivable Accounts Receivable, Net Temporary Equity, by Class of Stock [Table] Temporary Equity, by Class of Stock [Table] Temporary Equity [Line Items] Temporary Equity [Line Items] Increase (Decrease) in Temporary Equity [Roll Forward] Increase (Decrease) in Temporary Equity [Roll Forward] Beginning Balance Temporary Equity, Carrying Amount, Attributable to Parent Accretion of discount related to issuance costs Temporary Equity, Accretion to Redemption Value Dividends recorded Temporary Equity, Accretion of Dividends Ending Balance Debt Disclosure [Abstract] Summary of Long-term Debt Schedule of Debt [Table Text Block] Schedule of Carrying and Estimated Fair Values of Financial Instruments Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block] Income Taxes Income Tax Disclosure [Text Block] Debt Debt Disclosure [Text Block] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] 2017 Warrants 2017 Warrants [Member] 2017 Warrants [Member] Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Markets for Identical Item (Level 1) Fair Value, Inputs, Level 1 [Member] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] First Lien Note Facility, net of unamortized discount First Lien Note, Maturing June 30, 2022 [Member] First Lien Note, Maturing June 30, 2022 [Member] Second Lien Note Facility, net of unamortized discount Second Lien Note, Maturing August 15, 2020 [Member] Second Lien Note, Maturing August 15, 2020 [Member] 2021 Notes Senior Unsecured 8.875% Notes [Member] Senior Unsecured 8.875% Notes [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Long-term debt, carrying value Long-term Debt Long-term debt, fair value Long-term Debt, Fair Value Warrants, carrying value Warrants and Rights Outstanding Warrants, fair value Warrants Not Settleable in Cash, Fair Value Disclosure Total, carrying value Debt And Warrants Outstanding Debt And Warrants Outstanding Total, fair value Financial Liabilities Fair Value Disclosure Federal Current Federal Tax Expense (Benefit) State Current State and Local Tax Expense (Benefit) Total current Current Income Tax Expense (Benefit) Federal Deferred Federal Income Tax Expense (Benefit) State Deferred State and Local Income Tax Expense (Benefit) Total deferred Deferred Income Tax Expense (Benefit) Schedule of Accounts Receivable Aging Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Schedule of Consideration Transferred in Acquisition Schedule of Business Acquisitions, by Acquisition [Table Text Block] Schedule of Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Basis of Presentation Business Description and Basis of Presentation [Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Consolidation Consolidation, Policy [Policy Text Block] Business Combinations Business Combinations Policy [Policy Text Block] Cash and Cash Equivalents and Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Income Tax Authority [Axis] Income Tax Authority [Axis] Income Tax Authority [Domain] Income Tax Authority [Domain] Federal Domestic Tax Authority [Member] State State and Local Jurisdiction [Member] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Net operating loss carryforwards Operating Loss Carryforwards Net operating loss carryforwards subject to annual limitation Operating Loss Carryforwards, Limitations on Use, Amount Operating Loss Carryforwards, Limitations on Use, Amount Loss Contingencies [Table] Loss Contingencies [Table] Litigation Status [Axis] Litigation Status [Axis] Litigation Status [Domain] Litigation Status [Domain] Settled Litigation Settled Litigation [Member] Disposal Group Name [Axis] Disposal Group Name [Axis] Disposal Group Name [Domain] Disposal Group Name [Domain] Pharmacy Services Assets Sale Pharmacy Services Assets Sale [Member] Information reguarding theCompany's Pharmacy Services Asset Sale Litigation Case [Axis] Litigation Case [Axis] Litigation Case [Domain] Litigation Case [Domain] Walgreens Walgreens [Member] Walgreens [Member] Loss Contingencies Loss Contingencies [Line Items] Percent of total sales claimed in violation of agreement Loss Contingency, Damages Awarded, Percent Of Total Sales Claimed In Violation Of Agreement Loss Contingency, Damages Awarded, Percent of Total Sales Claimed in Violation of Agreement Damages awarded Loss Contingency, Damages Awarded, Value Percent awarded of total sought Loss Contingency, Damages Awarded, Percent Of Total Sought Loss Contingency, Damages Awarded, Percent Of Total Sought Document Entity Information [Abstract] Document Entity Information [Abstract] Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Document Type Document Type Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Senior Credit Facilities Senior Secured Revolving Credit Facility [Member] Senior Secured Revolving Credit Facility [Member] Capital leases Capital Lease Obligations [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Long-term debt Capital leases Capital Lease Obligations Less: Deferred financing costs Debt Issuance Costs, Net Total Debt Long-term Debt and Capital Lease Obligations, Including Current Maturities Less: Current portion Long-term Debt and Capital Lease Obligations, Current Long-term debt, net of current portion Long-term Debt and Capital Lease Obligations Stock-Based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Common stock, par value (in dollars per share) Convertible preferred stock series, par value (in dollars per share) Temporary Equity, Par or Stated Value Per Share Numerator: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Loss from continuing operations, net of income taxes Denominator - Basic and Diluted: Earnings Per Share, Basic, Other Disclosures [Abstract] Weighted average number of common shares outstanding, basic and diluted (in shares) Loss per Common Share: Earnings Per Share, Basic and Diluted [Abstract] Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Warrant exercise threshold Class Of Warrant Or Right, Exercise Threshold Class Of Warrant Or Right, Exercise Threshold Warrant holder outstanding common stock ownership limitation Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners Acquisitions Business Combination Disclosure [Text Block] Vesting [Axis] Vesting [Axis] Vesting [Domain] Vesting [Domain] Tranche A Share-based Compensation Award, Tranche One [Member] Tranche B Share-based Compensation Award, Tranche Two [Member] Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Equity issued in acquisition (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Risks and Uncertainties [Abstract] Concentration of Risk Concentration Risk Disclosure [Text Block] Statement of Financial Position [Abstract] Statement [Table] Statement [Table] Statement [Line Items] Statement [Line Items] Allowance for doubtful accounts Allowance for Doubtful Accounts Receivable, Current Convertible preferred stock series, shares authorized (in shares) Convertible preferred stock series, shares issued (in shares) Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Common stock, shares authorized (in shares) Common Stock, Shares Authorized Common stock, shares, issued (in shares) Common Stock, Shares, Issued Common stock, shares, outstanding (in shares) Common Stock, Shares, Outstanding Cash consideration paid Price of shares issued in acquisition (in dollars per share) Business Acquisition, Share Price Consecutive trading days Debt Instrument, Convertible, Threshold Consecutive Trading Days Loss Per Share Earnings Per Share [Text Block] Concentration Risk [Table] Concentration Risk [Table] Concentration Risk by Type [Axis] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Customer Concentration Risk Customer Concentration Risk [Member] Product Concentration Risk Product Concentration Risk [Member] Customer [Axis] Customer [Axis] Customer [Domain] Customer [Domain] United Healthcare UnitedHealthcare [Member] UnitedHealthcare [Member] Medicare Medicare [Member] Medicare [Member] Products and Services [Axis] Products and Services [Axis] Products and Services [Domain] Products and Services [Domain] Immune Globulin Immune Globulin [Member] Immune Globulin [Member] Concentration Risk [Line Items] Concentration Risk [Line Items] Percentage of concentration risk Concentration Risk, Percentage Restricted cash Restricted Cash and Cash Equivalents, Current Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Revolving Credit Facility Revolving Credit Facility [Member] Revolving Credit Facility Term Loan B Facility Term Loan B Facility [Member] Term Loan B Facility [Member] Delayed Draw Term Loan Facility Delayed Draw Term Loan B Facility [Member] Delayed Draw Term Loan B Facility [Member] Priming Credit Agreement Priming Credit Agreement [Member] Priming Credit Agreement [Member] First Lien Notes Second Lien Notes Second Lien Delayed Draw Notes Second Lien Delayed Draw Notes [Member] Second Lien Delayed Draw Notes [Member] Senior Unsecured 8.875% Notes Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Senior Secured Debt Senior Notes [Member] Line of Credit Line of Credit [Member] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Redemption Period One Debt Instrument, Redemption, Period One [Member] Redemption Period Two Debt Instrument, Redemption, Period Two [Member] Redemption Period Three Debt Instrument, Redemption, Period Three [Member] Debt Instrument, Accrued Interest Option [Axis] Debt Instrument, Accrued Interest Option [Axis] Debt Instrument, Accrued Interest Option [Axis] Debt Instrument, Accrued Interest Option [Domain] Debt Instrument, Accrued Interest Option [Domain] [Domain] for Debt Instrument, Accrued Interest Option [Axis] Option One Option One [Member] Option One [Member] Option Two Option Two [Member] Option Two [Member] Option Three Option Three [Member] Option Three [Member] Option Three, Half Cash Option Three, Half Cash [Member] Option Three, Half Cash [Member] Option Three, Half Capitalized Interest Option Three, Half Capitalized Interest [Member] Option Three, Half Capitalized Interest [Member] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] Base Rate Base Rate [Member] LIBOR London Interbank Offered Rate (LIBOR) [Member] Prime Rate Prime Rate [Member] Face amount of debt instruments Debt Instrument, Face Amount Additional debt allowed under debt agreements Debt Instrument, New Debt Permitted Per Agreement Debt Instrument, New Debt Permitted Per Agreement Period after closing of ability to issue new debt Debt Instrument, New Debt Permitted Per Agreement, Period After Closing Issuable Debt Instrument, New Debt Permitted Per Agreement, Period After Closing Issuable Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Stated rate on debt Debt Instrument, Interest Rate, Stated Percentage Amortization installment percentage of principal Debt Instrument, Amortization Installments, Percentage Of Principle Debt Instrument, Amortization Installments, Percentage Of Principle Early repayment premium base rate Debt Instrument, Early Repayment Premium, Base Rate Debt Instrument, Early Repayment Premium, Base Rate Early repayment premium rate Debt Instrument, Early Repayment Premium Rate Debt Instrument, Early Repayment Premium Rate Principal prepayment limit Debt Instrument, Principal Prepayment Limit Debt Instrument, Principal Prepayment Limit Default penalty interest rate increase Debt Instrument, Debt Default, Interest Rate, Penalty Increase Debt Instrument, Debt Default, Interest Rate, Penalty Increase Warrants classified within equity at fair value Debt discount Debt Instrument, Unamortized Discount Series A convertible preferred stock, $.0001 par value; 825,000 shares authorized; 21,645 shares issued and outstanding as of June 30, 2017 and December 31, 2016; and $2,754 and $2,603 liquidation preference as of June 30, 2017 and December 31, 2016, respectively Series C convertible preferred stock, $.0001 par value; 625,000 shares authorized; 614,177 shares issued and outstanding as of June 30, 2017 and December 31, 2016; and $79,858 and $75,491 liquidation preference as of June 30, 2017 and December 31, 2016, respectively ASSETS Assets [Abstract] Current assets Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Receivables, less allowance for doubtful accounts of $45,651 and $44,730 as of June 30, 2017 and December 31, 2016, respectively Receivables, Net, Current Inventory Inventory, Net Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Total current assets Assets, Current Property and equipment, net Property, Plant and Equipment, Net Intangible assets, net Finite-Lived Intangible Assets, Net Other non-current assets Other Assets, Noncurrent Total assets Assets LIABILITIES AND STOCKHOLDERS’ DEFICIT Liabilities and Equity [Abstract] Current liabilities Liabilities, Current [Abstract] Current portion of long-term debt Accounts payable Accounts Payable, Current Amounts due to plan sponsors Amounts due to plan sponsors Carrying value as of the balance sheet date of obligations incurred through that date which are related to rebates due from third party vendors and payable to customers, combined with reclassified credits in accounts receivable (amounts due to customers), and amounts that may arise and be deemed due on third party vendor audit. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued interest Interest Payable, Current Accrued expenses and other current liabilities Accrued expenses and other current liabilities Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Used to reflect the current portion of the liabilities, combined with the aggregate carrying amount, as of the balance sheet date, of current obligations not separately disclosed in the balance sheet due to materiality considerations. Total current liabilities Liabilities, Current Deferred taxes Deferred Tax Liabilities, Gross, Noncurrent Other non-current liabilities Other Liabilities, Noncurrent Total liabilities Liabilities Convertible preferred stock Stockholders’ deficit Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Preferred stock, $.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of June 30, 2017 and December 31, 2016, respectively Preferred Stock, Value, Issued Common stock, $.0001 par value; 250,000,000 shares authorized; 127,441,893 and 117,682,543 shares issued and outstanding as of June 30, 2017 and December 31, 2016, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital, Common Stock Accumulated deficit Retained Earnings (Accumulated Deficit) Total stockholders’ deficit Stockholders' Equity Attributable to Parent Total liabilities and stockholders’ deficit Liabilities and Equity Statement of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Less: (Loss) income from discontinued operations, net of income taxes Adjustments to reconcile net loss from continuing operations, net of income taxes to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation Amortization of deferred financing costs and debt discount Amortization of Debt Issuance Costs and Discounts Change in fair value of contingent consideration Increase (Decrease) in Fair Value of Contingent Consideration Increase (decrease) in fair value of contingent consideration. Change in deferred income tax Increase (Decrease) in Deferred Income Taxes Compensation under stock-based compensation plans Share-based Compensation Loss (gain) on dispositions Gain (Loss) on Disposition of Property Plant Equipment1 Gain (Loss) on Disposition of Property Plant Equipment1 Loss on extinguishment of debt Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Receivables, net of bad debt expense Increase (Decrease) in Receivables Inventory Increase (Decrease) in Inventories Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accounts payable Increase (Decrease) in Accounts Payable, Trade Amounts due to plan sponsors Increase (Decrease) in Amounts Due To Plan Sponsor The net change during the reporting period in the carrying value as of the balance sheet date of obligations incurred through that date which are related to rebates due from third party vendors and payable to customers, combined with reclassified credits in accounts receivable (amounts due to customers), and amounts that may arise and be deemed due on third party vendor audit. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued interest Increase (Decrease) in Interest Payable, Net Accrued expenses and other liabilities Increase (Decrease) in Other Accounts Payable and Accrued Liabilities Net cash used in operating activities from continuing operations Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash used in operating activities from discontinued operations Cash Provided by (Used in) Operating Activities, Discontinued Operations Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Proceeds from dispositions Proceeds from Sale of Property, Plant, and Equipment Investment in restricted cash Increase (Decrease) in Restricted Cash Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds from priming credit agreement, net of expenses Proceeds from Debt, Net of Issuance Costs Fees attributable to extinguishment of debt Payment for Debt Extinguishment or Debt Prepayment Cost Borrowings on long-term debt, net of expenses Proceeds from Issuance of Secured Debt Borrowings on revolving credit facility Proceeds from Long-term Lines of Credit Repayments on revolving credit facility Repayments of Long-term Lines of Credit Principal payments of long-term debt Repayments of Secured Debt Repayments of capital leases Repayments of Long-term Capital Lease Obligations Other Proceeds from (Payments for) Other Financing Activities Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Net change in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents - beginning of period Cash and cash equivalents - end of period DISCLOSURE OF CASH FLOW INFORMATION: Supplemental Cash Flow Information [Abstract] Cash paid during the period for interest Interest Paid, Net Cash paid during the period for income taxes Income Taxes Paid, Net DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: Noncash Investing and Financing Items [Abstract] Entry into capital lease Capital Lease Obligations Incurred Stockholders' Deficit Stockholders' Equity Note Disclosure [Text Block] Carrying value and activity of Preferred Shares Temporary Equity [Table Text Block] EX-101.PRE 11 bios-20170630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 12 logowithregisteredtm06.jpg begin 644 logowithregisteredtm06.jpg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end XML 13 R1.htm IDEA: XBRL DOCUMENT v3.7.0.1
Document and Entity Information - shares
 6 Months Ended
Jun. 30, 2017
Aug. 07, 2017
Document Entity Information [Abstract]    
Entity Registrant Name BioScrip, Inc.  
Entity Central Index Key 0001014739  
Current Fiscal Year End Date --12-31  
Entity Filer Category Accelerated Filer  
Document Type 10-Q  
Document Period End Date Jun. 30, 2017  
Document Fiscal Year Focus 2017  
Document Fiscal Period Focus Q2  
Amendment Flag false  
Entity Common Stock, Shares Outstanding   127,475,226
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.7.0.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2017
Dec. 31, 2016
Current assets    
Cash and cash equivalents $ 40,533 $ 9,569
Restricted cash 5,055 0
Receivables, less allowance for doubtful accounts of $45,651 and $44,730 as of June 30, 2017 and December 31, 2016, respectively 103,089 111,811
Inventory 28,822 36,165
Prepaid expenses and other current assets 12,998 18,507
Total current assets 190,497 176,052
Property and equipment, net 30,063 32,535
Goodwill 365,947 365,947
Intangible assets, net 24,672 31,043
Other non-current assets 2,204 2,163
Total assets 613,383 607,740
Current liabilities    
Current portion of long-term debt 1,731 18,521
Accounts payable 46,381 59,134
Amounts due to plan sponsors 4,825 3,799
Accrued interest 6,736 6,705
Accrued expenses and other current liabilities 43,209 42,191
Total current liabilities 102,882 130,350
Long-term debt, net of current portion 475,674 433,413
Deferred taxes 3,504 2,281
Other non-current liabilities 17,942 1,257
Total liabilities 600,002 567,301
Stockholders’ deficit    
Preferred stock, $.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of June 30, 2017 and December 31, 2016, respectively 0 0
Common stock, $.0001 par value; 250,000,000 shares authorized; 127,441,893 and 117,682,543 shares issued and outstanding as of June 30, 2017 and December 31, 2016, respectively 13 12
Additional paid-in capital 628,545 611,844
Accumulated deficit (692,045) (643,419)
Total stockholders’ deficit (63,487) (31,563)
Total liabilities and stockholders’ deficit 613,383 607,740
Series A convertible preferred stock, $.0001 par value; 825,000 shares authorized; 21,645 shares issued and outstanding as of June 30, 2017 and December 31, 2016; and $2,754 and $2,603 liquidation preference as of June 30, 2017 and December 31, 2016, respectively    
Current liabilities    
Convertible preferred stock 2,639 2,462
Series C convertible preferred stock, $.0001 par value; 625,000 shares authorized; 614,177 shares issued and outstanding as of June 30, 2017 and December 31, 2016; and $79,858 and $75,491 liquidation preference as of June 30, 2017 and December 31, 2016, respectively    
Current liabilities    
Convertible preferred stock $ 74,229 $ 69,540
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.7.0.1
CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
$ in Thousands
Jun. 30, 2017
Dec. 31, 2016
Allowance for doubtful accounts $ 45,651 $ 44,730
Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized (in shares) 5,000,000 5,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized (in shares) 250,000,000 250,000,000
Common stock, shares, issued (in shares) 127,441,893 117,682,543
Common stock, shares, outstanding (in shares) 127,441,893 117,682,543
Series A Preferred Stock    
Convertible preferred stock series, par value (in dollars per share) $ 0.0001 $ 0.0001
Convertible preferred stock series, shares authorized (in shares) 825,000 825,000
Convertible preferred stock series, shares issued (in shares) 21,645 21,645
Convertible preferred stock series, shares outstanding (in shares) 21,645 21,645
Convertible preferred stock series, liquidation preference $ 2,754 $ 2,603
Series C Preferred Stock    
Convertible preferred stock series, par value (in dollars per share) $ 0.0001 $ 0.0001
Convertible preferred stock series, shares authorized (in shares) 625,000 625,000
Convertible preferred stock series, shares issued (in shares) 614,177 614,177
Convertible preferred stock series, shares outstanding (in shares) 614,177 614,177
Convertible preferred stock series, liquidation preference $ 79,858 $ 75,491
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.7.0.1
UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Income Statement [Abstract]        
Net revenue $ 218,106 $ 232,462 $ 435,916 $ 470,924
Cost of revenue (excluding depreciation expense) 149,796 168,298 302,022 342,528
Gross profit 68,310 64,164 133,894 128,396
Other operating expenses 42,486 40,619 86,844 80,277
Bad debt expense 6,223 4,279 13,387 11,871
General and administrative expenses 10,025 9,414 19,504 20,465
Restructuring, acquisition, integration, and other expenses, net 3,911 4,291 7,134 6,958
Depreciation and amortization expense 6,789 4,252 13,777 8,790
Interest expense 12,715 9,469 25,459 18,881
Loss on extinguishment of debt 13,453 0 13,453 0
Loss (gain) on dispositions 685 0 685 (939)
Loss from continuing operations, before income taxes (27,977) (8,160) (46,349) (17,907)
Income tax expense 718 149 1,337 172
Loss from continuing operations, net of income taxes (28,695) (8,309) (47,686) (18,079)
(Loss) income from discontinued operations, net of income taxes (503) 75 (940) 308
Net loss (29,198) (8,234) (48,626) (17,771)
Accrued dividends on preferred stock (2,303) (2,056) (4,517) (4,054)
Deemed dividends on preferred stock (175) (173) (349) (345)
Loss attributable to common stockholders $ (31,676) $ (10,463) $ (53,492) $ (22,170)
Loss per common share:        
Loss from continuing operations, basic and diluted (in dollars per share) $ (0.26) $ (0.14) $ (0.44) $ (0.32)
Loss from discontinued operations, basic and diluted (in dollars per share) 0.00 0.00 (0.01) 0.00
Loss per common share, basic and diluted (in dollars per share) $ (0.26) $ (0.14) $ (0.45) $ (0.32)
Weighted average common shares outstanding, basic and diluted (in shares) 121,189 73,186 119,993 70,978
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.7.0.1
UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Cash flows from operating activities:    
Net loss $ (48,626) $ (17,771)
Less: (Loss) income from discontinued operations, net of income taxes (940) 308
Loss from continuing operations, net of income taxes (47,686) (18,079)
Adjustments to reconcile net loss from continuing operations, net of income taxes to net cash used in operating activities:    
Depreciation and amortization 13,777 8,790
Amortization of deferred financing costs and debt discount 2,875 1,987
Change in fair value of contingent consideration 0 102
Change in deferred income tax 1,223 352
Compensation under stock-based compensation plans 1,027 1,993
Loss (gain) on dispositions 685 (939)
Loss on extinguishment of debt 13,453 0
Changes in assets and liabilities:    
Receivables, net of bad debt expense 8,721 (1,281)
Inventory 7,343 10,537
Prepaid expenses and other assets 5,469 322
Accounts payable (12,753) (16,190)
Amounts due to plan sponsors 1,027 62
Accrued interest 31 (192)
Accrued expenses and other liabilities 714 (3,140)
Net cash used in operating activities from continuing operations (4,094) (15,676)
Net cash used in operating activities from discontinued operations (940) (5,913)
Net cash used in operating activities (5,034) (21,589)
Cash flows from investing activities:    
Purchases of property and equipment (4,292) (5,466)
Proceeds from dispositions 0 1,132
Investment in restricted cash (5,055) 0
Net cash used in investing activities (9,347) (4,334)
Cash flows from financing activities:    
Proceeds from priming credit agreement, net of expenses 23,060 0
Fees attributable to extinguishment of debt (311) 0
Net proceeds from issuance of equity, net of issuance costs 20,776 83,267
Borrowings on long-term debt, net of expenses 294,446 0
Borrowings on revolving credit facility 563 45,000
Repayments on revolving credit facility (55,863) (60,000)
Principal payments of long-term debt (236,770) (6,274)
Repayments of capital leases (401) (129)
Other (155) (93)
Net cash provided by financing activities 45,345 61,771
Net change in cash and cash equivalents 30,964 35,848
Cash and cash equivalents - beginning of period 9,569 15,577
Cash and cash equivalents - end of period 40,533 51,425
DISCLOSURE OF CASH FLOW INFORMATION:    
Cash paid during the period for interest 22,613 17,325
Cash paid during the period for income taxes 249 229
DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:    
Entry into capital lease $ 1,327 $ 0
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.7.0.1
BASIS OF PRESENTATION
 6 Months Ended
Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation
BASIS OF PRESENTATION
These Unaudited Consolidated Financial Statements should be read in conjunction with the Audited Consolidated Financial Statements, including the notes thereto, and other information included in the Annual Report on Form 10-K of BioScrip, Inc. and its wholly-owned subsidiaries (the “Company”) for the year ended December 31, 2016 (the “Annual Report”) filed with the U.S. Securities and Exchange Commission (“SEC”). These Unaudited Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information, and the instructions to Form 10-Q and Article 10 of Regulation S-X promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.
The information furnished in these Unaudited Consolidated Financial Statements reflects all adjustments, including normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the results for the interim periods presented. Operating results for the three months and six months ended June 30, 2017 require management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes and are not necessarily indicative of the results that may be expected for the full year ending December 31, 2017.
The Unaudited Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Business Combinations
Business combinations are accounted for using the acquisition method as of the acquisition date, the date on which control is transferred to the Company. Goodwill is measured at the acquisition date as the fair value of the consideration transferred, plus the fair value of the identifiable assets acquired and liabilities assumed. Transaction costs are expensed as incurred. Contingent consideration payable is measured at fair value at the acquisition date. Contingent consideration classified as equity is not re-measured and settlement is accounted for within equity.
Reclassifications
Prior period financial statement amounts have been reclassified to conform to current period presentation.
Cash and Cash Equivalents and Restricted Cash

Highly liquid investments with a maturity of three months or less when purchased are classified as cash equivalents. Restricted cash consists of cash balances held by financial institutions as collateral for letters of credit. These balances are reclassified to cash and cash equivalents when the underlying obligation is satisfied, or in accordance with the governing agreement. Restricted cash balances expected to become unrestricted during the next twelve months are recorded as current assets. As of June 30, 2017, the Company had a restricted cash balance, in a money market account, of $5.1 million to cash collateralize outstanding letters of credit.

Collectability of Accounts Receivable

The following table sets forth the aging of our net accounts receivable (net of allowance for contractual adjustments, and prior to allowance for doubtful accounts), aged based on date of service and categorized based on the three primary overall types of accounts receivable characteristics (in thousands):
 
 
June 30, 2017
 
December 31, 2016
 
 
0 - 180 days
 
Over 180 days
 
Total
 
0 - 180 days
 
Over 180 days
 
Total
Government
 
$
18,714

 
$
7,512

 
$
26,226

 
$
19,891

 
$
8,278

 
$
28,169

Commercial
 
84,190

 
23,589

 
107,779

 
97,744

 
19,848

 
117,592

Patient
 
5,195

 
9,540

 
14,735

 
3,955

 
6,825

 
10,780

Gross accounts receivable
 
$
108,099

 
$
40,641

 
148,740

 
$
121,590

 
$
34,951

 
156,541

Allowance for doubtful accounts
 
 
 
 
 
(45,651
)
 
 
 
 
 
(44,730
)
Net accounts receivable
 
 
 
 
 
$
103,089

 
 
 
 
 
$
111,811


Recent Accounting Pronouncements
In July 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-11—Earnings Per Share (Topic 260), Distinguishing Liabilities From Equity (Topic 480), and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features and II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. ASU 2017-11 eliminates the requirement that a down round feature precludes equity classification when assessing whether an instrument is indexed to an entity’s own stock. A freestanding equity-linked financial instrument no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. The effective date for ASU 2017-11 is for annual or any interim periods beginning after December 15, 2018. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements.
In May 2017, the FASB issued ASU 2017-09—Compensation–Stock Compensation (Topic 718): Scope of Modification Accounting. ASU 2017-09 modifies when a change to the terms or conditions of a share-based payment award must be accounted for as a modification. The new guidance requires modification accounting if the fair value, vesting condition or the classification of the award is not the same immediately before and after a change to the terms and conditions of the award. The effective date for ASU 2017-09 is for annual or any interim periods beginning after December 15, 2017. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements.
In January 2017, the FASB issued ASU 2017-04—Intangibles–Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. ASU 2017-04 modifies the accounting for goodwill impairment. The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The effective date for ASU 2017-04 is for annual or any interim periods beginning after December 15, 2019. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements.
In November 2016, the FASB issued ASU 2016-18—Statement of Cash Flows (Topic 230): Restricted Cash. ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The effective date for ASU 2016-18 is for annual or any interim periods beginning after December 15, 2017. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements.
In August 2016, the FASB issued ASU 2016-15—Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 provides guidance for eight specific cash flow issues with respect to how cash receipts and cash payments are classified in the statements of cash flows, with the objective of reducing diversity in practice. The effective date for ASU 2016-15 is for annual periods beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements.
In February 2016, the FASB issued ASU 2016-02—Leases (Topic 842), requiring lessees to recognize a right-of-use asset and a lease liability on the balance sheet for all leases with the exception of short-term leases. For lessees, leases will continue to be classified as either operating or finance leases in the income statement. The effective date of the new standard for public companies is for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition and requires application of the new guidance at the beginning of the earliest comparative period presented. The Company is evaluating the effect that the updated standard will have on its consolidated financial statements.
In May 2014, the FASB issued ASU 2014-09—Revenue from Contracts with Customers (Topic 606). The guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The FASB delayed the effective date to annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. In addition, in March and April 2016, the FASB issued new guidance intended to improve the operability and understandability of the implementation guidance on principal versus agent considerations. Both amendments permit the use of either a retrospective or cumulative effect transition method and are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017, with early application permitted. The Company has not elected early adoption and will apply the modified retrospective approach upon adoption. The Company continues to evaluate the impact of the adoption of the new revenue standard on its consolidated financial statements.
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.7.0.1
LOSS PER SHARE
 6 Months Ended
Jun. 30, 2017
Earnings Per Share [Abstract]  
Loss Per Share
LOSS PER SHARE
The Company presents basic and diluted loss per share for its common stock, par value $0.0001 per share (“Common Stock”). Basic loss per share is calculated by dividing the net loss attributable to common stockholders of the Company by the weighted average number of shares of Common Stock outstanding during the period. Diluted loss per share is determined by adjusting the profit or loss attributable to stockholders and the weighted average number of shares of Common Stock outstanding adjusted for the effects of all dilutive potential common shares comprised of options granted, unvested restricted stocks, stock appreciation rights, warrants and Series A and Series C Preferred Stock (as defined below). Potential Common Stock equivalents that have been issued by the Company related to outstanding stock options, unvested restricted stock and warrants are determined using the treasury stock method, while potential common shares related to Series A and Series C Preferred Stock are determined using the “if converted” method.
The Company's Series A Convertible Preferred Stock, par value $0.0001 per share (the “Series A Preferred Stock”), and Series C Convertible Preferred Stock, par value $0.0001 per share (the “Series C Preferred Stock” and, together with the Series A Preferred Stock, the “Preferred Stock”), is considered a participating security, which means the security may participate in undistributed earnings with Common Stock. The holders of the Preferred Stock would be entitled to share in dividends, on an as-converted basis, if the holders of Common Stock were to receive dividends. The Company is required to use the two-class method when computing loss per share when it has a security that qualifies as a participating security. The two-class method is an earnings allocation formula that determines loss per share for each class of common stock and participating security according to dividends declared (or accumulated) and participation rights in undistributed earnings. In determining the amount of net earnings to allocate to common stockholders, earnings are allocated to both common and participating securities based on their respective weighted-average shares outstanding during the period. Diluted loss per share for the Company’s Common Stock is computed using the more dilutive of the two-class method or the if-converted method.
The following table sets forth the computation of basic and diluted loss per common share (in thousands, except for per share amounts):
 
Three Months Ended 
 June 30,
 
Six Months Ended 
 June 30,
 
2017
 
2016
 
2017
 
2016
Numerator:
 
 
 
 
 
 
 
Loss from continuing operations, net of income taxes
$
(28,695
)
 
$
(8,309
)
 
$
(47,686
)
 
$
(18,079
)
Income (loss) from discontinued operations, net of income taxes
(503
)
 
75

 
(940
)
 
308

Net loss
$
(29,198
)
 
$
(8,234
)
 
$
(48,626
)
 
$
(17,771
)
Accrued dividends on preferred stock
(2,303
)
 
(2,056
)
 
(4,517
)
 
(4,054
)
Deemed dividend on preferred stock
(175
)
 
(173
)
 
(349
)
 
(345
)
Loss attributable to common stockholders
$
(31,676
)
 
$
(10,463
)
 
$
(53,492
)
 
$
(22,170
)
 
 
 
 
 
 
 
 
Denominator - Basic and Diluted:
 

 
 

 
 

 
 

Weighted average common shares outstanding
121,189

 
73,186

 
119,993

 
70,978

 
 
 
 
 
 
 
 
Loss per Common Share:
 
 
 
 
 
 
 
Loss from continuing operations, basic and diluted
$
(0.26
)
 
$
(0.14
)
 
$
(0.44
)
 
$
(0.32
)
Loss from discontinued operations, basic and diluted
—

 
—

 
(0.01
)
 
—

Loss per common share, basic and diluted
$
(0.26
)
 
$
(0.14
)
 
$
(0.45
)
 
$
(0.32
)

The loss attributable to common stockholders is used as the basis of determining whether the inclusion of common stock equivalents would be anti-dilutive. Accordingly, the computation of diluted shares for the three months ended June 30, 2017 and 2016 excludes the effect of 18.3 million and 14.0 million shares, respectively, and the computation of the diluted shares for the six months ended June 30, 2017 and 2016 excludes the effect of 18.4 million and 15.5 million shares, respectively, issued in connection with the PIPE Transaction and the Rights Offering, as well as the 2017 Warrants (see Note 3 - Stockholders’ Deficit), stock options and restricted stock awards, as their inclusion would be anti-dilutive to loss attributable to common stockholders.
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.7.0.1
STOCKHOLDERS' DEFICIT
 6 Months Ended
Jun. 30, 2017
Equity [Abstract]  
Stockholders' Deficit
STOCKHOLDERS’ DEFICIT
Securities Purchase Agreement
On March 9, 2015, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with Coliseum Capital Partners L.P., a Delaware limited partnership, Coliseum Capital Partners II, L.P., a Delaware limited partnership, and Blackwell Partners, LLC, Series A, a Georgia limited liability company (collectively, the “PIPE Investors”). Pursuant to the terms of the Purchase Agreement, the Company issued and sold to the PIPE Investors in a private placement (the “PIPE Transaction”) an aggregate of (a) 625,000 shares of Series A Preferred Stock at a purchase price per share of $100.00, (b) 1,800,000 Class A warrants (the “Class A Warrants”), and (c) 1,800,000 Class B warrants (the “Class B Warrants” and, together with Class A Warrants, the “PIPE Warrants”), for gross proceeds of $62.5 million. The initial conversion price for the Series A Preferred Stock is $5.17. The PIPE Warrants may be exercised to acquire shares of Common Stock. Pursuant to an addendum (the “Warrant Addendum”), dated as of March 23, 2015, to the Warrant Agreement, dated as of March 9, 2015, with the PIPE Investors, the PIPE Investors paid the Company $0.5 million in the aggregate, and the per share exercise price of the Class A Warrants and Class B Warrants was set at $5.17 and $6.45, respectively, reduced from $5.295 to $5.17 and from $6.595 to $6.45, respectively.
Series A, Series B, and Series C Convertible Preferred Stock
In connection with the PIPE Transaction, the Company authorized 825,000 shares and issued 625,000 shares of Series A Preferred Stock at $100.00 per share. In connection with the Rights Offering (as defined below), the Company issued an additional 10,822 shares of Series A Preferred Stock at $100.00 per share. The Series A Preferred Stock may, at the option of the holder, be converted into Common Stock and receive a Liquidation Preference upon voluntary or involuntary liquidation, dissolution, or winding up of the Company as described in the Annual Report. The Company may pay a noncumulative cash dividend on each share of the Series A Preferred Stock as previously disclosed in the Annual Report. In the event the Company does not declare and pay a cash dividend, the Liquidation Preference of the Series A Preferred Stock will be increased to an amount equal to the Liquidation Preference in effect at the start of the applicable quarterly dividend period, plus an amount equal to such then applicable Liquidation Preference multiplied by 11.5% per annum.
On June 10, 2016, in order to allow the shares of Common Stock reserved for issuance for the conversion of the Series A Preferred Stock and exercise of the PIPE Warrants to be released from reservation and sold pursuant to the 2016 Equity Offering (see below), we entered into an Exchange Agreement with the PIPE Investors (the “Series B Exchange Agreement”) pursuant to which the PIPE Investors agreed:
i)
to exchange 614,177 shares of the existing Series A Preferred Stock for an identical number of shares of Series B Convertible Preferred Stock (the “Series B Preferred Stock”), which have the same terms as the Series A Preferred Stock previously described in the Company’s prior public filings, except that the terms of the Series B Preferred Stock include the authority of the holders of the Series B Preferred Stock to waive the requirement that the Company reserve a sufficient number of shares of Common Stock reserved at all times to allow for the conversion of the Series B Preferred Stock; and
ii)
to waive the requirement under the Warrant Agreement governing the PIPE Warrants to reserve 3,600,000 shares of our Common Stock for the exercise of the PIPE Warrants.
On June 14, 2016, the Company entered into another Exchange Agreement (the “Series C Exchange Agreement”) with the PIPE Investors, pursuant to which the PIPE Investors agreed to exchange their shares of Series B Preferred Stock issued pursuant to the Series B Exchange Agreement on a one for one basis for shares of Series C Preferred Stock.
Under the terms of the Series C Exchange Agreement, the PIPE Investors agreed to exchange 614,177 shares of the Series B Preferred Stock for an identical number of shares of Series C Preferred Stock, which have the same terms as the Series B Preferred Stock, except that the terms of the Series C Preferred Stock provide that the 11.5% per annum rate of non-cash dividends payable on the shares of the Series C Preferred Stock will be reduced based on the achievement by the Company of specified “Consolidated EBITDA” as defined in the Senior Credit Facilities. In addition, pursuant to the Series C Exchange Agreement, the PIPE Investors agreed to waive the requirement under the Warrant Agreement governing the PIPE Warrants held by the PIPE Investors to reserve 3,600,000 shares of Common Stock for the exercise of the PIPE Warrants.
As a result of the exchanges discussed above, there are, as of June 30, 2017, (a) 21,645 shares of Series A Preferred Stock outstanding, of which 10,823 shares are owned by the PIPE Investors, (b) no shares of Series B Preferred Stock outstanding, and (c) 614,177 shares of Series C Preferred Stock outstanding, all of which are owned by the PIPE Investors.
As of June 30, 2017, the Liquidation Preference of the Series A Preferred Stock and Series C Preferred Stock was $2.8 million and $79.9 million, respectively.
PIPE Warrants
In connection with the PIPE Transaction, the Company issued 1,800,000 Class A Warrants and 1,800,000 Class B Warrants which may be exercised to acquire shares of Common Stock. The rights and terms of the Class A Warrants and the Class B Warrants are identical except for the exercise price. Pursuant to the Warrant Addendum with the PIPE Investors, the PIPE Investors paid the Company $0.5 million in the aggregate, and the per share exercise price of the Class A Warrants and Class B Warrants was set at $5.17 and $6.45, respectively, reduced from $5.295 to $5.17 and from $6.595 to $6.45, respectively.
The Company entered into a registration rights agreement, as amended (the “Registration Rights Agreement”), with the PIPE Investors that, among other things and subject to certain exceptions, requires the Company, upon the request of the PIPE Investors, to register the Common Stock of the Company issuable upon conversion of the PIPE Investors’ Series A Preferred Shares, the Series C Preferred Shares, or exercise of the PIPE Warrants. Pursuant to the terms of the Registration Rights Agreement, the costs incurred in connection with such registrations will be borne by the Company. As provided under the Registration Rights Agreement, the Company on April 1, 2016 filed a shelf registration statement on Form S-3 under the Securities Act of 1933, as amended (the “Securities Act”), to register, among other things, the Common Stock of the Company issuable upon conversion of the PIPE Investors’ Series A and Series C Preferred Shares.
Rights Offering
On June 30, 2015, the Company commenced a rights offering (the “Rights Offering”) pursuant to which the Company distributed subscription rights to purchase units consisting of (1) Series A Preferred Stock, each share convertible into shares of Common Stock at a conversion price of $5.17 per share, (2) Class A warrants to purchase one share of Common Stock at a price of $5.17 per share (the “Public Class A Warrants”), and (3) Class B warrants to purchase one share of Common Stock at a price of $6.45 per share (the “Public Class B Warrants” and, together with the Public Class A Warrants, the “Public Warrants”). The Rights Offering expired on July 27, 2015 and was completed on July 31, 2015. Stockholders of the Company exercised subscription rights to purchase 10,822 units, consisting of an aggregate of 10,822 shares of the Series A Preferred Stock, 31,025 Public Class A Warrants, and 31,025 Public Class B Warrants, at a subscription price of $100.00 per unit. Pursuant to the Rights Offering, the Company raised gross proceeds of approximately $1.1 million.
With the exception of the expiration date, the Class A Warrants issued pursuant to the PIPE Transaction, as amended by the Warrant Addendum, have the same terms as the Public Class A Warrants issued pursuant to the Rights Offering. Similarly, with the exception of the expiration date, the Class B Warrants issued pursuant to the PIPE Transaction, as amended by the Warrant Addendum, have the same terms as the Public Class B Warrants issued pursuant to the Rights Offering.
Carrying Value of Series A Preferred Stock
As of June 30, 2017, the following values were accreted pursuant to the terms of the Exchange Agreement, dated as of June 10, 2016, among the Company and the signatories thereto and recorded as a reduction of additional paid in capital in Stockholders’ Deficit and a deemed dividend on the Unaudited Consolidated Statements of Operations. In addition, dividends were accrued at 11.5% from the date of issuance to June 30, 2017. The following table sets forth the activity recorded during the six months ended June 30, 2017 related to the Series A Preferred Stock (in thousands):
Series A Preferred Stock carrying value at December 31, 2016
$
2,462

Accretion of discount related to issuance costs
26

Dividends recorded through June 30, 2017 1
151

Series A Preferred Stock carrying value June 30, 2017
$
2,639

1 Dividends recorded reflect the increase in the Liquidation Preference associated with unpaid dividends.
Carrying Value of Series C Preferred Stock
As of June 30, 2017, the following values were accreted pursuant to the terms of the Exchange Agreement, dated as of June 16, 2016, among the Company and the signatories thereto and recorded as a reduction of additional paid in capital in Stockholders’ Deficit and a deemed dividend on the Unaudited Consolidated Statements of Operations. In addition, dividends were accrued at 11.5% from the date of issuance to June 30, 2017. The following table sets forth the activity recorded during the six months ended June 30, 2017 related to the Series C Preferred Stock (in thousands):
Series C Preferred Stock carrying value at December 31, 2016
$
69,540

Accretion of discount related to issuance costs
323

Dividends recorded through June 30, 2017 1
4,366

Series C Preferred Stock carrying value June 30, 2017
$
74,229


1 Dividends recorded reflect the increase in the Liquidation Preference associated with unpaid dividends.
Shelf Registration Statement
The Company filed a shelf registration statement on Form S-3 under the Securities Act on April 1, 2016, which was declared effective May 2, 2016 (the “2016 Shelf”). Under the 2016 Shelf at the time of effectiveness, the Company had the ability to raise up to $200.0 million, in one or more transactions, by selling Common Stock, preferred stock, debt securities, warrants, units and rights.
2016 Equity Offering
On June 22, 2016 the Company completed an underwritten public offering of 45,200,000 shares of Common Stock, including 5,200,000 shares of Common Stock issued upon the underwriters’ full exercise of the over-allotment option, at a public offering price of $2.00 per share, less underwriting discounts and commissions and offering expenses payable by us (the “2016 Equity Offering”). The Company received net proceeds of approximately $83.3 million from the 2016 Equity Offering, after deducting underwriting discounts and commissions and offering costs.
A portion of the net proceeds from the 2016 Equity Offering was used to fund the Cash Consideration (as defined below) and pay fees and expenses in connection with the closing of the Home Solutions Transaction (see below).
Home Solutions Transaction
On September 9, 2016, the Company acquired substantially all of the assets and assumed certain liabilities of HS Infusion Holdings, Inc. (“Home Solutions”) and its subsidiaries (the “Home Solutions Transaction”) pursuant to an Asset Purchase Agreement dated June 11, 2016 (as amended, the “Home Solutions Agreement”), by and among Home Solutions, a Delaware corporation, certain subsidiaries of Home Solutions, the Company and HomeChoice Partners, Inc., a Delaware corporation. Home Solutions, a privately held company, provides home infusion and home nursing products and services to patients suffering from chronic and acute medical conditions. On June 16, 2016, the Company, HomeChoice Partners, Inc. and Home Solutions entered into an amendment to the Home Solutions Agreement (the “First Amendment”), which modified the terms of the consideration payable by the Company to Home Solutions thereunder. On September 2, 2016, the same parties entered into a second amendment to the Home Solutions Agreement (the “Second Amendment”), which amended the Home Solutions Agreement to eliminate the condition to closing that the Company receive stockholder approval to increase its authorized share capital (the “Charter Amendment”) and facilitated the timely consummation of the Home Solutions Transaction. The Second Amendment instead provided that the Company will hold a stockholder meeting after the closing of the Home Solutions Transaction to seek stockholder approval of the Charter Amendment, and if the approval is not obtained at the first special meeting, the Company will submit the proposal on a twice per year basis beginning in 2017, at either the annual meeting or a special meeting of stockholders. The Charter Amendment was approved at a special meeting of stockholders held on November 30, 2016.
The aggregate consideration paid by the Company in the Home Solutions Transaction was equal to (i) $67.5 million in cash (the “Cash Consideration”); plus (ii) (a) 3,750,000 shares of Company common stock (the “Transaction Closing Equity Consideration”) and (b) the right to receive contingent equity securities of the Company, in the form of restricted shares of Company common stock (the “RSUs”), issuable in two tranches, Tranche A and Tranche B, with different vesting conditions (collectively, the “Contingent Shares”). The number of shares of Company common stock in Tranche A is 3.1 million and the number of shares of Company common stock in Tranche B is 4.0 million, each subject to certain vesting conditions. Upon close of the Home Solutions Transaction the RSUs had no intrinsic value, but are reported in our consolidated financial statements at their estimated fair value at the date of issuance. The Home Solutions Agreement provides Home Solutions with certain customary registration rights that required us, within 30 days following the closing of the Home Solutions Transaction, to file a registration statement for the selling stockholder’s resale of the Transaction Closing Equity Consideration and the Contingent Shares pursuant to the Securities Act. The Company filed the registration statement on October 7, 2016 and it was declared effective on October 27, 2016.
The Company will issue the shares of our Common Stock issuable to Home Solutions pursuant to the RSUs in Tranche A promptly, and in any event within five business days, following the earlier of (a) the closing price of our Common Stock, as reported by NASDAQ, averaging $4.00 per share or above over 20 consecutive trading days during the period beginning on September 9, 2016 and ending December 31, 2019, or (b) a change of control that occurs on or prior to December 31, 2017 or a change of control thereafter but on or prior to December 31, 2019, pursuant to which the consideration payable per share equals or exceeds $4.00 per share. The Company will issue the shares of our Common Stock issuable to Home Solutions pursuant to the RSUs in Tranche B promptly, and in any event within five business days, following the earlier of (a) the closing price of our Common Stock, as reported by NASDAQ, averaging $5.00 per share or above over 20 consecutive trading days during the period beginning on September 9, 2016 and ending December 31, 2019, or (b) a change of control that occurs on or prior to December 31, 2017, or a change of control thereafter but on or prior to December 31, 2019, pursuant to which the consideration payable per share equals or exceeds $5.00 per share. The Home Solutions Agreement provides for a cash settlement option related to the RSUs, effective June 15, 2021, if, and only if, authorized shares are unavailable when the vesting conditions of Tranche A and Tranche B are met. At the date of acquisition, the Company did not have sufficient authorized shares available to satisfy the issuance of Tranche A and Tranche B RSUs and, accordingly, recognized a liability for the fair value of the contingent consideration. As of November 30, 2016, upon approval of the Charter Amendment, the Company had sufficient authorized shares available should the vesting conditions be met and the RSUs become issuable. The liability was reclassified to equity and a gain on the change in the fair value of the RSUs was recognized as of November 30, 2016. On March 13, 2017, the Company filed with the SEC a Registration Statement on Form S-3 to register the Contingent Shares and it was declared effective on April 18, 2017.
The Cash Consideration and the Transaction Closing Equity Consideration were paid at closing and were funded by cash on-hand and borrowings from our Revolving Credit Facility.
First Quarter 2017 Private Placement
On March 1, 2017, the Company entered into a Stock Purchase Agreement (the “First Quarter Stock Purchase Agreement”) with Venor Capital Master Fund Ltd., Map 139 Segregated Portfolio of LMA SPC, Venor Special Situations Fund II LP and Trevithick LP (the “First Quarter Stockholders”). Pursuant to the First Quarter Stock Purchase Agreement, the Company sold an aggregate of 3.3 million shares of its common stock (the “First Quarter Shares”) for aggregate gross proceeds of approximately $5.1 million in a private placement transaction (the “First Quarter 2017 Private Placement”). The purchase price for each Share was $1.5366, which was negotiated between the Company and the First Quarter Stockholders based on the volume-weighted average price of the Company's common stock on the NASDAQ Global Market on March 1, 2017.
In connection with the First Quarter 2017 Private Placement, the Company entered into a Registration Rights Agreement (the “First Quarter 2017 Registration Rights Agreement”) with the First Quarter Stockholders. Pursuant to the First Quarter 2017 Registration Rights Agreement, the Company agreed to prepare and file a registration statement with the SEC within ten days of the date it files its annual report on Form 10-K for the fiscal year ended December 31, 2016, for purposes of registering the resale of the First Quarter Shares and any shares of common stock issued as a dividend or other distribution with respect to the First Quarter Shares.
As provided under the First Quarter 2017 Registration Rights Agreement, the Company, on March 13, 2017, filed a shelf registration statement on Form S-3 under the Securities Act to register the First Quarter Shares and it was declared effective April 18, 2017.
Proceeds from the First Quarter 2017 Private Placement were used for working capital and general corporate purposes.
2017 Warrants
In connection with the Second Lien Note Facility (as defined below), the Company also issued warrants (the “2017 Warrants”) to the purchasers of the Second Lien Notes (as defined below) pursuant to a Warrant Purchase Agreement dated as of June 29, 2017 (the “Warrant Purchase Agreement”). The 2017 Warrants entitle the purchasers of the Warrants to purchase shares of Common Stock, representing at the time of any exercise of the 2017 Warrants an equivalent number of shares equal to 4.99% of the Common Stock of the Company on a fully diluted basis, subject to the terms of the Warrant Agreement governing the Warrants, dated as of June 29, 2017 (the “Warrant Agreement”); provided, however, the Warrants may not be converted to the extent that, after giving effect to such conversion, the holders of the 2017 Warrants would beneficially own, in the aggregate, in excess of (i) 19.99% of the shares of Common Stock outstanding as of June 29, 2017 (the “Closing Date”) minus (ii) the shares of Common Stock that were sold pursuant to the Second Quarter 2017 Private Placement (as defined below) (the “Conversion Cap”). The Conversion Cap will not apply to the 2017 Warrants if the Company obtains the approval of its stockholders for the removal of the Conversion Cap, which the Company is required to take certain steps to attempt to obtain, subject to the terms of the Warrant Agreement.
The 2017 Warrants have a 10-year term and an initial exercise price of $2.00 per share, and may be exercised by payment of the exercise price in cash or surrender of shares of Common Stock into which the Warrants are being converted in an aggregate amount sufficient to pay the exercise price.  The exercise price and the number of shares that may be acquired upon exercise of the 2017 Warrants is subject to adjustment in certain situations, including price based anti-dilution protection whereby, subject to certain exceptions, if the Company later issues Common Stock or certain Common Stock Equivalents (as defined in the Warrant Agreement) at a price less than either the then-current market price per share or exercise price of the 2017 Warrants, then the exercise price will be decreased and the percentage of shares of Common Stock issuable upon exercise of the Warrants will remain the same, giving effect to such issuance. Additionally, the 2017 Warrants have standard anti-dilution protections if the Company effects a stock split, subdivision, reclassification or combination of its Common Stock or fixes a record date for the making of a dividend or distribution to stockholders of cash or certain assets. Upon the occurrence of certain business combinations the 2017 Warrants will be converted into the right to acquire shares of stock or other securities or property (including cash) of the successor entity.
Second Quarter 2017 Private Placement
On June 29, 2017, the Company entered into a Stock Purchase Agreement (the “Second Quarter Stock Purchase Agreement”) with a fund managed by Ares Management L.P. (“Ares” or the “Second Quarter Stock Purchaser”). Pursuant to the terms of the Second Quarter Stock Purchase Agreement, the Company issued and sold to the Second Quarter Stock Purchaser in a private placement (the “Second Quarter 2017 Private Placement”) 6,359,350 shares of Common Stock (the “Second Quarter Shares”) at a price of $2.50 per share, for proceeds of approximately $15.9 million, net of $0.2 million in associated costs.
Second Quarter Registration Rights Agreement
In connection with the 2017 Warrants and the Second Quarter 2017 Private Placement, the Company entered into a Registration Rights Agreement (the “Second Quarter 2017 Registration Rights Agreement”) with the holders of the 2017 Warrants and the Second Quarter Stock Purchaser. Pursuant to the Second Quarter 2017 Registration Rights Agreement, subject to certain exceptions, the Company is required, upon the request of the Second Quarter Stock Purchaser and holders of the 2017 Warrants, to register the resale of the Second Quarter Shares and the shares of Common Stock issuable upon exercise of the 2017 Warrants. Pursuant to the terms of the Second Quarter 2017 Registration Rights Agreement, these registration rights will not become effective until twelve months after the Closing Date, and the costs incurred in connection with such registrations will be borne by the Company.
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.7.0.1
ACQUISITIONS
 6 Months Ended
Jun. 30, 2017
Business Combinations [Abstract]  
Acquisitions
ACQUISITIONS
On September 9, 2016, the Company completed the Home Solutions Transaction pursuant to the Home Solutions Agreement. The aggregate consideration paid by the Company in the Home Solutions Transaction was equal to (i) the Cash Consideration; plus (ii)(a) the Transaction Closing Equity Consideration and (b) the RSUs, issuable in two tranches, Tranche A and Tranche B, with different vesting conditions. The number of shares of Company common stock in Tranche A is 3.1 million and the number of shares of Company common stock in Tranche B is 4.0 million, each subject to vesting conditions (see Note 3 - Stockholders’ Deficit). Upon close of the Home Solutions Transaction the RSUs had no intrinsic value, but are reported in our consolidated financial statements at their estimated fair value at the date of issuance. Upon approval of the Charter Amendment on November 30, 2016, the date at which sufficient shares were available should the RSUs vest and become issuable, the liability was remeasured to its then-current fair value and reclassified to equity.
The following table sets forth the consideration transferred in connection with the acquisition of Home Solutions as of September 9, 2016 (in thousands):
Cash
$
67,516

Equity issued at closing
9,938

Capital lease obligation assumed
301

Fair value of contingent consideration
15,400

Total consideration
$
93,155


The following table sets forth the preliminary estimate of fair value of the assets acquired and liabilities assumed upon acquisition of Home Solutions (in thousands):
Accounts receivable
$
11,956

Inventories
3,199

Prepaids and other assets
852

Total current assets
$
16,007

Property and equipment
4,651

Goodwill
57,218

Managed care contracts
24,700

Licenses
5,400

Trade name
1,800

Non-compete agreements
200

Other non-current assets
891

Total assets
$
110,867

Accounts payable
14,576

Accrued liabilities
3,136

Current liabilities
$
17,712

Total fair value of cash and contingent consideration
$
93,155


The excess of the purchase price over the fair value of the tangible and identifiable intangible assets acquired and liabilities assumed in the acquisition was allocated to goodwill. The value of the goodwill represents the value the Company expects to be created by combining the operations of the companies, including the ability to cross-sell its services on a national basis with an expanded footprint in home infusion and the opportunity to focus on higher margin therapies.
In accordance with ASC Topic 805 Business Combinations (“ASC 805”), the allocation of the purchase price is subject to adjustment during the measurement period after the closing date (September 9, 2016) when additional information on assets and liability valuations becomes available. The Company has not finalized its valuation of certain assets and liabilities recorded pursuant to the acquisition including intangible assets and contingent consideration. Thus, the provisional measurements recorded are subject to change. Any changes will be recorded as adjustments to the fair value of the assets and liabilities with residual amounts allocated to goodwill.
Under the Home Solutions Agreement, the Company did not purchase, among other things, any accounts receivable associated with governmental payors. However, the Home Solutions Agreement stipulates that collections of government receivables, as of the first anniversary of the closing date, in an amount less than the amount estimated as government receivables in the Closing Certificate, must be paid to the seller. The Company continues to evaluate the collectability of the government receivables and will record a liability in the event collections fall short of the guarantee.
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.7.0.1
RESTRUCTURING, ACQUISITION, INTERGRATION, AND OTHER EXPENSES, NET
 6 Months Ended
Jun. 30, 2017
Restructuring and Related Activities [Abstract]  
Restructuring, Acquisition, Integration, and Other Expenses, Net
RESTRUCTURING, ACQUISITION, INTEGRATION, AND OTHER EXPENSES, NET
Restructuring, acquisition, integration and other expenses include non-operating costs associated with restructuring, acquisition, and integration initiatives such as employee severance costs, certain legal and professional fees, training costs, redundant wage costs, impacts recorded from the change in contingent consideration obligations, and other costs related to contract terminations and closed branches/offices.
Restructuring, acquisition, integration, and other expenses, net in the Unaudited Consolidated Statements of Operations for the three months and six months ended June 30, 2017 and 2016 consisted of the following (in thousands):
 
Three Months Ended 
 June 30,
 
Six Months Ended 
 June 30,
 
2017
 
2016
 
2017
 
2016
Restructuring expense
$
3,648

 
$
1,316

 
$
6,854

 
$
3,932

Acquisition and integration expense
263

 
2,924

 
280

 
2,924

Change in fair value of contingent consideration
—

 
51

 
—

 
102

Total restructuring, acquisition, integration, and other expense, net
$
3,911

 
$
4,291

 
$
7,134

 
$
6,958
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.7.0.1
DEBT
 6 Months Ended
Jun. 30, 2017
Debt Disclosure [Abstract]  
Debt
DEBT
As of June 30, 2017 and December 31, 2016, the Company’s debt consisted of the following (in thousands):
 
June 30,
2017
 
December 31,
2016
Senior Credit Facilities
$
—

 
$
265,507

First Lien Note Facility, net of unamortized discount
198,000

 
—

Second Lien Note Facility, net of unamortized discount
82,931

 
—

2021 Notes, net of unamortized discount
197,008

 
196,670

Capital leases
3,134

 
2,209

Less: Deferred financing costs
(3,668
)
 
(12,452
)
Total Debt
477,405

 
451,934

Less: Current portion
(1,731
)
 
(18,521
)
Long-term debt, net of current portion
$
475,674

 
$
433,413


Debt Facilities
The Company was previously obligated under (i) a senior secured first-lien revolving credit facility in an aggregate principal amount of $75.0 million (the “Revolving Credit Facility”), (ii) a senior secured first-lien term loan B in an aggregate principal amount of $250.0 million (the “Term Loan B Facility”) and (iii) a senior secured first-lien delayed draw term loan B in an aggregate principal amount of $150.0 million (the “Delayed Draw Term Loan Facility” and, together with the Revolving Credit Facility and the Term Loan B Facility, the “Senior Credit Facilities”) with SunTrust Bank (“SunTrust”), Jefferies Finance LLC and Morgan Stanley Senior Funding, Inc., originally entered on July 31, 2013 and amended from time to time.
On January 6, 2017, the Company entered into a credit agreement (the “Priming Credit Agreement” and, together with the Senior Credit Facilities, the “Prior Credit Agreements”) with certain existing lenders under the Senior Credit Facilities and SunTrust, as administrative agent for itself and the lenders. The Priming Credit Agreement provided an aggregate borrowing commitment of $25.0 million, which was fully drawn at closing.
On June 29, 2017 (the “Closing Date”), the Company entered into (i) a first lien note purchase agreement (the “First Lien Note Facility”), among the Company, which is the issuer under the agreement, the financial institutions and note purchasers from time to time party to the agreement (the “First Lien Note Purchasers”), and Wells Fargo Bank, National Association, in its capacity as collateral agent for itself and the First Lien Note Purchasers (the “First Lien Collateral Agent”), pursuant to which the Company issued first lien senior secured notes in an aggregate principal amount of $200.0 million (the “First Lien Notes”); and (ii) a second lien note purchase agreement (the “Second Lien Note Facility” and, together with the First Lien Note Facility, the “Notes Facilities”) among the Company, which is the issuer under the agreement, the financial institutions and note purchasers from time to time party to the agreement (the “Second Lien Note Purchasers”), and Wells Fargo Bank, National Association, in its capacity as collateral agent for itself and the Second Lien Note Purchasers (the “Second Lien Collateral Agent” and, together with the First Lien Collateral Agent, the “Collateral Agent”), pursuant to which the Company (a) issued second lien senior secured notes in an aggregate initial principal amount of $100.0 million (the “Initial Second Lien Notes”) and (b) has the ability to draw upon the Second Lien Note Facility and issue second lien delayed draw senior secured notes in an aggregate initial principal amount of $10.0 million for a period of 18 months after the Closing Date, subject to certain terms and conditions (the “Second Lien Delayed Draw Notes” and, together with the Initial Second Lien Notes, the “Second Lien Notes”; the Second Lien Notes, together with the First Lien Notes, the “Notes”). Funds managed by Ares are acting as lead purchasers for the Notes Facilities.
The Company used the proceeds of the sale of the First Lien Notes and the Initial Second Lien Notes to repay in full all amounts outstanding under the Prior Credit Agreements and extinguished the liability. Each of the Prior Credit Agreements was terminated following such repayment. The Company used the remaining proceeds of $15.9 million, net of $0.2 million in issuance costs, from the Notes Facilities and the Second Quarter 2017 Private Placement for working capital and general corporate purposes.
The First Lien Notes accrue interest, payable monthly in arrears, at a floating rate or rates equal to, at the option of the Company, (i) the base rate (defined as the highest of the Federal Funds Rate plus 0.5% per annum, the Prime Rate as published by The Wall Street Journal and the one-month London Interbank Offered Rate (“LIBOR”) (subject to a 1.0% floor) plus 1.0%), or (ii) the one-month LIBOR rate (subject to a 1.0% floor), plus a margin of 6.0% if the base rate is selected or 7.0% if the LIBOR Option is selected. The First Lien Notes mature on August 15, 2020, provided that if the Company’s existing 8.875% Senior Notes due 2021 (the “2021 Notes”) are refinanced prior to August 15, 2020, then the scheduled maturity date of the First Lien Notes shall be June 30, 2022.
The First Lien Notes will amortize in equal quarterly installments equal to 0.625% of the aggregate principal amount of the First Lien Note Facility, commencing on September 30, 2019, and on the last day of each third month thereafter, with the balance payable at maturity. The First Lien Notes are pre-payable at the Company’s option at specified premiums to the principal amount that will decline over the term of the First Lien Note Facility. If the First Lien Notes are prepaid prior to the second anniversary of the Closing Date, the Company will be required to pay a make-whole premium based on the present value (using a discount rate based on the specified treasury rate plus 50 basis points) of all remaining interest payments on the First Lien Notes being prepaid prior to the second anniversary of the Closing Date, plus 4.0% of the principal amount of First Lien Notes being prepaid. On or after the second anniversary of the Closing Date, the prepayment premium is 4.0%, which declines to 2.0% on or after the third anniversary of the Closing Date, and declines to 0.0% on or after the fourth anniversary of the Closing Date. At any time, the Company may pre-pay up to $50.0 million in aggregate principal amount of the First Lien Notes from internally generated cash without incurring any make-whole or prepayment premium. The occurrence of certain events of default may increase the applicable rate of interest by 2.0% and could result in the acceleration of the Company’s obligations under the First Lien Note Facility prior to stated maturity and an obligation of the Company to pay the full amount of its obligations under the First Lien Note Facility.
The First Lien Note Facility contains customary events of default that include, among others, non-payment of principal, interest or fees, violation of covenants, inaccuracy of representations and warranties, bankruptcy and insolvency events, material judgments, cross-defaults to material indebtedness and events constituting a change of control. In addition, the obligations under the First Lien Note Facility will be guaranteed by joint and several guarantees from the Company’s subsidiaries.
In connection with the First Lien Note Facility, the Company, its subsidiaries and the First Lien Collateral Agent entered into a First Lien Guaranty and Security Agreement, dated as of June 29, 2017 (the “First Lien Guaranty and Security Agreement”). Pursuant to the First Lien Guaranty and Security Agreement, the obligations under the First Lien Notes will be secured by first priority liens on, and security interests in, substantially all of the assets of the Company and its subsidiaries.
The Second Lien Notes accrue interest, payable monthly in arrears, at a floating rate or rates equal to, at the option of the Company, (i) one-month LIBOR (subject to a 1.25% floor) plus 9.25% per annum in cash, (ii) one-month LIBOR (subject to a 1.25% floor) plus 11.25% per annum, which amount will be capitalized on each interest payment date, or (iii) one-month LIBOR (subject to a 1.25% floor) plus 10.25% per annum, of which one-half LIBOR plus 4.625% per annum will be payable in cash and one-half LIBOR plus 5.625% per annum will be capitalized on each interest payment date, provided that, in each case, if any permitted refinancing indebtedness with which the 2021 Notes are refinanced requires or permits the payment of cash interest, all of the interest on the Second Lien Notes shall be paid in cash. The Second Lien Notes mature on August 15, 2020, provided that if the 2021 Notes are refinanced prior to August 15, 2020, then the scheduled maturity date of the Second Lien Notes shall be June 30, 2022.
In connection with the Second Lien Note Facility, the Company also issued warrants (the “2017 Warrants”) to the purchasers of the Second Lien Notes pursuant to a Warrant Purchase Agreement dated as of June 29, 2017 (the “Warrant Purchase Agreement”). The 2017 Warrants entitle the purchasers of the Warrants to purchase shares of Common Stock, representing at the time of any exercise of the 2017 Warrants an equivalent number of shares equal to 4.99% of the Common Stock of the Company on a fully diluted basis, subject to the terms of the Warrant Agreement governing the Warrants, dated as of June 29, 2017 (the “Warrant Agreement”). The 2017 Warrants, considered a derivative and subject to remeasurement at each reporting period, are reflected in other non-current liabilities at a fair value of $16.9 million.
The Second Lien Notes are not subject to scheduled amortization installments. The Second Lien Notes are pre-payable at the Company’s option at specified premiums to the principal amount that will decline over the term of the Second Lien Note Facility. If the Second Lien Notes are prepaid prior to the third anniversary of the Closing Date, the Company will need to pay a make-whole premium based on the present value (using a discount rate based on the specified treasury rate plus 50 basis points) of all remaining interest payments on the Second Lien Notes being prepaid prior to the third anniversary of the Closing Date, plus 4.0% of the principal amount of Second Lien Notes being prepaid. On or after the third anniversary of the Closing Date, the prepayment premium is 4.0%, which declines to 2.0% on or after the fourth anniversary of the Closing Date, and declines to 0.0% on or after the fifth anniversary of the Closing Date. The occurrence of certain events of default may increase the applicable rate of interest by 2.0% and could result in the acceleration of the Company’s obligations under the Second Lien Note Facility prior to stated maturity and an obligation of the Company to pay the full amount of its obligations under the Second Lien Note Facility.
The Second Lien Note Facility contains customary events of default that include, among others, non-payment of principal, interest or fees, violation of covenants, inaccuracy of representations and warranties, bankruptcy and insolvency events, material judgments, cross-defaults to material indebtedness and events constituting a change of control. In addition, the obligations under the Second Lien Note Facility will be guaranteed by joint and several guarantees from the Company’s subsidiaries.
In connection with the Second Lien Note Facility, the Company, its subsidiaries and the Second Lien Collateral Agent entered into a Second Lien Guaranty and Security Agreement, dated as of June 29, 2017 (the “Second Lien Guaranty and Security Agreement”). Pursuant to the Second Lien Guaranty and Security Agreement, the obligations under the Second Lien Notes will be secured by second priority liens on, and security interests in, substantially all of the assets of the Company and its subsidies.
In connection with the First Lien Note Facility and the Second Lien Note Facility, the Company, the First Lien Collateral Agent and the Second Lien Collateral Agent, entered into an intercreditor agreement containing customary provisions to, among other things, subordinate the lien priority of the liens granted under the Second Lien Note Facility to the liens granted under the First Lien Note Facility.
2021 Notes
On February 11, 2014, the Company issued $200.0 million aggregate principal amount of the 2021 Notes. The 2021 Notes are senior unsecured obligations of the Company and are fully and unconditionally guaranteed by all existing and future subsidiaries of the Company.
Interest on the 2021 Notes accrues at a fixed rate of 8.875% per annum and is payable in cash semi-annually on February 15 and August 15 of each year. The debt discount of $5.0 million at issuance is being amortized as interest expense through maturity which will result in the accretion over time of the outstanding debt balance to the principal amount. The 2021 Notes are the Company’s senior unsecured obligations and rank equally in right of payment with all of its other existing and future senior unsecured indebtedness and senior in right of payment to all of its existing and future subordinated indebtedness.
The 2021 Notes are guaranteed on a full, joint and several basis by each of the Company’s existing and future domestic restricted subsidiaries that is a borrower under any of the Company’s credit facilities or that guarantees any of the Company’s debt or that of any of its restricted subsidiaries, in each case incurred under the Company’s credit facilities. As of June 30, 2017, the Company does not have any independent assets or operations, and as a result, its direct and indirect subsidiaries (other than minor subsidiaries), each being 100% owned by the Company, are fully and unconditionally, jointly and severally, providing guarantees on a senior unsecured basis to the 2021 Notes.
Fair Value of Financial Instruments
The following details our financial instruments where the carrying value and the fair value differ (in thousands):
Financial Instrument
 
Carrying Value as of June 30, 2017
 
Markets for Identical Item (Level 1)
 
Significant Other Observable Inputs (Level 2)
 
Significant Unobservable Inputs (Level 3)
First Lien Note Facility
 
$
198,000

 
$
—

 
$
198,000

 
$
—

Second Lien Note Facility
 
82,931

 
—

 
82,931

 
—

2017 Warrants
 
16,908

 
—

 
16,908

 
—

2021 Notes
 
197,008

 
—

 
178,109

 
—

Total
 
$
494,847

 
$
—

 
$
475,948

 
$
—


The fair value hierarchy for disclosure of fair value measurements is as follows:
Level 1:  Quoted prices (unadjusted) in active markets for identical assets or liabilities.
Level 2:  Quoted prices, other than quoted prices included in Level 1, which are observable for the assets or liabilities, either directly or indirectly.
Level 3:  Inputs that are unobservable for the assets or liabilities. Financial assets with carrying values approximating fair value include cash and cash equivalents and accounts receivable. Financial liabilities with carrying values approximating fair value include accounts payable and capital leases. The carrying value of these financial assets and liabilities approximates fair value due to their short maturities.
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.7.0.1
COMMITMENTS AND CONTINGENCIES
 6 Months Ended
Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
COMMITMENTS AND CONTINGENCIES
Legal Proceedings
Breach of Contract Litigation in the Delaware Court of Chancery
On November 3, 2015, Walgreen Co. and various affiliates (“Walgreens”) filed a lawsuit in the Delaware Court of Chancery against the Company and certain of its subsidiaries (collectively, the “Defendants”). The complaint alleges that the Company breached certain non-compete provisions contained in the Community Pharmacy and Mail Business Purchase Agreement dated as of February 1, 2012, by and among Walgreens and certain subsidiaries and the Company and certain subsidiaries. The complaint seeks both money damages and injunctive relief. On December 7, 2015, the Defendants filed a motion to dismiss the case. Walgreens filed an answering brief on January 11, 2016 and the Defendants filed a reply on January 25, 2016. On March 11, 2016, the Court held oral argument on the Company’s motion to dismiss and granted the motion, holding that Walgreens’ breach of contract claims for money damages must be resolved in accordance with the 2012 Purchase Agreement’s alternative dispute resolution procedure. On March 15, 2016, Walgreens informed the Court that it would not be pursuing any claims for injunctive relief in the Court at that time, but instead would engage in the required alternative dispute resolution procedure. Walgreens requested that the Court keep the case open pending the results of that process. On March 16, 2016, the Court stayed the lawsuit and removed the trial from its calendar, but did not grant Walgreens any other relief or enjoin the Company from taking any action. On December 8, 2016, the parties submitted the dispute to an arbitrator. On December 28, 2016, the arbitrator rendered its decision, finding that the Company had not violated the non-compete, except for certain limited sales of oral oncology, HIV and transplant pharmaceuticals, constituting approximately 3 percent of the total sales that Walgreens claimed were made in violation of the agreement. The arbitrator also concluded that Walgreens was not entitled to recover its lost profits or lost revenues as a result of any such sales. Despite that ruling, the arbitrator awarded Walgreens $5.8 million in damages, or approximately 20 percent of the total amount requested. Such amount is included as a component of Accrued expenses and other current liabilities within the Consolidated Balance Sheets as of June 30, 2017 (unaudited) and December 31, 2016. The Company believes that arbitrator’s damages award ignored applicable law, contradicted the arbitrator’s liability findings and exceeded the scope of the arbitrator’s authority in light of both parties’ arbitration submissions. Accordingly, on January 13, 2017, the Company filed a motion to vacate the arbitration award. On February 10, 2017, Walgreens opposed the Company’s motion and filed a motion to confirm the arbitration award and for other relief. On July 19, 2017, the Court confirmed the arbitration award and denied Walgreens’ request for injunctive relief. The Company intends to continue to vigorously defend itself, but the Company can provide no assurance that any continued challenge to the award will be successful.
Derivative Lawsuit in the Delaware Court of Chancery
On May 7, 2015, a derivative complaint was filed in the Delaware Court of Chancery (the “Derivative Complaint”) by the Park Employees’ & Retirement Board Employees’ Annuity & Benefit Fund of Chicago (the “Derivative Plaintiff”). The Derivative Complaint names as defendants certain current and former directors of the Company, consisting of Richard M. Smith, Myron Holubiak, Charlotte Collins, Samuel Frieder, David Hubers, Richard Robbins, Stuart Samuels and Gordon Woodward (collectively, the “Director Defendants”), certain current and former officers of the Company, consisting of Kimberlee Seah, Hai Tran and Patricia Bogusz (collectively the “Officer Defendants”), Kohlberg & Co., L.L.C., Kohlberg Management V, L.L.C., Kohlberg Investors V, L.P., Kohlberg Partners V, L.P., Kohlberg TE Investors V, L.P., KOCO Investors V, L.P., and Jefferies LLC. The Company is also named as a nominal defendant in the Derivative Complaint. The Derivative Complaint was filed in the Delaware Court of Chancery as Park Employees and Retirement Board Employees’ Annuity and Benefit Fund of Chicago v. Richard M. Smith, Myron Z. Holubiak, Charlotte W. Collins, Samuel P. Frieder, David R. Huber, Richard L. Robbins, Stuart A. Samuels, Gordon H. Woodward, Kimberlee C. Seah, Hai V.Tran, Patricia Bogusz, Kohlberg & Co., L.L.C., Kohlberg Management V, L.L.C., Kohlberg Investors V, L.P., Kohlberg Partners V, L.P., Kohlberg TE Investors V, L.P., KOCO Investors V, L.P., Jefferies LLC and BioScrip, Inc., C.A. No. 11000-VCG (Del. Ch. Ct., May 7, 2015).
The Derivative Complaint alleges generally that certain defendants breached their fiduciary duties with respect to the Company’s public disclosures, oversight of Company operations, secondary stock offerings and stock sales. The Derivative Complaint also contends that certain defendants aided and abetted those alleged breaches. The damages sought are not quantified but include, among other things, claims for money damages, restitution, disgorgement, equitable relief, reasonable attorneys’ fees, costs and expenses, and interest. The Derivative Complaint incorporates the same factual allegations from In re BioScrip, Inc., Securities Litigation (described below). On June 16, 2015, all defendants moved to dismiss the case. Briefing for the motion to dismiss was completed on November 30, 2015, and the court heard oral argument on the motion to dismiss on January 12, 2016. During the hearing, the court requested additional briefing, which was completed on February 12, 2016. On May 31, 2016, the court determined that the Derivative Plaintiff’s claims could not proceed as pled but granted the Derivative Plaintiff thirty days in which to make a motion to amend the Derivative Complaint. The court reserved decision on the motion to dismiss and on June 29, 2016, the Derivative Plaintiff filed a motion for leave to file an amended complaint. On October 10, 2016, all defendants moved to dismiss the amended complaint and the Court heard oral argument on January 19, 2017. On April 18, 2017, the Court granted the defendants’ motion to dismiss. Plaintiffs filed a notice of appeal on May 12, 2017.
The Company, Director Defendants and the Officer Defendants deny any allegations of wrongdoing in this lawsuit. The Company and those persons believe all of the claims in this lawsuit are without merit and intend to vigorously defend against these claims. However, there is no assurance that the defense will be successful or that insurance will be available or adequate to fund any settlement, judgment or litigation costs associated with this action. Certain of the defendants have sought indemnification from the Company pursuant to certain indemnification agreements, for which there may be no insurance coverage. Additional similar lawsuits may be filed. The Company is unable to predict the outcome or reasonably estimate a range of possible loss at this time. While no assurance can be given as to the ultimate outcome of this matter, the Company believes that the final resolution of this action is not likely to have a material adverse effect on results of operations, financial position, liquidity or capital resources.
Government Regulation
Various federal and state laws and regulations affecting the healthcare industry do or may impact the Company’s current and planned operations, including, without limitation, federal and state laws prohibiting kickbacks in government health programs, federal and state antitrust and drug distribution laws, and a wide variety of consumer protection, insurance and other state laws and regulations. While management believes the Company is in substantial compliance with all existing laws and regulations material to the operation of its business, such laws and regulations are often uncertain in their application to our business practices as they evolve and are subject to rapid change. As controversies continue to arise in the healthcare industry, federal and state regulation and enforcement priorities in this area can be expected to increase, the impact of which cannot be predicted.
From time to time, the Company responds to investigatory subpoenas and requests for information from governmental agencies and private parties. The Company cannot predict with certainty what the outcome of any of the foregoing might be. While the Company believes it is in substantial compliance with all laws, rules and regulations that affects its business and operations, there can be no assurance that the Company will not be subject to scrutiny or challenge under one or more existing laws or that any such challenge would not be successful. Any such challenge, whether or not successful, could have a material effect upon the Company’s Consolidated Financial Statements. A violation of the Federal anti-kickback statute, for example, may result in substantial criminal penalties, as well as suspension or exclusion from the Medicare and Medicaid programs. Moreover, the costs and expenses associated with defending these actions, even where successful, can be significant. Further, there can be no assurance the Company will be able to obtain or maintain any of the regulatory approvals that may be required to operate its business, and the failure to do so could have a material effect on the Company’s Consolidated Financial Statements.
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.7.0.1
CONCENTRATION OF RISK
 6 Months Ended
Jun. 30, 2017
Risks and Uncertainties [Abstract]  
Concentration of Risk
CONCENTRATION OF RISK
Customer and Credit Concentration Risk
The Company provides trade credit to its customers in the normal course of business. One commercial payor, United Healthcare, accounted for approximately 21.9% and 24.4% of revenue during the three months ended June 30, 2017 and 2016, respectively, and approximately 22.4% and 25.2% of revenue during the six months ended June 30, 2017 and 2016, respectively. This contract, exclusive of certain provisions, will terminate effective September 30, 2017. In addition, Medicare accounted for approximately 7.1% and 8.3% of revenue during the three months ended June 30, 2017 and 2016, respectively, and 7.0% and 7.8% of revenue during the six months ended June 30, 2017 and 2016.
Therapy Revenue Concentration Risk
The Company sells products related to the Immune Globulin therapy, which represented 21.1% and 17.2% of revenue for the three months ended June 30, 2017 and 2016, respectively, and 21.6% and 17.2% of revenue for the six months ended June 30, 2017 and 2016.
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.7.0.1
INCOME TAXES
 6 Months Ended
Jun. 30, 2017
Income Tax Disclosure [Abstract]  
Income Taxes
INCOME TAXES
The Company’s federal and state income tax provision from continuing operations for the three months and six months ended June 30, 2017 and 2016 is summarized in the following table (in thousands):
 
Three Months Ended 
 June 30,
 
Six Months Ended 
 June 30,
 
2017
 
2016
 
2017
 
2016
Current
 
 
 
 
 
 
 
Federal
$
—

 
$
—

 
$
—

 
$
—

State
190

 
25

 
226

 
25

Total current
190

 
25

 
226

 
25

Deferred
 

 
 

 
 

 
 

Federal
437

 
108

 
932

 
125

State
91

 
16

 
179

 
22

Total deferred
528

 
124

 
1,111

 
147

Total income tax expense
$
718

 
$
149

 
$
1,337

 
$
172


The income tax expense recognized for the three months and six months ended June 30, 2017 is a result of an increase in the deferred tax liability.
The Company’s reconciliation of the statutory rate from continuing operations to the effective income tax rate for the three months and six months ended June 30, 2017 and 2016 is summarized as follows (in thousands):
 
Three Months Ended 
 June 30,
 
Six Months Ended 
 June 30,
 
2017
 
2016
 
2017
 
2016
Tax benefit at statutory rate
$
(9,790
)
 
$
(2,844
)
 
$
(16,236
)
 
$
(6,271
)
State tax expense, net of federal taxes
190

 
3

 
226

 
3

Valuation allowance changes affecting income tax provision
10,266

 
1,926

 
17,242

 
5,314

Non-deductible transaction costs and other
52

 
1,064

 
105

 
1,126

Income tax expense
$
718

 
$
149

 
$
1,337

 
$
172


At June 30, 2017, the Company had Federal net operating loss (“NOL”) carry forwards of approximately $373.8 million, of which $14.3 million is subject to an annual limitation, which will begin expiring in 2026 and later. The Company has post-apportioned state NOL carry forwards of approximately $414.4 million, the majority of which will begin expiring in 2017 and later.
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.7.0.1
STOCK-BASED COMPENSATION
 6 Months Ended
Jun. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock-Based Compensation
STOCK-BASED COMPENSATION
BioScrip Equity Incentive Plans
Under the Company’s Amended and Restated 2008 Equity Incentive Plan (the “2008 Plan”), the Company may issue, among other things, incentive stock options, non-qualified stock options, stock appreciation rights (“SARs”), restricted stock grants, restricted stock units, performance shares and performance units to key employees and directors. While SARs are authorized under the 2008 Plan, they may also be issued outside of the plan. The 2008 Plan is administered by the Company’s Management Development and Compensation Committee (the “Compensation Committee”), a standing committee of the Board of Directors.
On November 30, 2016, at a special meeting, the stockholders approved (i) an amendment to the Company’s Second Amended and Restated Certificate of Incorporation to increase the number of shares of Common Stock that the Company is authorized to issue from 125 million shares to 250 million shares (the “Charter Amendment”); (ii) an amendment to the 2008 Plan to (a) increase the number of shares of Common Stock in the aggregate that may be subject to awards by 5,250,000 shares, from 9,355,000 to 14,605,000 shares and (b) increase the annual grant caps under the Company’s 2008 Plan from 500,000 Options, 500,000 Stock Appreciation Rights and 350,000 Stock Grants and Restricted Stock Units that are intended to comply with the requirements of Section 162(m) of the Code to a cap of no more than a total of 3,000,000 Options, Stock Appreciation Rights, Stock Grants and Restricted Stock Units that are intended to comply with the requirements of Section 162(m) of the Code combined; and (iii) if necessary, an adjournment of the Stockholders’ Meeting if there were insufficient votes in favor of the Charter Amendment.
As of June 30, 2017, 4,360,887 shares remain available for grant under the 2008 Plan.
Stock Options
The Company recognized compensation expense related to stock options of $0.3 million and $0.7 million during the three months ended June 30, 2017 and 2016, respectively, and $0.6 million and $1.7 million during the six months ended June 30, 2017 and 2016, respectively.
Restricted Stock
The Company recognized $0.1 million and a nominal amount of compensation expense related to restricted stock awards during the three months ended June 30, 2017 and 2016, respectively, and $0.3 million and a nominal amount of compensation expense during the six months ended June 30, 2017 and 2016, respectively.
Stock Appreciation Rights and Market Based Cash Awards
The Company recognized nominal amounts of compensation expense related to stock appreciation rights awards during the three months ended June 30, 2017 and 2016, and nominal and $0.1 million of compensation expense during the six months ended June 30, 2017 and 2016, respectively.
The Company recognized nominal compensation expense and $0.2 million compensation benefit related to market based cash awards during the three months ended June 30, 2017 and 2016, respectively, and nominal and $0.1 million compensation expense during six months ended June 30, 2017 and 2016, respectively.
Employee Stock Purchase Plan
On May 7, 2013, the Company’s stockholders approved the BioScrip, Inc. Employee Stock Purchase Plan (the “ESPP”). The ESPP is administered by the Compensation Committee. The ESPP provides all eligible employees, as defined under the ESPP, the opportunity to purchase up to a maximum number of shares of Common Stock of the Company as determined by the Compensation Committee. Participants in the ESPP may acquire the Common Stock at a cost of 85% of the lower of the fair market value on the first or last day of the quarterly offering period. The Company filed a Registration Statement on Form S-8 to register 750,000 shares of Common Stock, par value $0.0001 per share, for issuance under the ESPP.
As of June 30, 2017, 136,713 shares remained available for grant under the ESPP. Since inception, the ESPP’s third-party service provider has purchased 613,287 shares on the open market and delivered these shares to the Company’s employees pursuant to the ESPP. During the three months ended June 30, 2017 and 2016, and the six months ended June 30, 2017 and 2016, the Company incurred less than $0.1 million of expense related to the ESPP.
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.7.0.1
BASIS OF PRESENTATION (Policies)
 6 Months Ended
Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation
These Unaudited Consolidated Financial Statements should be read in conjunction with the Audited Consolidated Financial Statements, including the notes thereto, and other information included in the Annual Report on Form 10-K of BioScrip, Inc. and its wholly-owned subsidiaries (the “Company”) for the year ended December 31, 2016 (the “Annual Report”) filed with the U.S. Securities and Exchange Commission (“SEC”). These Unaudited Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information, and the instructions to Form 10-Q and Article 10 of Regulation S-X promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.
The information furnished in these Unaudited Consolidated Financial Statements reflects all adjustments, including normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the results for the interim periods presented. Operating results for the three months and six months ended June 30, 2017 require management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes and are not necessarily indicative of the results that may be expected for the full year ending December 31, 2017.
Consolidation
The Unaudited Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Business Combinations
Business Combinations
Business combinations are accounted for using the acquisition method as of the acquisition date, the date on which control is transferred to the Company. Goodwill is measured at the acquisition date as the fair value of the consideration transferred, plus the fair value of the identifiable assets acquired and liabilities assumed. Transaction costs are expensed as incurred. Contingent consideration payable is measured at fair value at the acquisition date. Contingent consideration classified as equity is not re-measured and settlement is accounted for within equity.
Cash and Cash Equivalents and Restricted Cash
Cash and Cash Equivalents and Restricted Cash

Highly liquid investments with a maturity of three months or less when purchased are classified as cash equivalents. Restricted cash consists of cash balances held by financial institutions as collateral for letters of credit. These balances are reclassified to cash and cash equivalents when the underlying obligation is satisfied, or in accordance with the governing agreement. Restricted cash balances expected to become unrestricted during the next twelve months are recorded as current assets.
Recent Accounting Pronouncements
Recent Accounting Pronouncements
In July 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-11—Earnings Per Share (Topic 260), Distinguishing Liabilities From Equity (Topic 480), and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features and II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. ASU 2017-11 eliminates the requirement that a down round feature precludes equity classification when assessing whether an instrument is indexed to an entity’s own stock. A freestanding equity-linked financial instrument no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. The effective date for ASU 2017-11 is for annual or any interim periods beginning after December 15, 2018. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements.
In May 2017, the FASB issued ASU 2017-09—Compensation–Stock Compensation (Topic 718): Scope of Modification Accounting. ASU 2017-09 modifies when a change to the terms or conditions of a share-based payment award must be accounted for as a modification. The new guidance requires modification accounting if the fair value, vesting condition or the classification of the award is not the same immediately before and after a change to the terms and conditions of the award. The effective date for ASU 2017-09 is for annual or any interim periods beginning after December 15, 2017. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements.
In January 2017, the FASB issued ASU 2017-04—Intangibles–Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. ASU 2017-04 modifies the accounting for goodwill impairment. The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The effective date for ASU 2017-04 is for annual or any interim periods beginning after December 15, 2019. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements.
In November 2016, the FASB issued ASU 2016-18—Statement of Cash Flows (Topic 230): Restricted Cash. ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The effective date for ASU 2016-18 is for annual or any interim periods beginning after December 15, 2017. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements.
In August 2016, the FASB issued ASU 2016-15—Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 provides guidance for eight specific cash flow issues with respect to how cash receipts and cash payments are classified in the statements of cash flows, with the objective of reducing diversity in practice. The effective date for ASU 2016-15 is for annual periods beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements.
In February 2016, the FASB issued ASU 2016-02—Leases (Topic 842), requiring lessees to recognize a right-of-use asset and a lease liability on the balance sheet for all leases with the exception of short-term leases. For lessees, leases will continue to be classified as either operating or finance leases in the income statement. The effective date of the new standard for public companies is for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition and requires application of the new guidance at the beginning of the earliest comparative period presented. The Company is evaluating the effect that the updated standard will have on its consolidated financial statements.
In May 2014, the FASB issued ASU 2014-09—Revenue from Contracts with Customers (Topic 606). The guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The FASB delayed the effective date to annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. In addition, in March and April 2016, the FASB issued new guidance intended to improve the operability and understandability of the implementation guidance on principal versus agent considerations. Both amendments permit the use of either a retrospective or cumulative effect transition method and are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017, with early application permitted. The Company has not elected early adoption and will apply the modified retrospective approach upon adoption. The Company continues to evaluate the impact of the adoption of the new revenue standard on its consolidated financial statements.
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.7.0.1
BASIS OF PRESENTATION (Tables)
 6 Months Ended
Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Accounts Receivable Aging
The following table sets forth the aging of our net accounts receivable (net of allowance for contractual adjustments, and prior to allowance for doubtful accounts), aged based on date of service and categorized based on the three primary overall types of accounts receivable characteristics (in thousands):
 
 
June 30, 2017
 
December 31, 2016
 
 
0 - 180 days
 
Over 180 days
 
Total
 
0 - 180 days
 
Over 180 days
 
Total
Government
 
$
18,714

 
$
7,512

 
$
26,226

 
$
19,891

 
$
8,278

 
$
28,169

Commercial
 
84,190

 
23,589

 
107,779

 
97,744

 
19,848

 
117,592

Patient
 
5,195

 
9,540

 
14,735

 
3,955

 
6,825

 
10,780

Gross accounts receivable
 
$
108,099

 
$
40,641

 
148,740

 
$
121,590

 
$
34,951

 
156,541

Allowance for doubtful accounts
 
 
 
 
 
(45,651
)
 
 
 
 
 
(44,730
)
Net accounts receivable
 
 
 
 
 
$
103,089

 
 
 
 
 
$
111,811
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.7.0.1
LOSS PER SHARE (Tables)
 6 Months Ended
Jun. 30, 2017
Earnings Per Share [Abstract]  
Schedule of Basic and Diluted Loss Per Share
The following table sets forth the computation of basic and diluted loss per common share (in thousands, except for per share amounts):
 
Three Months Ended 
 June 30,
 
Six Months Ended 
 June 30,
 
2017
 
2016
 
2017
 
2016
Numerator:
 
 
 
 
 
 
 
Loss from continuing operations, net of income taxes
$
(28,695
)
 
$
(8,309
)
 
$
(47,686
)
 
$
(18,079
)
Income (loss) from discontinued operations, net of income taxes
(503
)
 
75

 
(940
)
 
308

Net loss
$
(29,198
)
 
$
(8,234
)
 
$
(48,626
)
 
$
(17,771
)
Accrued dividends on preferred stock
(2,303
)
 
(2,056
)
 
(4,517
)
 
(4,054
)
Deemed dividend on preferred stock
(175
)
 
(173
)
 
(349
)
 
(345
)
Loss attributable to common stockholders
$
(31,676
)
 
$
(10,463
)
 
$
(53,492
)
 
$
(22,170
)
 
 
 
 
 
 
 
 
Denominator - Basic and Diluted:
 

 
 

 
 

 
 

Weighted average common shares outstanding
121,189

 
73,186

 
119,993

 
70,978

 
 
 
 
 
 
 
 
Loss per Common Share:
 
 
 
 
 
 
 
Loss from continuing operations, basic and diluted
$
(0.26
)
 
$
(0.14
)
 
$
(0.44
)
 
$
(0.32
)
Loss from discontinued operations, basic and diluted
—

 
—

 
(0.01
)
 
—

Loss per common share, basic and diluted
$
(0.26
)
 
$
(0.14
)
 
$
(0.45
)
 
$
(0.32
)
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.7.0.1
STOCKHOLDERS' DEFICIT (Tables)
 6 Months Ended
Jun. 30, 2017
Equity [Abstract]  
Carrying value and activity of Preferred Shares
The following table sets forth the activity recorded during the six months ended June 30, 2017 related to the Series C Preferred Stock (in thousands):
Series C Preferred Stock carrying value at December 31, 2016
$
69,540

Accretion of discount related to issuance costs
323

Dividends recorded through June 30, 2017 1
4,366

Series C Preferred Stock carrying value June 30, 2017
$
74,229


1 Dividends recorded reflect the increase in the Liquidation Preference associated with unpaid dividends.
The following table sets forth the activity recorded during the six months ended June 30, 2017 related to the Series A Preferred Stock (in thousands):
Series A Preferred Stock carrying value at December 31, 2016
$
2,462

Accretion of discount related to issuance costs
26

Dividends recorded through June 30, 2017 1
151

Series A Preferred Stock carrying value June 30, 2017
$
2,639

1 Dividends recorded reflect the increase in the Liquidation Preference associated with unpaid dividends.
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.7.0.1
ACQUISITIONS (Tables)
 6 Months Ended
Jun. 30, 2017
Business Combinations [Abstract]  
Schedule of Consideration Transferred in Acquisition
The following table sets forth the consideration transferred in connection with the acquisition of Home Solutions as of September 9, 2016 (in thousands):
Cash
$
67,516

Equity issued at closing
9,938

Capital lease obligation assumed
301

Fair value of contingent consideration
15,400

Total consideration
$
93,155
Schedule of Assets Acquired and Liabilities Assumed
The following table sets forth the preliminary estimate of fair value of the assets acquired and liabilities assumed upon acquisition of Home Solutions (in thousands):
Accounts receivable
$
11,956

Inventories
3,199

Prepaids and other assets
852

Total current assets
$
16,007

Property and equipment
4,651

Goodwill
57,218

Managed care contracts
24,700

Licenses
5,400

Trade name
1,800

Non-compete agreements
200

Other non-current assets
891

Total assets
$
110,867

Accounts payable
14,576

Accrued liabilities
3,136

Current liabilities
$
17,712

Total fair value of cash and contingent consideration
$
93,155
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.7.0.1
RESTRUCTURING, ACQUISITION, INTERGRATION, AND OTHER EXPENSES, NET (Tables)
 6 Months Ended
Jun. 30, 2017
Restructuring and Related Activities [Abstract]  
Schedule of Restructuring, Acquisition, Integration, and Other Expenses, Net
Restructuring, acquisition, integration, and other expenses, net in the Unaudited Consolidated Statements of Operations for the three months and six months ended June 30, 2017 and 2016 consisted of the following (in thousands):
 
Three Months Ended 
 June 30,
 
Six Months Ended 
 June 30,
 
2017
 
2016
 
2017
 
2016
Restructuring expense
$
3,648

 
$
1,316

 
$
6,854

 
$
3,932

Acquisition and integration expense
263

 
2,924

 
280

 
2,924

Change in fair value of contingent consideration
—

 
51

 
—

 
102

Total restructuring, acquisition, integration, and other expense, net
$
3,911

 
$
4,291

 
$
7,134

 
$
6,958
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.7.0.1
DEBT (Tables)
 6 Months Ended
Jun. 30, 2017
Debt Disclosure [Abstract]  
Summary of Long-term Debt
As of June 30, 2017 and December 31, 2016, the Company’s debt consisted of the following (in thousands):
 
June 30,
2017
 
December 31,
2016
Senior Credit Facilities
$
—

 
$
265,507

First Lien Note Facility, net of unamortized discount
198,000

 
—

Second Lien Note Facility, net of unamortized discount
82,931

 
—

2021 Notes, net of unamortized discount
197,008

 
196,670

Capital leases
3,134

 
2,209

Less: Deferred financing costs
(3,668
)
 
(12,452
)
Total Debt
477,405

 
451,934

Less: Current portion
(1,731
)
 
(18,521
)
Long-term debt, net of current portion
$
475,674

 
$
433,413
Schedule of Carrying and Estimated Fair Values of Financial Instruments
The following details our financial instruments where the carrying value and the fair value differ (in thousands):
Financial Instrument
 
Carrying Value as of June 30, 2017
 
Markets for Identical Item (Level 1)
 
Significant Other Observable Inputs (Level 2)
 
Significant Unobservable Inputs (Level 3)
First Lien Note Facility
 
$
198,000

 
$
—

 
$
198,000

 
$
—

Second Lien Note Facility
 
82,931

 
—

 
82,931

 
—

2017 Warrants
 
16,908

 
—

 
16,908

 
—

2021 Notes
 
197,008

 
—

 
178,109

 
—

Total
 
$
494,847

 
$
—

 
$
475,948

 
$
—
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.7.0.1
INCOME TAXES (Tables)
 6 Months Ended
Jun. 30, 2017
Income Tax Disclosure [Abstract]  
Schedule of Federal and State Income Tax Provision (Benefit)
The Company’s federal and state income tax provision from continuing operations for the three months and six months ended June 30, 2017 and 2016 is summarized in the following table (in thousands):
 
Three Months Ended 
 June 30,
 
Six Months Ended 
 June 30,
 
2017
 
2016
 
2017
 
2016
Current
 
 
 
 
 
 
 
Federal
$
—

 
$
—

 
$
—

 
$
—

State
190

 
25

 
226

 
25

Total current
190

 
25

 
226

 
25

Deferred
 

 
 

 
 

 
 

Federal
437

 
108

 
932

 
125

State
91

 
16

 
179

 
22

Total deferred
528

 
124

 
1,111

 
147

Total income tax expense
$
718

 
$
149

 
$
1,337

 
$
172
Reconciliation of the Income Tax Rate
The Company’s reconciliation of the statutory rate from continuing operations to the effective income tax rate for the three months and six months ended June 30, 2017 and 2016 is summarized as follows (in thousands):
 
Three Months Ended 
 June 30,
 
Six Months Ended 
 June 30,
 
2017
 
2016
 
2017
 
2016
Tax benefit at statutory rate
$
(9,790
)
 
$
(2,844
)
 
$
(16,236
)
 
$
(6,271
)
State tax expense, net of federal taxes
190

 
3

 
226

 
3

Valuation allowance changes affecting income tax provision
10,266

 
1,926

 
17,242

 
5,314

Non-deductible transaction costs and other
52

 
1,064

 
105

 
1,126

Income tax expense
$
718

 
$
149

 
$
1,337

 
$
172
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.7.0.1
BASIS OF PRESENTATION - Additional Information (Details) - USD ($)
$ in Thousands
Jun. 30, 2017
Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Restricted cash $ 5,055 $ 0
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.7.0.1
BASIS OF PRESENTATION - Accounts Receivable Aging (Details) - USD ($)
$ in Thousands
Jun. 30, 2017
Dec. 31, 2016
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Gross accounts receivable $ 148,740 $ 156,541
Allowance for doubtful accounts (45,651) (44,730)
Net accounts receivable 103,089 111,811
Government    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Gross accounts receivable 26,226 28,169
Commercial    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Gross accounts receivable 107,779 117,592
Patient    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Gross accounts receivable 14,735 10,780
Receivables 0 to 180 Days Past Due    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Gross accounts receivable 108,099 121,590
Receivables 0 to 180 Days Past Due | Government    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Gross accounts receivable 18,714 19,891
Receivables 0 to 180 Days Past Due | Commercial    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Gross accounts receivable 84,190 97,744
Receivables 0 to 180 Days Past Due | Patient    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Gross accounts receivable 5,195 3,955
Receivables Over 180 Days Past Due    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Gross accounts receivable 40,641 34,951
Receivables Over 180 Days Past Due | Government    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Gross accounts receivable 7,512 8,278
Receivables Over 180 Days Past Due | Commercial    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Gross accounts receivable 23,589 19,848
Receivables Over 180 Days Past Due | Patient    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Gross accounts receivable $ 9,540 $ 6,825
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.7.0.1
LOSS PER SHARE (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Dec. 31, 2016
Earnings Per Share [Abstract]          
Common stock, par value (in dollars per share) $ 0.0001   $ 0.0001   $ 0.0001
Numerator:          
Loss from continuing operations, net of income taxes $ (28,695) $ (8,309) $ (47,686) $ (18,079)  
(Loss) income from discontinued operations, net of income taxes (503) 75 (940) 308  
Net loss (29,198) (8,234) (48,626) (17,771)  
Accrued dividends on preferred stock (2,303) (2,056) (4,517) (4,054)  
Deemed dividends on preferred stock (175) (173) (349) (345)  
Loss attributable to common stockholders $ (31,676) $ (10,463) $ (53,492) $ (22,170)  
Denominator - Basic and Diluted:          
Weighted average number of common shares outstanding, basic and diluted (in shares) 121,189 73,186 119,993 70,978  
Loss per Common Share:          
Loss from continuing operations, basic and diluted (in dollars per share) $ (0.26) $ (0.14) $ (0.44) $ (0.32)  
Loss from discontinued operations, basic and diluted (in dollars per share) 0.00 0.00 (0.01) 0.00  
Loss per common share, basic and diluted (in dollars per share) $ (0.26) $ (0.14) $ (0.45) $ (0.32)  
Antidilutive securities excluded from computation of earnings per share (in shares) 18,300 14,000 18,400 15,500  
Series A Preferred Stock          
Class of Stock [Line Items]          
Convertible preferred stock series, par value (in dollars per share) $ 0.0001   $ 0.0001   0.0001
Series C Preferred Stock          
Class of Stock [Line Items]          
Convertible preferred stock series, par value (in dollars per share) $ 0.0001   $ 0.0001   $ 0.0001
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.7.0.1
STOCKHOLDERS' DEFICIT - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
 6 Months Ended
Jun. 22, 2016
Jun. 14, 2016
Jul. 31, 2015
Mar. 09, 2015
Jun. 30, 2017
Jun. 30, 2016
Dec. 31, 2016
May 02, 2016
Jun. 30, 2015
Class of Warrant or Right [Line Items]                  
Proceeds from issuance of equity and temporary equity     $ 1,100            
Amount of equity able to raise               $ 200,000  
Value of stock issued in secondary offering         $ 20,776 $ 83,267      
Common Stock | Secondary Offering                  
Class of Warrant or Right [Line Items]                  
Share price (in dollars per share) $ 2.00                
Stock issued (in shares) 45,200,000                
Value of stock issued in secondary offering $ 83,300                
Common Stock | Over-Allotment Option                  
Class of Warrant or Right [Line Items]                  
Stock issued (in shares) 5,200,000                
PIPE Warrants                  
Class of Warrant or Right [Line Items]                  
Additional contribution by investors       $ 500          
PIPE Warrants | Common Stock                  
Class of Warrant or Right [Line Items]                  
Common stock reserved for future issuance (in shares)         3,600,000        
Class A Warrants                  
Class of Warrant or Right [Line Items]                  
Warrants issued (in shares)     31,025 1,800,000          
Exercise price of warrants (in dollars per share)       $ 5.17         $ 5.17
Class B Warrants                  
Class of Warrant or Right [Line Items]                  
Warrants issued (in shares)     31,025 1,800,000          
Exercise price of warrants (in dollars per share)       $ 6.45         6.45
Class A Warrants Prior to Addendum                  
Class of Warrant or Right [Line Items]                  
Exercise price of warrants (in dollars per share)       5.295          
Class B Warrants Prior to Addendum                  
Class of Warrant or Right [Line Items]                  
Exercise price of warrants (in dollars per share)       $ 6.595          
Series A Preferred Stock                  
Class of Warrant or Right [Line Items]                  
Shares issued (in shares)     10,822 625,000 21,645   21,645    
Share price (in dollars per share)     $ 100 $ 100.00          
Proceeds from issuance of equity and temporary equity       $ 62,500          
Redemption price (in dollars per share)       $ 5.17          
Exercise price of warrants (in dollars per share)                 $ 5.17
Series A convertible preferred stock, shares authorized (in shares)       825,000 825,000   825,000    
Dividend accrual rate         11.50%        
Convertible preferred stock series, shares outstanding (in shares)         21,645   21,645    
Convertible preferred stock series, liquidation preference         $ 2,754   $ 2,603    
Series A Preferred Stock | PIPE Warrants                  
Class of Warrant or Right [Line Items]                  
Shares issued (in shares)         10,823        
Series B Preferred Stock                  
Class of Warrant or Right [Line Items]                  
Shares converted (in shares)   614,177              
Convertible preferred stock series, shares outstanding (in shares)         0        
Series C Preferred Stock                  
Class of Warrant or Right [Line Items]                  
Shares issued (in shares)         614,177   614,177    
Series A convertible preferred stock, shares authorized (in shares)         625,000   625,000    
Shares issued in conversion (in shares)   614,177              
Dividend rate of non-cash dividend payable         11.50%        
Convertible preferred stock series, shares outstanding (in shares)         614,177   614,177    
Convertible preferred stock series, liquidation preference         $ 79,858   $ 75,491    
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.7.0.1
STOCKHOLDERS' DEFICIT - Activity Related to Series A and C Preferred Stock (Details)
$ in Thousands
 6 Months Ended
Jun. 30, 2017
USD ($)
Series A Preferred Stock  
Increase (Decrease) in Temporary Equity [Roll Forward]  
Beginning Balance $ 2,462
Accretion of discount related to issuance costs 26
Dividends recorded 151
Ending Balance 2,639
Series C Preferred Stock  
Increase (Decrease) in Temporary Equity [Roll Forward]  
Beginning Balance 69,540
Accretion of discount related to issuance costs 323
Dividends recorded 4,366
Ending Balance $ 74,229
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.7.0.1
STOCKHOLDERS' DEFICIT - Home Solutions Transaction (Details) - Home Solutions
$ / shares in Units, $ in Thousands
Sep. 09, 2016
USD ($)
Days
$ / shares
shares
Business Acquisition [Line Items]  
Cash consideration paid | $ $ 67,516
Equity issued in acquisition (in shares) 3,750,000
Restricted Stock Units (RSUs) | Tranche A  
Business Acquisition [Line Items]  
Equity issued in acquisition (in shares) 3,100,000
Price of shares issued in acquisition (in dollars per share) | $ / shares $ 4.00
Consecutive trading days | Days 20
Restricted Stock Units (RSUs) | Tranche B  
Business Acquisition [Line Items]  
Equity issued in acquisition (in shares) 4,000,000
Price of shares issued in acquisition (in dollars per share) | $ / shares $ 5.00
Consecutive trading days | Days 20
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.7.0.1
STOCKHOLDERS' DEFICIT - First Quarter 2017 Private Placement (Details) - USD ($)
$ / shares in Units, $ in Thousands
 6 Months Ended
Jun. 29, 2017
Mar. 01, 2017
Jun. 30, 2017
Jun. 30, 2016
Class of Stock [Line Items]        
Net proceeds from issuance of equity, net of issuance costs     $ 20,776 $ 83,267
Private Placement | Common Stock        
Class of Stock [Line Items]        
Stock issued (in shares) 6,359,350 3,300,000.0    
Net proceeds from issuance of equity, net of issuance costs $ 15,900 $ 5,100    
Stock offering price (in dollars per share) $ 2.50 $ 1.5366    
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.7.0.1
STOCKHOLDERS' DEFICIT - 2017 Warrants (Details) - Common Stock - 2017 Warrants - $ / shares
Jun. 29, 2017
Jun. 30, 2017
Class of Warrant or Right [Line Items]    
Warrant exercise threshold 4.99%  
Warrant holder outstanding common stock ownership limitation 19.99%  
Exercise price of warrants (in dollars per share)   $ 2.00
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.7.0.1
STOCKHOLDERS' DEFICIT - Second Quarter 2017 Private Placement (Details) - USD ($)
$ / shares in Units, $ in Thousands
 6 Months Ended
Jun. 29, 2017
Mar. 01, 2017
Jun. 30, 2017
Jun. 30, 2016
Class of Stock [Line Items]        
Net proceeds from issuance of equity, net of issuance costs     $ 20,776 $ 83,267
Private Placement | Common Stock        
Class of Stock [Line Items]        
Stock issued (in shares) 6,359,350 3,300,000.0    
Stock offering price (in dollars per share) $ 2.50 $ 1.5366    
Net proceeds from issuance of equity, net of issuance costs $ 15,900 $ 5,100    
Associated costs with private placement $ 200      
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.7.0.1
ACQUISITIONS - Additional Information (Details) - Home Solutions
Sep. 09, 2016
shares
Business Acquisition [Line Items]  
Equity issued in acquisition (in shares) 3,750,000
Tranche A | Restricted Stock Units (RSUs)  
Business Acquisition [Line Items]  
Equity issued in acquisition (in shares) 3,100,000
Tranche B | Restricted Stock Units (RSUs)  
Business Acquisition [Line Items]  
Equity issued in acquisition (in shares) 4,000,000
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.7.0.1
ACQUISITIONS - Consideration Transferred in Acquisition (Details) - Home Solutions
$ in Thousands
Sep. 09, 2016
USD ($)
Business Acquisition [Line Items]  
Cash $ 67,516
Equity issued at closing 9,938
Capital lease obligation assumed 301
Fair value of contingent consideration 15,400
Total consideration $ 93,155
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.7.0.1
ACQUISITIONS - Assets Acquired and Liabilities Assumed (Details) - USD ($)
$ in Thousands
Jun. 30, 2017
Dec. 31, 2016
Sep. 09, 2016
Business Acquisition [Line Items]      
Goodwill $ 365,947 $ 365,947  
Home Solutions      
Business Acquisition [Line Items]      
Accounts receivable     $ 11,956
Inventories     3,199
Prepaids and other assets     852
Total current assets     16,007
Property and equipment     4,651
Goodwill     57,218
Other non-current assets     891
Total assets     110,867
Accounts payable     14,576
Accrued liabilities     3,136
Current liabilities     17,712
Total fair value of cash and contingent consideration     93,155
Home Solutions | Managed care contracts      
Business Acquisition [Line Items]      
Intangible assets     24,700
Home Solutions | Licenses      
Business Acquisition [Line Items]      
Intangible assets     5,400
Home Solutions | Trade name      
Business Acquisition [Line Items]      
Intangible assets     1,800
Home Solutions | Non-compete agreements      
Business Acquisition [Line Items]      
Intangible assets     $ 200
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.7.0.1
RESTRUCTURING, ACQUISITION, INTERGRATION, AND OTHER EXPENSES, NET (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Restructuring and Related Activities [Abstract]        
Restructuring expense $ 3,648 $ 1,316 $ 6,854 $ 3,932
Acquisition and integration expense 263 2,924 280 2,924
Change in fair value of contingent consideration 0 51 0 102
Total restructuring, acquisition, integration, and other expense, net $ 3,911 $ 4,291 $ 7,134 $ 6,958
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.7.0.1
DEBT - Summary of Long-term Debt (Details) - USD ($)
$ in Thousands
Jun. 30, 2017
Dec. 31, 2016
Debt Instrument [Line Items]    
Less: Deferred financing costs $ (3,668) $ (12,452)
Total Debt 477,405 451,934
Less: Current portion (1,731) (18,521)
Long-term debt, net of current portion 475,674 433,413
Senior Credit Facilities    
Debt Instrument [Line Items]    
Long-term debt 0 265,507
First Lien Note Facility, net of unamortized discount    
Debt Instrument [Line Items]    
Long-term debt 198,000 0
Second Lien Note Facility, net of unamortized discount    
Debt Instrument [Line Items]    
Long-term debt 82,931 0
2021 Notes    
Debt Instrument [Line Items]    
Long-term debt 197,008 196,670
Capital leases    
Debt Instrument [Line Items]    
Capital leases $ 3,134 $ 2,209
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.7.0.1
DEBT - Additional Information (Details) - USD ($)
 6 Months Ended
Jun. 29, 2017
Mar. 01, 2017
Jun. 30, 2017
Jun. 30, 2016
Jan. 06, 2017
Feb. 11, 2014
Jul. 31, 2013
Debt Instrument [Line Items]              
Net proceeds from issuance of equity, net of issuance costs     $ 20,776,000 $ 83,267,000      
Common Stock | 2017 Warrants              
Debt Instrument [Line Items]              
Warrant exercise threshold 4.99%            
Warrants classified within equity at fair value     $ 16,900,000        
Private Placement | Common Stock              
Debt Instrument [Line Items]              
Net proceeds from issuance of equity, net of issuance costs $ 15,900,000 $ 5,100,000          
Associated costs with private placement 200,000            
Term Loan B Facility | Senior Secured Debt              
Debt Instrument [Line Items]              
Face amount of debt instruments             $ 250,000,000.0
Delayed Draw Term Loan Facility | Senior Secured Debt              
Debt Instrument [Line Items]              
Face amount of debt instruments             150,000,000.0
Priming Credit Agreement | Line of Credit              
Debt Instrument [Line Items]              
Face amount of debt instruments         $ 25,000,000    
First Lien Notes | Senior Secured Debt              
Debt Instrument [Line Items]              
Face amount of debt instruments 200,000,000            
Amortization installment percentage of principal     0.625%        
Early repayment premium base rate     5.00%        
Principal prepayment limit     $ 50,000,000        
Default penalty interest rate increase     2.00%        
First Lien Notes | Senior Secured Debt | Base Rate              
Debt Instrument [Line Items]              
Basis spread on variable rate     6.00%        
First Lien Notes | Senior Secured Debt | LIBOR              
Debt Instrument [Line Items]              
Basis spread on variable rate     7.00%        
First Lien Notes | Senior Secured Debt | Prime Rate              
Debt Instrument [Line Items]              
Basis spread on variable rate     1.00%        
First Lien Notes | Senior Secured Debt | Redemption Period One              
Debt Instrument [Line Items]              
Early repayment premium rate     4.00%        
First Lien Notes | Senior Secured Debt | Redemption Period Two              
Debt Instrument [Line Items]              
Early repayment premium rate     2.00%        
First Lien Notes | Senior Secured Debt | Redemption Period Three              
Debt Instrument [Line Items]              
Early repayment premium rate     0.00%        
Second Lien Notes | Senior Secured Debt              
Debt Instrument [Line Items]              
Face amount of debt instruments 100,000,000            
Early repayment premium base rate     5.00%        
Default penalty interest rate increase     2.00%        
Second Lien Notes | Senior Secured Debt | Option One              
Debt Instrument [Line Items]              
Basis spread on variable rate     9.25%        
Second Lien Notes | Senior Secured Debt | Option Two              
Debt Instrument [Line Items]              
Basis spread on variable rate     11.25%        
Second Lien Notes | Senior Secured Debt | Option Three              
Debt Instrument [Line Items]              
Basis spread on variable rate     10.25%        
Second Lien Notes | Senior Secured Debt | Option Three, Half Cash              
Debt Instrument [Line Items]              
Basis spread on variable rate     4.625%        
Second Lien Notes | Senior Secured Debt | Option Three, Half Capitalized Interest              
Debt Instrument [Line Items]              
Basis spread on variable rate     5.625%        
Second Lien Notes | Senior Secured Debt | Redemption Period One              
Debt Instrument [Line Items]              
Early repayment premium rate     4.00%        
Second Lien Notes | Senior Secured Debt | Redemption Period Two              
Debt Instrument [Line Items]              
Early repayment premium rate     2.00%        
Second Lien Notes | Senior Secured Debt | Redemption Period Three              
Debt Instrument [Line Items]              
Early repayment premium rate     0.00%        
Second Lien Delayed Draw Notes | Senior Secured Debt              
Debt Instrument [Line Items]              
Additional debt allowed under debt agreements $ 10,000,000            
Period after closing of ability to issue new debt 18 months            
Senior Unsecured 8.875% Notes              
Debt Instrument [Line Items]              
Face amount of debt instruments           $ 200,000,000.0  
Stated rate on debt     8.875%     8.875%  
Debt discount           $ 5,000,000  
Revolving Credit Facility | Revolving Credit Facility | Senior Secured Debt              
Debt Instrument [Line Items]              
Face amount of debt instruments             $ 75,000,000.0
Minimum | First Lien Notes | Senior Secured Debt | Base Rate              
Debt Instrument [Line Items]              
Basis spread on variable rate     0.50%        
Minimum | First Lien Notes | Senior Secured Debt | LIBOR              
Debt Instrument [Line Items]              
Basis spread on variable rate     1.00%        
Minimum | Second Lien Notes | Senior Secured Debt | Option One | LIBOR              
Debt Instrument [Line Items]              
Basis spread on variable rate     1.25%        
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.7.0.1
DEBT - Carrying and Estimated Fair Values of Financial Instruments (Details) - USD ($)
$ in Thousands
Jun. 30, 2017
Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total, carrying value $ 494,847  
First Lien Note Facility, net of unamortized discount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt, carrying value 198,000 $ 0
Second Lien Note Facility, net of unamortized discount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt, carrying value 82,931 0
2021 Notes    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt, carrying value 197,008 $ 196,670
Markets for Identical Item (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Warrants, fair value 0  
Total, fair value 0  
Markets for Identical Item (Level 1) | First Lien Note Facility, net of unamortized discount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt, fair value 0  
Markets for Identical Item (Level 1) | Second Lien Note Facility, net of unamortized discount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt, fair value 0  
Markets for Identical Item (Level 1) | 2021 Notes    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt, fair value 0  
Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Warrants, fair value 16,908  
Total, fair value 475,948  
Significant Other Observable Inputs (Level 2) | First Lien Note Facility, net of unamortized discount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt, fair value 198,000  
Significant Other Observable Inputs (Level 2) | Second Lien Note Facility, net of unamortized discount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt, fair value 82,931  
Significant Other Observable Inputs (Level 2) | 2021 Notes    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt, fair value 178,109  
Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Warrants, fair value 0  
Total, fair value 0  
Significant Unobservable Inputs (Level 3) | First Lien Note Facility, net of unamortized discount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt, fair value 0  
Significant Unobservable Inputs (Level 3) | Second Lien Note Facility, net of unamortized discount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt, fair value 0  
Significant Unobservable Inputs (Level 3) | 2021 Notes    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt, fair value 0  
2017 Warrants | Common Stock    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Warrants, carrying value 16,908  
Warrants, fair value $ 16,900  
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.7.0.1
COMMITMENTS AND CONTINGENCIES (Details) - Settled Litigation - Pharmacy Services Assets Sale - Walgreens
$ in Millions
Dec. 28, 2016
USD ($)
Loss Contingencies  
Percent of total sales claimed in violation of agreement 3.00%
Damages awarded $ 5.8
Percent awarded of total sought 20.00%
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.7.0.1
CONCENTRATION OF RISK (Details)
 3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Customer Concentration Risk | United Healthcare        
Concentration Risk [Line Items]        
Percentage of concentration risk 21.90% 24.40% 22.40% 25.20%
Customer Concentration Risk | Medicare        
Concentration Risk [Line Items]        
Percentage of concentration risk 7.10% 8.30% 7.00% 7.80%
Product Concentration Risk | Immune Globulin        
Concentration Risk [Line Items]        
Percentage of concentration risk 21.10% 17.20% 21.60% 17.20%
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.7.0.1
INCOME TAXES - Schedule of Federal and State Income Tax Provision (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Income Tax Disclosure [Abstract]        
Federal $ 0 $ 0 $ 0 $ 0
State 190 25 226 25
Total current 190 25 226 25
Federal 437 108 932 125
State 91 16 179 22
Total deferred 528 124 1,111 147
Total income tax expense $ 718 $ 149 $ 1,337 $ 172
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.7.0.1
INCOME TAXES - Reconciliation of the Income Tax Rate (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Income Tax Disclosure [Abstract]        
Tax benefit at statutory rate $ (9,790) $ (2,844) $ (16,236) $ (6,271)
State tax expense, net of federal taxes 190 3 226 3
Valuation allowance changes affecting income tax provision 10,266 1,926 17,242 5,314
Non-deductible transaction costs and other 52 1,064 105 1,126
Total income tax expense $ 718 $ 149 $ 1,337 $ 172
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.7.0.1
INCOME TAXES - Additional Information (Details)
$ in Millions
Jun. 30, 2017
USD ($)
Federal  
Operating Loss Carryforwards [Line Items]  
Net operating loss carryforwards $ 373.8
Net operating loss carryforwards subject to annual limitation 14.3
State  
Operating Loss Carryforwards [Line Items]  
Net operating loss carryforwards $ 414.4
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.7.0.1
STOCK-BASED COMPENSATION (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 6 Months Ended
Nov. 30, 2016
May 07, 2013
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Dec. 31, 2016
Nov. 29, 2016
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]                
Par value of common stock (in dollars per share)     $ 0.0001   $ 0.0001   $ 0.0001  
Equity Option                
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]                
Share-based compensation expense     $ 0.3 $ 0.7 $ 0.6 $ 1.7    
Stock Appreciation Rights (SARs)                
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]                
Share-based compensation expense         0.1      
Restricted Stock                
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]                
Share-based compensation expense     $ 0.1   $ 0.3      
Market Based Cash Awards                
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]                
Share-based compensation expense       (0.2)   0.1    
Employee Stock                
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]                
Number of shares authorized (in shares)   750,000            
Number of shares available for grant (in shares)     136,713   136,713      
Share-based compensation expense     $ 0.1 $ 0.1 $ 0.3 $ 0.3    
Purchase price of common stock, percent   85.00%            
Par value of common stock (in dollars per share)   $ 0.0001            
Shares purchased on the open market for award (in shares)         613,287      
Charter Amendment                
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]                
Number of shares authorized (in shares) 250,000,000             125,000,000
2008 Plan                
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]                
Number of shares authorized (in shares) 3,000,000              
Number of shares available for grant (in shares)     4,360,887   4,360,887      
2008 Plan | Equity Option                
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]                
Number of shares authorized (in shares)               500,000
2008 Plan | Stock Appreciation Rights (SARs)                
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]                
Number of shares authorized (in shares)               500,000
2008 Plan | Restricted Stock                
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]                
Number of shares authorized (in shares)               350,000
2008 Plan | Common Stock                
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]                
Number of shares authorized (in shares) 14,605,000             9,355,000
Adjustment to number of shares authorized (in shares) 5,250,000              
EXCEL 58 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 59 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 60 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 62 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 168 221 1 false 70 0 false 5 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.bioscrip.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.bioscrip.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1001001 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.bioscrip.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.bioscrip.com/role/UnauditedConsolidatedStatementsOfOperations UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 1003000 - Statement - UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.bioscrip.com/role/UnauditedConsolidatedStatementsOfCashFlows UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 5 false false R6.htm 2101100 - Disclosure - BASIS OF PRESENTATION Sheet http://www.bioscrip.com/role/BasisOfPresentation BASIS OF PRESENTATION Notes 6 false false R7.htm 2102100 - Disclosure - LOSS PER SHARE Sheet http://www.bioscrip.com/role/LossPerShare LOSS PER SHARE Notes 7 false false R8.htm 2103100 - Disclosure - STOCKHOLDERS' DEFICIT Sheet http://www.bioscrip.com/role/StockholdersDeficit STOCKHOLDERS' DEFICIT Notes 8 false false R9.htm 2104100 - Disclosure - ACQUISITIONS Sheet http://www.bioscrip.com/role/Acquisitions ACQUISITIONS Notes 9 false false R10.htm 2105100 - Disclosure - RESTRUCTURING, ACQUISITION, INTERGRATION, AND OTHER EXPENSES, NET Sheet http://www.bioscrip.com/role/RestructuringAcquisitionIntergrationAndOtherExpensesNet RESTRUCTURING, ACQUISITION, INTERGRATION, AND OTHER EXPENSES, NET Notes 10 false false R11.htm 2106100 - Disclosure - DEBT Sheet http://www.bioscrip.com/role/Debt DEBT Notes 11 false false R12.htm 2107100 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.bioscrip.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 12 false false R13.htm 2108100 - Disclosure - CONCENTRATION OF RISK Sheet http://www.bioscrip.com/role/ConcentrationOfRisk CONCENTRATION OF RISK Notes 13 false false R14.htm 2109100 - Disclosure - INCOME TAXES Sheet http://www.bioscrip.com/role/IncomeTaxes INCOME TAXES Notes 14 false false R15.htm 2110100 - Disclosure - STOCK-BASED COMPENSATION Sheet http://www.bioscrip.com/role/StockBasedCompensation STOCK-BASED COMPENSATION Notes 15 false false R16.htm 2201201 - Disclosure - BASIS OF PRESENTATION (Policies) Sheet http://www.bioscrip.com/role/BasisOfPresentationPolicies BASIS OF PRESENTATION (Policies) Policies 16 false false R17.htm 2301302 - Disclosure - BASIS OF PRESENTATION (Tables) Sheet http://www.bioscrip.com/role/BasisOfPresentationTables BASIS OF PRESENTATION (Tables) Tables http://www.bioscrip.com/role/BasisOfPresentation 17 false false R18.htm 2302301 - Disclosure - LOSS PER SHARE (Tables) Sheet http://www.bioscrip.com/role/LossPerShareTables LOSS PER SHARE (Tables) Tables http://www.bioscrip.com/role/LossPerShare 18 false false R19.htm 2303301 - Disclosure - STOCKHOLDERS' DEFICIT (Tables) Sheet http://www.bioscrip.com/role/StockholdersDeficitTables STOCKHOLDERS' DEFICIT (Tables) Tables http://www.bioscrip.com/role/StockholdersDeficit 19 false false R20.htm 2304301 - Disclosure - ACQUISITIONS (Tables) Sheet http://www.bioscrip.com/role/AcquisitionsTables ACQUISITIONS (Tables) Tables http://www.bioscrip.com/role/Acquisitions 20 false false R21.htm 2305301 - Disclosure - RESTRUCTURING, ACQUISITION, INTERGRATION, AND OTHER EXPENSES, NET (Tables) Sheet http://www.bioscrip.com/role/RestructuringAcquisitionIntergrationAndOtherExpensesNetTables RESTRUCTURING, ACQUISITION, INTERGRATION, AND OTHER EXPENSES, NET (Tables) Tables http://www.bioscrip.com/role/RestructuringAcquisitionIntergrationAndOtherExpensesNet 21 false false R22.htm 2306301 - Disclosure - DEBT (Tables) Sheet http://www.bioscrip.com/role/DebtTables DEBT (Tables) Tables http://www.bioscrip.com/role/Debt 22 false false R23.htm 2309301 - Disclosure - INCOME TAXES (Tables) Sheet http://www.bioscrip.com/role/IncomeTaxesTables INCOME TAXES (Tables) Tables http://www.bioscrip.com/role/IncomeTaxes 23 false false R24.htm 2401403 - Disclosure - BASIS OF PRESENTATION - Additional Information (Details) Sheet http://www.bioscrip.com/role/BasisOfPresentationAdditionalInformationDetails BASIS OF PRESENTATION - Additional Information (Details) Details 24 false false R25.htm 2401404 - Disclosure - BASIS OF PRESENTATION - Accounts Receivable Aging (Details) Sheet http://www.bioscrip.com/role/BasisOfPresentationAccountsReceivableAgingDetails BASIS OF PRESENTATION - Accounts Receivable Aging (Details) Details 25 false false R26.htm 2402402 - Disclosure - LOSS PER SHARE (Details) Sheet http://www.bioscrip.com/role/LossPerShareDetails LOSS PER SHARE (Details) Details http://www.bioscrip.com/role/LossPerShareTables 26 false false R27.htm 2403402 - Disclosure - STOCKHOLDERS' DEFICIT - Additional Information (Details) Sheet http://www.bioscrip.com/role/StockholdersDeficitAdditionalInformationDetails STOCKHOLDERS' DEFICIT - Additional Information (Details) Details 27 false false R28.htm 2403403 - Disclosure - STOCKHOLDERS' DEFICIT - Activity Related to Series A and C Preferred Stock (Details) Sheet http://www.bioscrip.com/role/StockholdersDeficitActivityRelatedToSeriesAndCPreferredStockDetails STOCKHOLDERS' DEFICIT - Activity Related to Series A and C Preferred Stock (Details) Details 28 false false R29.htm 2403404 - Disclosure - STOCKHOLDERS' DEFICIT - Home Solutions Transaction (Details) Sheet http://www.bioscrip.com/role/StockholdersDeficitHomeSolutionsTransactionDetails STOCKHOLDERS' DEFICIT - Home Solutions Transaction (Details) Details 29 false false R30.htm 2403405 - Disclosure - STOCKHOLDERS' DEFICIT - First Quarter 2017 Private Placement (Details) Sheet http://www.bioscrip.com/role/StockholdersDeficitFirstQuarter2017PrivatePlacementDetails STOCKHOLDERS' DEFICIT - First Quarter 2017 Private Placement (Details) Details 30 false false R31.htm 2403406 - Disclosure - STOCKHOLDERS' DEFICIT - 2017 Warrants (Details) Sheet http://www.bioscrip.com/role/StockholdersDeficit2017WarrantsDetails STOCKHOLDERS' DEFICIT - 2017 Warrants (Details) Details 31 false false R32.htm 2403407 - Disclosure - STOCKHOLDERS' DEFICIT - Second Quarter 2017 Private Placement (Details) Sheet http://www.bioscrip.com/role/StockholdersDeficitSecondQuarter2017PrivatePlacementDetails STOCKHOLDERS' DEFICIT - Second Quarter 2017 Private Placement (Details) Details 32 false false R33.htm 2404402 - Disclosure - ACQUISITIONS - Additional Information (Details) Sheet http://www.bioscrip.com/role/AcquisitionsAdditionalInformationDetails ACQUISITIONS - Additional Information (Details) Details 33 false false R34.htm 2404403 - Disclosure - ACQUISITIONS - Consideration Transferred in Acquisition (Details) Sheet http://www.bioscrip.com/role/AcquisitionsConsiderationTransferredInAcquisitionDetails ACQUISITIONS - Consideration Transferred in Acquisition (Details) Details 34 false false R35.htm 2404404 - Disclosure - ACQUISITIONS - Assets Acquired and Liabilities Assumed (Details) Sheet http://www.bioscrip.com/role/AcquisitionsAssetsAcquiredAndLiabilitiesAssumedDetails ACQUISITIONS - Assets Acquired and Liabilities Assumed (Details) Details 35 false false R36.htm 2405402 - Disclosure - RESTRUCTURING, ACQUISITION, INTERGRATION, AND OTHER EXPENSES, NET (Details) Sheet http://www.bioscrip.com/role/RestructuringAcquisitionIntergrationAndOtherExpensesNetDetails RESTRUCTURING, ACQUISITION, INTERGRATION, AND OTHER EXPENSES, NET (Details) Details http://www.bioscrip.com/role/RestructuringAcquisitionIntergrationAndOtherExpensesNetTables 36 false false R37.htm 2406402 - Disclosure - DEBT - Summary of Long-term Debt (Details) Sheet http://www.bioscrip.com/role/DebtSummaryOfLongTermDebtDetails DEBT - Summary of Long-term Debt (Details) Details 37 false false R38.htm 2406403 - Disclosure - DEBT - Additional Information (Details) Sheet http://www.bioscrip.com/role/DebtAdditionalInformationDetails DEBT - Additional Information (Details) Details 38 false false R39.htm 2406404 - Disclosure - DEBT - Carrying and Estimated Fair Values of Financial Instruments (Details) Sheet http://www.bioscrip.com/role/DebtCarryingAndEstimatedFairValuesOfFinancialInstrumentsDetails DEBT - Carrying and Estimated Fair Values of Financial Instruments (Details) Details 39 false false R40.htm 2407401 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://www.bioscrip.com/role/CommitmentsAndContingenciesDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://www.bioscrip.com/role/CommitmentsAndContingencies 40 false false R41.htm 2408401 - Disclosure - CONCENTRATION OF RISK (Details) Sheet http://www.bioscrip.com/role/ConcentrationOfRiskDetails CONCENTRATION OF RISK (Details) Details http://www.bioscrip.com/role/ConcentrationOfRisk 41 false false R42.htm 2409402 - Disclosure - INCOME TAXES - Schedule of Federal and State Income Tax Provision (Details) Sheet http://www.bioscrip.com/role/IncomeTaxesScheduleOfFederalAndStateIncomeTaxProvisionDetails INCOME TAXES - Schedule of Federal and State Income Tax Provision (Details) Details 42 false false R43.htm 2409403 - Disclosure - INCOME TAXES - Reconciliation of the Income Tax Rate (Details) Sheet http://www.bioscrip.com/role/IncomeTaxesReconciliationOfIncomeTaxRateDetails INCOME TAXES - Reconciliation of the Income Tax Rate (Details) Details 43 false false R44.htm 2409404 - Disclosure - INCOME TAXES - Additional Information (Details) Sheet http://www.bioscrip.com/role/IncomeTaxesAdditionalInformationDetails INCOME TAXES - Additional Information (Details) Details 44 false false R45.htm 2410401 - Disclosure - STOCK-BASED COMPENSATION (Details) Sheet http://www.bioscrip.com/role/StockBasedCompensationDetails STOCK-BASED COMPENSATION (Details) Details http://www.bioscrip.com/role/StockBasedCompensation 45 false false All Reports Book All Reports bios-20170630.xml bios-20170630.xsd bios-20170630_cal.xml bios-20170630_def.xml bios-20170630_lab.xml bios-20170630_pre.xml true true ZIP 64 0001628280-17-008259-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-17-008259-xbrl.zip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